ΠΑΒ 676

ΒΟΥΛΗ ΤΩΝ ΕΛΛΗΝΩΝ

ΧΡΙΣΤΙΑΝΟΔΗΜΟΚΡΑΤΙΚΟ ΚΟΜΜΑ ΑΝΑΤΡΟΠΗΣ

ΝΙΚΟΛΑΟΣ Ι. ΝΙΚΟΛΟΠΟΥΛΟΣ
ΒΟΥΛΕΥΤΗΣ Ν. ΑΧΑΙΑΣ
Κ.Ο. ΑΝΕΞΑΡΤΗΤΟΙ ΔΗΜΟΚΡΑΤΙΚΟΙ ΒΟΥΛΕΥΤΕΣ

ΑΝΑΦΟΡΑ ΠΡΟΣ:

ΤΟΝ ΥΠΟΥΡΓΟ ΠΑΙΔΕΙΑΣ & ΘΡΗΣΚΕΥΜΑΤΩΝ

Παρακαλούμε για την τοποθέτησή σας επί υπομνήματος ένστασης, πληροφοριακού υλικού & σχετικής αλληλογραφίας που παραλάβαμε μέσω ταχυδρομείου από τον καθηγητή Χημείας, κο Ι. Ματσούκα, σχετικά με την απόρριψη της πρότασης ομοτιμοποίησής του .

Ο Αναφέρων Βουλευτής

Νικόλαος Ι. Νικολόπουλος
Πρόεδρος του
Χριστιανοδημοκρατικού Κόμματος Ανατροπής

αναφορά Πανδώρα

Πρύτανη Πανεπιστημίου Πατρών
Κύριο Γεώργιο Παναγιωτάκη

ΠΑΝΕΠΙΣΤΗΜΙΟ ΠΑΤΡΩΝ
Αρ. Πρωτοκόλλου 10.031
Ημερομηνία 11-7-2014

Θέμα: Απόρριψη Πρότασης Ομοτιμοποίησης
Ενημέρωση Συγκλήτου, Κοσμητείας ΣΘΕ, Σ.Ι.

Κύριε Πρύτανη,

Παρακαλώ για την ενημέρωση της Συγκλήτου
σχετικά με την επισυναπτόμενη επιστολή μου.

Γιάννης Ματσούκας
Καθηγητής Χημείας

Πρύτανη Πανεπιστημίου Πατρών
Κύριο Γεώργιο Παναγιωτάκη

Υπόψη: Σύγκλητος Πανεπιστημίου Πατρών, Κοσμητεία ΣΘΕ, Συμβούλιο Ιδρύματος

Θέμα: Απόρριψη Πρότασης Ομοτιμοποίησης – Ενημέρωση Συγκλήτου, Κοσμητείας ΣΘΕ, Σ.Ι.

Κύριε Πρύτανη,

Η επιστολή αυτή αναφέρεται σε γεγονότα τα οποία άπτονται της αξιοκρατίας και της αξιοπρέπειας του Πανεπιστημίου και παρακαλώ για την ενημέρωση της Συγκλήτου και κάθε αρμόδιου Φορέα.

Η Γ.Σ. του Τμήματος Χημείας την 10η Ιουνίου 2014 απέρριψε την Πρόταση Ομοτιμοποίησής μου, η οποία έχει υπογραφεί από εσάς, ως Καθηγητής Ιατρικής και ως Πρύτανης, και από τους διακεκριμένους Καθηγητές του Τμήματος Χημείας κ.κ. Κλεομένη Μπάρλο και Σπύρο Περλεπέ.

Η απόρριψη έγινε μετά την αιφνιδιαστική υποβολή στο Τμήμα από τους Καθηγητές Χημείας κ.κ. Καραμάνο και Καλλίτση, αντίγραφου αγωγής εναντίον μου, των κ.κ. Κουμπιά, Καραμάνου, Καλλίτση, Μπούρα, το οποίο έφεραν στην Γ.Σ. του Τμήματος ακριβώς πριν την συζήτηση της πρότασης Ομοτιμοποίησης, πέρα από κάθε δεοντολογία και ηθική.

Η αγωγή, η οποία υπεβλήθη στις 28 Μαΐου 2014, μετά από επτά μήνες από υποτιθέμενη στιχομυθία στις 17 Οκτωβρίου 2013 σε κυλικείο του Πανεπιστημίου, έγινε με στόχο την αποτροπή της προφανούς και αυτονόητης Ομοτιμοποίησής μου, την οποία και πέτυχαν. Η αγωγή στηρίχθηκε σε **ΨΕΥΔΗ** και **ΑΝΥΠΑΡΚΤΑ** στοιχεία και σε **ΦΑΝΤΑΣΤΙΚΗ** στιχομυθία, που δεν πραγματοποιήθηκε ποτέ.

Επιπλέον στην Αγωγή εναντίον μου, τα τέσσερα μέλη ΔΕΠ ζητούν να τους καταβάλω το ποσό των 140.000€, ως αποζημίωση (35.000 καθένας από τους τέσσερις ενάγοντες) για μια στιχομυθία που δεν έγινε ποτέ! Οι κρίσεις είναι δικές σας…

Η συζήτηση, στη Γ.Σ. του Τμήματος, επί της Ομοτιμοποίησής μου **δεν στηρίχτηκε στο Ερευνητικό Έργο, το Βιογραφικό και την Προσφορά μου**, αλλά αντίθετα εξετράπη σε **συκοφαντία και λασπολογία** εις βάρος μου, από συγκεκριμένα μέλη ΔΕΠ. Η συζήτηση αναπόφευκτα οδήγησε στην απόρριψη - με 16 ψήφους εναντίον μου, 10 υπέρ και 3 λευκά – καθώς νεότερα Μέλη ΔΕΠ αιφνιδιάστηκαν και βρέθηκαν στην δυσχερή θέση να αποφασίσουν για ένα θέμα που αφορούσε το Ήθος μου που ετέθη υπό αμφισβήτηση, και όχι το Έργο μου.

Ο απώτερος στόχος των – με προφανή την γνωστή εμπάθεια στο πρόσωπό μου – ήταν και είναι η εκδίωξή μου από το Πανεπιστήμιο και η διακοπή ενός πολυβραβευμένου, διεθνούς αναγνώρισης Έργου, που έχει χαρακτηριστεί Εθνικός Στόχος. Το Έργο αυτό, στο οποίο έχουν γίνει πολύ μεγάλες επενδύσεις, συνδέεται με την πρόοδο του Πανεπιστημίου και με την Κοινωνία και η υλοποίησή του θα συμβάλει στην ανάπτυξη της χώρας.

Κύριε Πρύτανη, πέραν της ψυχικής ταλαιπωρίας που έχει προκληθεί σε εμένα και την οικογένειά μου από την συνεχή και άδικη επίθεση εναντίον μου, πρωτοφανή για τα δεδομένα του Πανεπιστημίου, σας γνωρίζω ότι θα συνεχίσω την προσπάθεια και τους αγώνες μου μαζί με τους συνεργάτες μου και τους φοιτητές μου, για ένα καλύτερο Πανεπιστήμιο.

Επισυνάπτω την Πρόταση Ομοτιμοποίησης και παρακαλώ όπως η Κοσμητεία ΣΘΕ και η Σύγκλητος επιληφθούν αυτού του πολύ σοβαρού θέματος που άπτεται της δικαιοσύνης, της αξιοκρατίας και της αξιοπρέπειας του Πανεπιστημίου.

Επιφυλάσσομαι, στα πλαίσια της διαύγειας και διαφάνειας, να κοινοποιήσω την επιστολή μου στην Πανεπιστημιακή Κοινότητα και να ενημερώσω κάθε αρμόδιο φορέα.

Με εκτίμηση,

Γιάννης Ματσούκας
Καθηγητής Χημείας
Επιστημονικός Υπεύθυνος και Διευθυντής ΜΠΣ «Ιατρική Χημεία», 1998 – 2013
Πρόεδρος Τμήματος Χημείας, 2005-2007

Πρόταση Ομοτιμοποίησης Καθηγητή Χημείας Γιάννη Ματσούκα

Ο Καθηγητής Χημείας Γιάννης Ματσούκας υπηρέτησε το Τμήμα και το Πανεπιστήμιο επί 37 χρόνια από το 1976, όταν προσελήφθη ως βοηθός στο Εργαστήριο Οργανικής Χημείας, έως σήμερα. Ο κ. Ματσούκας, κατάγεται από την Πάτρα και είναι από την πρώτη σειρά φοιτητών του Πανεπιστημίου Πατρών το 1966. Ήταν επίσης στην πρώτη σειρά αποφοίτων το 1971.

Κατά τη διάρκεια της ακαδημαϊκής του θητείας έχει επιδείξει ένα σημαντικό εκπαιδευτικό και ερευνητικό έργο και μία προσφορά, η οποία τιμά το Τμήμα και το Πανεπιστήμιο. Σημαντικά επιτεύγματα της δραστηριότητάς του υπήρξαν η ερευνητική και εκπαιδευτική του δραστηριότητα και η σύνδεσή της με την Κοινωνία, καθώς και οι προσπάθειές του να γίνει η Βασική του Έρευνα Εφαρμοσμένη.

Το ερευνητικό του έργο, **που στηρίζεται στην διαδρομή του στα Πανεπιστήμια New Brunswick (Department of Chemistry), Fredericton και Calgary (Department of Medicine), Alberta του Καναδά και στο Πανεπιστήμιο Πατρών**, αποτυπώνεται συνοπτικά:

- σε ένα πλούσιο Συγγραφικό Έργο άνω των 500 άρθρων (Δημοσιεύσεις σε έγκριτα περιοδικά [135], Δημοσιεύσεις Ανακοινώσεων (Abstracts) σε Περιοδικά με Κριτές [38], Δημοσιεύσεις σε Πρακτικά Συνεδρίων [89], Περιλήψεις Ανακοινώσεων σε Πρακτικά Συνεδρίων [172], Μονογραφίες σε Βιβλία [50], Πατέντες [26])
- στην Επίβλεψη 25 Διδακτορικών Διατριβών και 28 Μεταπτυχιακών Διπλωμάτων Ειδίκευσης και άνω των 150 Διπλωματικών Προπτυχιακών Εργασιών.
- στην Διεθνή Αναγνώρισή του (άνω των 1800 αναφορών, h index 23, WOS)

Υπήρξε επικεφαλής του Μεταπτυχιακού Προγράμματος **"Ιατρική Χημεία: Σχεδιασμός και Ανάπτυξη Φαρμακευτικών Προϊόντων"** για 16 χρόνια, από το 1998, από το οποίο Πρόγραμμα έχουν αποφοιτήσει μέχρι σήμερα άνω των 250 φοιτητών με μεταπτυχιακούς τίτλους, Διδακτορικά Διπλώματα (ΔΔ) και Μεταπτυχιακά Διπλώματα Ειδίκευσης (ΜΔΕ). Το Πρόγραμμα ήταν το πρώτο στην Ελλάδα που, μετά από αξιολόγηση, έλαβε τον τίτλο **"Euromaster"** ενώ χαρακτηρίστηκε από το Εθνικό Συμβούλιο Έρευνας και Τεχνολογίας (ΕΣΕΤ) και το Υπουργείο Παιδείας ως ένα Πρόγραμμα Αριστείας (excellence.minedu.gov.gr/listing/106-graduateprogram, www.youtube.com/watch?v=i1dQDILrp_k&feature=youtu.be).

Η Έρευνά του έχει προσελκύσει μεγάλο αριθμό **Εθνικών, Ευρωπαϊκών και Ιδιωτικών Χρηματοδοτήσεων** άνω των 12 εκ. €, που έχουν μεταφρασθεί σε δεκάδες υποτροφίες, πολλές θέσεις εργασίας και εξοπλισμό υψηλής τεχνολογίας. Η Έρευνά του, επιπλέον έχει οδηγήσει σε μεγάλη επένδυση Φαρμακευτικής Εταιρείας για την αξιοποίηση των αποτελεσμάτων της Έρευνάς του.

Είναι Συντονιστής ανταγωνιστικού Προγράμματος **«Συνεργασία»** της ΓΓΕΤ, το οποίο εγκρίθηκε με την τρίτη μεγαλύτερη βαθμολογία μεταξύ 620 προτάσεων και με την μεγαλύτερη χρηματοδότηση (3.000.000€) με στόχο την αξιοποίηση της Καινοτομίας και δραστικών συνθέσεων, που έχουν συντεθεί από την ερευνητική του ομάδα.

Ως αποτέλεσμα πολύχρονης, ευδόκιμης συνεργασίας του με το Πανεπιστήμιο Calgary, έχει διοριστεί Καθηγητής στο Τμήμα Ιατρικής του Πανεπιστημίου Calgary, **με ανανέωση του διορισμού του για την τριετία 2014-2017**.

Για το πολύπλευρο Ερευνητικό και Εκπαιδευτικό του Έργο έχει τιμηθεί από την Ακαδημία Αθηνών, καθώς και από πολλούς Ακαδημαϊκούς και Κοινωνικούς φορείς από Ελλάδα και Εξωτερικό, όπως φαίνεται στο Βιογραφικό του Σημείωμα. Για το Έργο του και την προσφορά του στο Πανεπιστήμιο έχουν εκφραστεί με θερμά λόγια διακκεριμένοι ερευνητές. Έχει προσκληθεί δύο φορές στη Βουλή να παρουσιάσει στις Διακομματικές Επιτροπές Έρευνας και Τεχνολογίας και Κοινωνικών Υποθέσεων το Έργο της Ερευνητικής του Ομάδας και τις Προοπτικές της Φαρμακευτικής Έρευνας στην Ελλάδα.

Επισυνάπτονται:

1. Συνοπτικά Στοιχεία Ακαδημαϊκής Σταδιοδρομίας
2. Σύντομο Βιογραφικό Σημείωμα
3. Συνοπτική Περιγραφή Εκπαιδευτικών και Ερευνητικών δραστηριοτήτων και Βραβεύσεών του.

Το πλήρες βιογραφικό βρίσκεται στο site www.johnmatsoukas.gr

Για όλους αυτούς τους λόγους προτείνουμε την απονομή του τίτλου του Ομότιμου Καθηγητή του Τμήματος Χημείας στον Γιάννη Ματσούκα.

ΠΑΝΕΠΙΣΤΗΜΙΟ ΠΑΤΡΩΝ
ΤΜΗΜΑ ΧΗΜΕΙΑΣ
60404
21-3-14

ΣΥΝΟΠΤΙΚΑ ΣΤΟΙΧΕΙΑ ΑΚΑΔΗΜΑΪΚΗΣ ΣΤΑΔΙΟΔΡΟΜΙΑΣ

ΣΠΟΥΔΕΣ

- Πτυχίο Χημείας από το Πανεπιστήμιο Πατρών, 1971
- MSc στην Οργανική Σύνθεση στο Τμήμα Χημείας του Πανεπιστημίου New Brunswick στον Καναδά. Ολική Σύνθεση Φυσικών Προϊόντων στα πλαίσια εκπόνησης διατριβής, 1973. Τίτλος Ερευνητικής Εργασίας (Thesis): **"Total Synthesis of Epi-ramulosin"**.
- Διδακτορικό Δίπλωμα στο Τμήμα Χημείας του Πανεπιστημίου Πατρών με αντικείμενο διατριβής στην Πεπτιδική Σύνθεση και στην Φασματοσκοπία Πυρηνικού Μαγνητικού Συντονισμού, 1979. Τίτλος Ερευνητικής Εργασίας (Thesis): **"Synthesis and conformational properties of N-alkylamido derivatives of the C-terminal tripeptide of oxytocin, [β-Ala^9]-oxytocin and N-Trt-α-benzyl derivatives of glutamine and asparagine"**.

ΜΕΤΑΔΙΔΑΚΤΟΡΙΚΗ ΕΡΕΥΝΑ

- University of New Brunswick, Canada, Natural Products, Απομόνωση-Ταυτοποίηση-Βιολογική Αξιολόγηση Φυσικών Προϊόντων, 1981-1982
- University of Calgary, Alberta, Canada, Πεπτιδική Σύνθεση-Φασματοσκοπική Ανάλυση-Βιολογική Αξιολόγηση της πεπτιδικής ορμόνης Αγγειοτενσίνη, 1982-1984

ΕΠΙΣΚΕΠΤΗΣ ΚΑΘΗΓΗΤΗΣ (VISITING AND ADJUNCT PROFESSOR)

- Reappointment for third time as a Faculty Professor of Medical School, University of Calgary, Alberta, Canada, 2014-2017
- Immunology and Vaccine Laboratory, Macfarlane Burnet Institute for Medical Research and Public Health, Melbourne, Australia
- Department of Immunology, Old Dominion University, Virginia, U.S.A

ΑΚΑΔΗΜΑΪΚΗ ΣΤΑΔΙΟΔΡΟΜΙΑ

1. Επίκουρος Καθηγητής, Τμήμα Χημείας, Πανεπιστήμιο Πατρών 1985-1990
2. Αναπληρωτής Καθηγητής, Τμήμα Χημείας, Πανεπιστήμιο Πατρών 1990-1995
3. Καθηγητής, Τμήμα Χημείας, Πανεπιστήμιο Πατρών 1995-2013
4. Τομεάρχης στον Ά Τομέα του Τμήματος Χημείας, Πανεπιστήμιο Πατρών, 1997-1999
5. Αναπληρωτής Πρόεδρος του Τμήματος Χημείας, Πανεπιστήμιο Πατρών, 1999-2001
6. Πρόεδρος του Τμήματος Χημείας, Πανεπιστήμιο Πατρών, 2001
7. Πρόεδρος του Τμήματος Χημείας, Πανεπιστήμιο Πατρών, 2005-2007
8. Επιστημονικός Υπεύθυνος και Διευθυντής ΜΠΣ «Ιατρική Χημεία», 1998 -2013

ΒΡΑΒΕΥΣΕΙΣ

- Ακαδημία Αθηνών
- ΟΒΙ (Οργανισμός Βιομηχανικής Ιδιοκτησίας), Υπουργείο Ανάπτυξης
- ΕΣΕΤ (Εθνικό Συμβούλιο Έρευνας και Τεχνολογίας), Υπουργείο Παιδείας
- ECTN (European Chemistry Thematic Network)
- EPS (European Peptide Society)
- Νομαρχιακή Αυτοδιοίκηση Αχαΐας
- Δήμος Πατρέων

Σύντομο Βιογραφικό Σημείωμα
Καθηγητή Γιάννη Μ. Ματσούκα

Ο Γιάννης Μ. Ματσούκας γεννήθηκε στην Πάτρα. Απεφοίτησε από το 1° Γυμνάσιο Πατρών και το 1971 έλαβε το Πτυχίο Χημείας από το Πανεπιστήμιο Πατρών. Μετά την εκπλήρωση των στρατιωτικών του υποχρεώσεων το 1973 εντάχθηκε με υποτροφία στην ομάδα του Καθηγητή J. Findlay στο Τμήμα Χημείας του Πανεπιστημίου New Brunswick στον Καναδά, όπου εργάστηκε στην οργανική σύνθεση φυσικών προϊόντων στα πλαίσια εκπόνησης διατριβής για τον τίτλο Master's. Ο τίτλος της διατριβής του ήταν "Total Synthesis of Epiramulosin. Το 1976 εντάχθηκε στην ερευνητική ομάδα του Καθηγητή Δ. Θεοδωρόπουλου στο Τμήμα Χημείας του Πανεπιστημίου Πατρών και το 1979 αναγορεύθηκε Διδάκτωρ Χημείας με αντικείμενο διατριβής στην Πεπτιδική Σύνθεση και Φασματοσκοπία Πυρηνικού Μαγνητικού Συντονισμού. Από το 1981 έως το 1984 εργάστηκε ως μεταδιδακτορικός ερευνητής στα Πανεπιστήμια New Brunswick και Calgary του Καναδά και στην συνέχεια ώς Επισκέπτης Καθηγητής στο Πανεπιστήμιο Calgary (Visiting Professor), το οποίο επισκέπτετο σε ετήσια βάση επί εικοσαετία. Η έρευνά του ήταν αντίστοιχα σε Ολική Σύνθεση (Total Synthesis), Απομόνωση-Ταυτοποίηση-Βιολογική Αξιολόγηση Φυσικών Προϊόντων (New Brunswick) και στη συνέχεια σε Πεπτιδική Σύνθεση-Φασματοσκοπική Ανάλυση-Βιολογική Αξιολόγηση της αγγειοδιασταλτικής πεπτιδικής ορμόνης Αγγειοτενσίνη (Calgary). Η εξέλιξή του στις βαθμίδες Επίκουρου, Αναπληρωτή και Καθηγητή έγινε αντίστοιχα τα έτη 1985, 1990, 1995, ενώ έχει υπηρετήσει το Τμήμα Χημείας ώς Τομεάρχης του Ά Τομέα, ως Αναπληρωτής Πρόεδρος και ως Πρόεδρος.

Τα κύρια ερευνητικά ενδιαφέροντα του Καθηγητή Ι. Ματσούκα εστιάζονται στον Ορθολογικό Σχεδιασμό (Rational Design), την Σύνθεση (Οργανική και Πεπτιδική) και Βιολογική Αξιολόγηση Πεπτιδικών Αναλόγων και Μιμητών της Αγγειοτενσίνης, Επιτόπων της Μυελίνης και Δραστικών Αλληλουχιών του Υποδοχέα της Θρομβίνης και της GnRH, που εμπλέκονται αντίστοιχα στην Υπέρταση, Σκλήρυνση κατά Πλάκας και Καρκίνο. Έχει δημοσιεύσει άνω των τα 500 άρθρων (Δημοσιεύσεις, Πρακτικά Συνεδρίων, Άρθρα Βιβλίων, Μονογραφίες, Ανακοινώσεις). Οι δημοσιεύσεις του είναι σε περιοδικά της ειδικότητάς του με υψηλούς δείκτες απήχησης. Είναι Συντονιστής ενός μεγάλου Δικτύου Βιοϊατρικής Έρευνας στο οποίο συμμετέχουν ερευνητές πολλών εργαστηρίων από Ελλάδα και Εξωτερικό. Έχει επίσης συντονίσει πολλά Εθνικά και Κοινοτικά Προγράμματα Έρευνας και Ανάπτυξης Προϊόντων με Φαρμακευτικό ενδιαφέρον άνω των 10 εκατομυρίων ευρώ. Έχει δώσει σειρά διαλέξεων σε Σεμινάρια και Συνέδρια πολλών Πανεπιστημίων και Ερευνητικών Ιδρυμάτων διαφόρων χωρών και έχει αναπτύξει συνεργασίες με ερευνητικά Ιδρύματα σε Ελλάδα και Εξωτερικό. Έχει επιβλέψει 25 Διδακτορικά Διπλώματα, 28 Διπλώματα Ειδίκευσης (Master's) και άνω των 150 Διπλωματικών Εργασιών τεταρτοετών φοιτητών, σε πρωτότυπα ερευνητικά αντικείμενα, ενώ έχει συμμετάσχει σε μεγάλο αριθμό Συμβουλευτικών Τριμελών Επιτροπών Παρακολούθησης Μεταπτυχιακών Φοιτητών.

Έχει βραβευθεί από την Ακαδημία Αθηνών το 1999 για εξαίρετη έρευνα στο σύστημα Ρενίνης – Αγγειοτενσίνης και από τον Οργανισμό Βιομηχανικής Ιδιοκτησίας (ΟΒΙ) για Δίπλωμα Ευρεσιτεχνίας του (4/10/2004). Έχει πολλές διακρίσεις για το ερευνητικό του έργο στην Ελλάδα και το Εξωτερικό από την Διεθνή Ακαδημαϊκή Κοινότητα και την Τοπική Κοινωνία. Είναι πρωτοπόρος στην ανάπτυξη της Τεχνολογίας Μιμητών Πεπτιδίων- η οποία αποτελεί μια Νέα γεννια Φαρμακευτικών Προϊόντων-και την οποία Τεχνολογία έχει αναπτύξει με τον συνεργάτη του Καθηγητή Graham Moore του Πανεπιστημίου Calgary στον Καναδά.

Υπήρξε Επιστημονικός Υπεύθυνος και Διευθυντής του Μεταπτυχιακού Προγράμματος «Ιατρική Χημεία: Σχεδιασμός και Ανάπτυξη Φαρμακευτικών Προϊόντων» των Τμημάτων Χημείας, Ιατρικής και Φαρμακευτικής, το οποίο έχει αξιολογηθεί από το Υπουργείο Παιδείας ως Πρόγραμμα Αριστείας, το πρώτο που έχει λάβει τον τίτλο Euromaster. Το Πρόγραμμα έχει διοργανώσει δεκατέσσερα (14) Συνέδρια με Διεθνή συμμετοχή και έχει προσελκύσει το ενδιαφέρον κορυφαίων ερευνητών για το υψηλής στάθμης εκπαιδευτικό και ερευνητικό έργο που πραγματοποιεί. Μεταξύ των προσκληθέντων ήταν οι Νομπελίστες Jean-Marie Lehn, Andrew V. Scally, James D. Watson και Ada Yonath. Η ερευνητική του δραστηριότητα έχει αποφέρει στο Πανεπιστήμιο Πατρών και στην Πόλη χρηματατοδοτήσεις ύψους άνω των 10.000.000 € από τις οποίες έχει ωφεληθεί η Έρευνα στο Πανεπιστήμιο Πατρών, με την δημιουργία πολλών θέσεων εργασίας. Το ερευνητικό του έργο στο σύστημα Ρενίνης-Αγγειοτενσίνης (RAS) και οι Καινοτομικές Εργαστηριακές Συνθέσεις του (Σαρτάνες, Νέα Γενιά Αντι-υπερτασικών), αποτέλεσαν την βάση μιας μεγάλης επένδυσης από την Φαρμακευτική Εταιρεία ΒΙΑΝΕΞ με στόχο την αξιοποίησή των. Η επένδυση έγινε μέσω σύστασης Τεχνοβλαστού, ELDRUG, ο οποίος στεγάζεται στο Επιστημονικό Πάρκο Πατρών και στον οποίο συμμετέχουν συνεργάτες του ερευνητές καθώς και το Πανεπιστήμιο Πατρών. Ο κ. Ματσούκας έχει διδάξει Οργανική Χημεία και Φασματοσκοπία Πυρηνικού Μαγνητικού Συντονισμού, σε προπτυχιακούς και μεταπτυχιακούς φοιτητές. Είναι παντρεμένος με τρία παιδιά.

Περίληψη - Σύνοψη
Ακαδημαϊκών Δραστηριοτήτων – Βραβεύσεων
Διακρίσεων Καθηγητή Χημείας Γιάννη Ματσούκα
και της Ερευνητικής του Ομάδας

1. Έχει βραβευθεί από την Ακαδημία Αθηνών και τον ίδιο τον Πρόεδρο της Δημοκρατίας κ. Κωστή Στεφανόπουλο για την εξαιρετική και διεθνώς πρωτοποριακή Έρευνα στο πεδίο του Συστήματος Ρενίνη-Αγγειοτενσίνη για νέα Προϊόντα, που έχει πραγματοποιήσει τόσο στον Καναδά στο Πανεπιστήμιο Calgary με τον συνεργάτη του Καθηγητή Graham Moore, όσο και στο Πανεπιστήμιο Πατρών με την ερευνητική του ομάδα.

2. Έχει βραβευθεί από τον Οργανισμό Βιομηχανικής Ιδιοκτησίας (OBI) του Υπουργείου Ανάπτυξης και τον τότε Υπουργό Ανάπτυξης (2004) για Ευρεσιτεχνία του σε Καινοτομική Φαρμακευτική Έρευνα Νέων Εργαστηριακών Αντι-υπερτασικών Συνθέσεων.

3. Έχει βραβευθεί από την Νομαρχιακή Αυτοδιοίκηση Αχαΐας και τον Νομάρχη Αχαΐας για την προσφορά του στην Τοπική Κοινωνία και στο Ελληνικό Πανεπιστήμιο και για την προβολή του Πανεπιστημίου Πατρών και της πόλης στην Ελλάδα και Διεθνώς.

4. Έχει βραβευθεί από το Δήμαρχο Πατρέων και το Δημοτικό Συμβούλιο του Δήμου, με Εύφημο Μνεία, για το Ερευνητικό, Εκπαιδευτικό και Κοινωνικό του Έργο και την Προσφορά του στο Ελληνικό Δημόσιο Πανεπιστήμιο.

5. Έχει βραβευθεί από το Δήμο Ρίου, για την προσφορά του στην Έρευνα και στην Τεχνολογική Ανάπτυξη της περιοχής και της χώρας.

6. Διετέλεσε Πρόεδρος του Τμήματος Χημείας την Διετία 2005-2007 με έναν απολογισμό σημαντικού Διοικητικού Έργου και Έργων Υποδομής που πραγματοποιήθηκε σε πολύ μικρό χρονικό διάστημα επ' ωφελεία του Τμήματος και του Πανεπιστημίου, προβάλλοντας επίσης το Εκπαιδευτικό και Ερευνητικό Έργο του Τμήματος, το πρώτο Τμήμα που αξιολογήθηκε στο Πανεπιστήμιο Πατρών.

7. Το Ερευνητικό του έργο έχει φέρει στο Πανεπιστήμιο Πατρών και την Πόλη, χρηματοδοτήσεις (Εθνικές, Κοινοτικές, Επενδύσεις) ύψους άνω των 10.000.000 €, οι οποίες έχουν αναβαθμίσει το επίπεδο της Έρευνας στο Τμήμα Χημείας και στο Πανεπιστήμιο.

8. Έχει δημοσιεύσει περί τα 500 Άρθρα, (Δημοσιεύσεις, Πρακτικά Συνεδρίων, Βιβλία, Μονογραφίες και Ανακοινώσεις) σε έγκυρα Χημικά και Βιο-ιατρικά Επιστημονικά Περιοδικά της ειδικότητάς του, Υψηλού Συντελεστή Απήχησης (Impact Factor ~ 4-6) με άνω των 2.000 Αναφορών του Έργου του στην Διεθνή Βιβλιογραφία.

9. Έχει είκοσι έξι Ευρεσιτεχνίες, εγκεκριμένα Διπλώματα και υποβληθείσες Αιτήσεις Ευρεσιτεχνιών, από Διεθνείς Οργανισμούς Καινοτομίας και Ευρεσιτεχνίας που αφορούν Καινοτομικές Συνθέσεις και Μεθόδους. Στις Ευρεσιτεχνίες του έχουν γίνει μεγάλες επενδύσεις από Φαρμακευτικές Εταιρείες και το Δημόσιο, για την αξιοποίηση των Καινοτομιών και Προϊόντων της Ερευνητικής του ομάδας.

10. Έχει επιβλέψει 25 Διδακτορικά Διπλώματα, 28 Μεταπτυχιακά Διπλώματα Ειδίκευσης και άνω των 200 Διπλωματικών εργασιών.

11. Έχει δώσει μεγάλο αριθμό διαλέξεων σε Πανεπιστήμια και Ερευνητικά Ινστιτούτα σε διάφορες χώρες, Ευρώπη, Αυστραλία, ΗΠΑ, Καναδά, Ασία.

12. Υπήρξε Προσκεκλημένος Έκδότης (Guest Editor) Διεθνών Εκδόσεων έγκυρων Βιοϊατρικών Περιοδικών και Εκδοτικών Οίκων (όπως Current Medicinal Chemistry, Letter in Peptide Science (LIPS), Pharmacology and Pharmacokinetics, Drug Discovery and Design, Ios Press, Escom, Bentham, κ.α.), αφιερωμένων στην έρευνά του.

13. Το εξώφυλλο πολλών Επιστημονικών Εκδόσεων και Τευχών με Δημοσιεύσεις του, είναι αφιερωμένο σ' αυτές και το ερευνητικό του έργο (Cover Figures). (Current Medicinal Chemistry, Letters in Peptide Science, Pharmacology and Pharmacokinetics, IOS Press κ.α.).

14. Του έχει απονεμηθεί ο τίτλος του Επισκέπτη Καθηγητή (Adjunct Professor) από τα Πανεπιστήμια Virginia, Calgary και Μελβούρνης στις ΗΠΑ, στον Καναδά και στην Αυστραλία αντίστοιχα, λόγω της προσφοράς του και των πολλών και ευδόκιμων συνεργασιών του με εκεί ερευνητές.

. Είναι επικεφαλής και συντονίζει ένα Διεθνές Δίκτυο Βιοϊατρικής Έρευνας στον Σχεδιασμό, Σύνθεση και Ανάπτυξη Νέων Φαρμακευτικών Προϊόντων (Drug Design and Discovery) στο οποίο συμμετέχουν ερευνητές από πολές χώρες. Η Κοινοτική του Πρόταση BIOMED "Drug Discovery of Non Peptide Angiotensin II Mimetics, a New Generation of Antihypertensives" αξιολογήθηκε για χρηματοδότηση ως 2η μεταξύ 1000 περίπου Κοινοτικών Προτάσεων (1994-1997).

16. Το Διατμηματικό Μεταπτυχιακό Πρόγραμμα «Ιατρική Χημεία», του οποίου υπήρξε Διευθυντής και Επιστημονικός Υπεύθυνος επί 16 χρόνια, έχει προσελκύσει το ενδιαφέρον Κορυφαίων Παγκοσμίως Ερευνητών για συνεργασία μαζί του, μεταξύ των οποίων οι κ.κ. Κυριάκος Νικολάου, Αριστείδης Πατρινός, Χαράλαμπος Γαβράς, Χρήστος Πλατσούκας, Βάσω Αποστολοπούλου και πρόσφατα των Καθηγητών Jean-Marie Lehn (Nobel Χημείας), Andrew V. Schally (Nobel Ιατρικής), James Watson (Nobel Ιατρικής) και Ada Yonath (Nobel Χημείας).

17. Το ΜΠΣ «Ιατρική Χημεία» Βραβεύθηκε το 2010 με τον τίτλο Euromaster, μετά από αξιολόγησή του από την Ευρωπαϊκή Επιτροπή ECTN (*European Chemistry Thematic Network*). Είναι το πρώτο ΜΠΣ στην Ελλάδα που αποκτά αυτόν τον τίτλο.

18. Το ΜΠΣ «Ιατρική Χημεία» Βραβεύθηκε το 2012 για τη συμβολή του στην επίτευξη Αριστείας στο Ελληνικό Πανεπιστήμιο και έχει αναρτηθεί στον κόμβο Αριστείας του Υπουργείου Παιδείας (http://excellence.minedu.gov.gr/listing/106-graduateprogram). Το πρόγραμμα επελέγη από το Εθνικό Συμβούλιο Έρευνας και Τεχνολογίας (ΕΣΕΤ) και παρουσιάστηκε πρώτο μεταξύ 232 Δράσεων Αριστείας από όλα τα Πανεπιστημιακά και Ερευνητικά Ιδρύματα της χώρας στην Ημερίδα με τίτλο «Ο θεσμός της Αριστείας στην Ανώτατη Εκπαίδευση» που πραγματοποιήθηκε στο Υπουργείο Παιδείας στις 17 Δεκεμβρίου 2012.

19. Το ΜΠΣ "Ιατρική Χημεία" έχει μια εξαιρετική διαδρομή στην εκπαίδευση και την έρευνα. Έχει διοργανώσει δεκατέσσερα Συνέδρια με Διεθνή Συμμετοχή, με θετικό αντίκτυπο στην Κοινωνία και στην ευρύτερη Πανεπιστημιακή Κοινότητα, και έχει προσελκύσει Κορυφαίους Ερευνητές όπως οι Καθηγητές Ada Yonath (Nobel Χημείας) (2013), Κλεομένης Μπάρλος (2012), James D. Watson (Nobel Ιατρικής) (2011), Andrew Schally (Nobel Ιατρικής) (2010), Δημήτριος Νανόπουλος (2009), Jean-Marie Lehn (Nobel Χημείας) (2008), Κυριάκος Νικολάου (2007), Άρης Πατρινός (2006), Χαράλαμπος Γαβράς (2005), Κωνσταντίνος Σέκερης (2004), Μιχάλης Μαραγκουδάκις (2003), Χρήστος Πλατσούκας (2002), Αθανάσιος Γιάννης (2001) και Βάσω Αποστολοπούλου (2000), οι οποίοι έχουν Τιμηθεί από το Πρόγραμμα και συνεργάζονται με τους ερευνητές του. Στην διάρκεια λειτουργίας του Προγράμματος (1998-2013) έχουν αποφοιτήσει περίπου 250 Μεταπτυχιακοί Φοιτητές του με Μεταπτυχιακό Δίπλωμα Ειδίκευσης και Διδακτορικό Δίπλωμα, με λαμπρές Ακαδημαϊκές και Επαγγελματικές Σταδιοδρομίες στην Ελλάδα και το Εξωτερικό. Έχουν προκύψει εκατοντάδες δημοσιεύσεις και πολλές ευρεσιτεχνίες των Μεταπτυχιακών Φοιτητών και των Ερευνητών του, στα πλαίσια των διατριβών του Προγράμματος, οι οποίες έχουν συμβάλλει στην Αναβάθμιση.

20. Η Έρευνά του έχει προσελκύσει το ενδιαφέρον της ΒΙΑΝΕΞ, μιας των μεγαλυτέρων Φαρμακευτικών Βιομηχανιών στην Ελλάδα, της οικογένειας Παύλου, Αθανάσιου και Κωνσταντίνου Γιαννακόπουλου, με αποτέλεσμα την σύσταση της ELDRUG, Τεχνοβλαστού Υψηλής Τεχνολογίας στην ανάπτυξη Αντι-υπερτασικών Προϊόντων και προϊόντων για την Σκλήρυνση κατά Πλάκας, η οποία στεγάζεται στο Επιστημονικό Πάρκο Πατρών. Η επένδυση, η μεγαλύτερη από Ελληνική Φαρμακευτική Εταιρεία σε Ελληνική Ερευνητική Ομάδα, έχει δημιουργήσει πολλές νέες θέσεις εργασίας χημικών (δέκα) και προσωπικού και έχει επιτρέψει την απόκτηση Εξοπλισμού Υψηλής Τεχνολογίας μοναδικού για την Ελλάδα ο οποίος επιτρέπει την Ανάλυση, Ταυτοποίηση και Σύνθεση των Νέων Συνθέσεων με μεγάλες προοπτικές για πρώτη φορά Κλινικών Δοκιμών, Ανάπτυξης και Αξιοποίησης διεθνώς Ελληνικών Προϊόντων και Τεχνολογίας.

21. Έγκριση Έργου του Προγράμματος "Συνεργασία" της ΓΓΕΤ, με τη τρίτη μεγαλύτερη βαθμολογία (92/100) και με τη μεγαλύτερη χρηματοδότησή, 3.000.000€, από όλα τα εγκριθέντα προγράμματα Πανελλαδικά και σε σύνολο 620 υποβληθέντων προτάσεων. Το Έργο αφορούσε την ανάπτυξη Δραστικής Φαρμακευτικής Ύλης .

22. Βραβεύσεις δύο Έργων Έρευνας και Ανάπτυξης Φαρμακ/ων Προϊόντων στον Πανελλήνιο Διαγωνισμό Εφαρμοσμένης Έρευνας και Καινοτομίας, "Η Ελλάδα Καινοτομεί" του ΣΕΒ και Ομίλου Eurobank. Τα δύο Έργα προκρίθηκαν στα 10 καλύτερα Εφαρμοσμένης Έρευνας μεταξύ 310 έργων συνολικά υποβληθέντων.

23. Έχει Προσκληθεί στην Βουλή των Ελλήνων το 2010 για Ενημέρωσή της και έχει μιλήσει στην Ειδική Μόνιμη Διακομματική Επιτροπή Έρευνας και Τεχνολογίας της Βουλής (23 Μαρτίου 2010) και στην Επιτροπή Κοινωνικών Υποθέσεων (28 Απριλίου 2010). Οι Ομιλίες του με έμφαση στην Καινοτομία και Ανάπτυξη και με Τίτλο: «Ανταγωνιστικά Φαρμακευτικά Προϊόντα Υψηλής Τεχνολογίας στην Υπηρεσία της Υγείας και Κοινωνίας:

Η Ελληνική Συμβολή» απέσπασαν την επιδοκιμασία του συνόλου σχεδόν των παρισταμένων Βουλευτών, ως Έργο που τιμά την Ελλάδα.

<u>Δηλώσεις Κορυφαίων Διεθνώς Ερευνητών για το Ερευνητικό Έργο του Ι. Ματσούκα και το ΜΠΣ "Ιατρική Χημεία":</u>

James D. Watson (Cold Spring Harbor Laboratory):
"My visit for the 12th Med Chem Conference was a memorable one. Congratulations for an excellent activity"

Κυριάκος Νικολάου (Scripps Research Institute, U.S.A.):
"Τα πιο θερμά συγχαρητήρια για αυτά τα σπουδαία που κάνεις και για την μεγάλη σου συμβολή στην ανάπτυξη της Χημείας στην Ελλάδα".

Δημήτριος Νανόπουλος (Texas AM University U.S.A.):
" Τα πιο θερμά μου συγχαρητήρια σε εσάς και την ερευνητική σας ομάδα, για την διεθνή αναγνώριση του ερευνητικού σας έργου".

Άρης Πατρινός (Synthetic Genomics, U.S.A., τ. Πρόεδρος Κέντρου Έρευνας και Τεχνολογίας U.S.A.):
" Είναι μεγάλη τιμή για μένα να συνεργάζομαι με την ερευνητική σου ομάδα."

Βάσω Αποστολοπούλου (Austin Research Institute, Αυστραλία):
" Θερμά συγχαρητήρια για την αέναη προσπάθειά σου και το σπουδαίο σου έργο. Είσαι ένας Πρεσβευτής για όλους τους Φοιτητές και Ερευνητές στην Ελλάδα".

Οι Υπογράφοντες

Παναγιωτάκης Γιώργος Καθηγητής

Μπέλλος Χλεομένης " Κλεάνθης

Περλέπες Δημήτριος " Περλέπες



σε τραπεζικό δανεισμό.

Τα ενεχυροδανειστήρια σε αυτές τις περιπτώσεις επιτελούσαν τον «κοινωνικό τους ρόλο» και έβγαζαν από το αδιέξοδο ανθρώπους απελπισμένους.

Σήμερα, οι συναλλαγές με τα ενεχυροδανειστήρια έχουν **πολλαπλασιαστεί**. Και φαίνεται πως δεν τα επισκέπτεται πλέον μόνο η λεγόμενη κατώτερη οικονομική τάξη, αλλά άνθρωποι

έχουν φτάσει στά όριά τους, έχουν αυξήσει το χρέος τους και δεν βρίσκουν λύση απλά ρευστοποιώντας δαχτυλίδια ή καδένες. Πάνε για πολύ μεγαλύτερα ποσά. Έτσι προτίθενται να πάρουν το ρίσκο να χάσουν κάποιο περιουσιακό τους στοιχείο, προκειμένου να βρουν τα χρήματα που χρειάζονται. Αυτές οι περιπτώσεις έχουν αυξηθεί πολύ. Συνήθως είναι επιχειρηματίες ηλικίας 40-50 ετών που έχουν βρει κλειστές τις κάνουλες χρηματοδότησης από τις τράπεζες και αδυνατούν να ανταποκριθούν στις οφειλές τους», μας δηλώνουν ενεχυροδανειστές.

» ΠΑΡΕΜΒΑΣΗ ΤΣΕΛΕΝΤΗ ΓΙΑ ΜΑΤΣΟΥΚΑ:

«Ευτυχώς... πρόλαβα και έφυγα»

Ο σεισμολόγος στο πλευρό του καθηγητή Χημείας που τον «τιμώρησαν» και δεν τον έκαναν ομότιμο

Εντονες οι αντιδράσεις στην Πανεπιστημιακή Κοινότητα *μετά τις αποκαλύψεις του «Κόσμου»* για τον τρόπο με τον οποίον «πέταξαν» εκτός, τον καθηγητή Χημείας **Γιάννη Ματσούκα** από το Πανεπιστήμιο Πατρών, μη αποδεχόμενοι να τον κάνουν ομότιμο καθηγητή, έστω και αν τον είχε προτείνει **ο ίδιος ο πρύτανης Γιώργος Παναγιωτάκης**! Ο ίδιος ο καθηγητής μιλώντας **στον Max Fm** έκανε λόγο για σαφή δίωξή του, καίτοι το επιστημονικό του έργο είναι διεθνώς αναγνωρισμένο, ενώ ο ίδιος κατάφερε και έφερε στην Πάτρα διεθνείς προσωπικότητες από το χώρο της επιστήμης, όπως τον Νομπελίστα **Watson** κ.α.

Από την πλευρά του Τμήματος Χημείας πάντως δεν **υπήρξε καμία απάντηση**! Ούτε στα όσα διαδίδονται στο διαδίκτυο πως καθηγητής που συνελήφθη να κάνει σεξ με φοιτήτρια στις τουαλέτες της σχολής, έμεινε... ατιμώρητος, την ίδια ώρα που το τμήμα έχει αναστατωθεί και από τη μήνυση που έχουν υποβάλει τέσσερις καθηγητές εναντίον του κ. Ματσούκα για εξύβριση, **κάτι που ο ίδιος δεν αποδέχεται**.

Ωστόσο οι μηνυτές του επιμένουν και η συνέχεια θα δοθεί στο Δικαστήριο. Να υπενθυμίσουμε πως το Τμήμα Χημείας με ψήφους 17 κατά έναντι 10 υπέρ... δεν δέχθηκε να τον ανακηρύξει σε ομότιμο καθηγητή κάτι το οποίο συνηθίζεται για καθηγητές με **«βαρύ βιογραφικό»** όπως αυτό του κ. Γιάννη Ματσούκα.

Τι είχε τραβήξει ο Τσελέντης

Στο μεταξύ παρέμβαση για το θέμα έκανε και ο καθηγητής σεισμολογίας **Άκης Τσελέντης** ο οποίος δημοσίως υπερασπίστηκε τον καθηγητή Γιάννη Ματσούκα. Ο γνωστός σεισμολόγος δήλωσε τα εξής:

«Ευτυχώς πρόλαβα και έφυγα. Άλλωστε εμένα μου το είπε κατάμουτρα ο τότε πρόεδρος του Γεωλογικού και πολέμιος της δημιουργίας Σεισμολογικού Ινστιτούτου "δε θα σε κάνουμε ομότιμο όταν τελειώσεις τη καριέρα σου!" Ποσώς με νοιάζει έχει και αλλού πορτοκαλιές που κάνουν λωτούς όχι λεμόνια» απάντησε ειρωνικά ο καθηγητής. Αναφερόμενος σε όσα συνέβησαν στο Χημικό δήλωσε: *«Ο Καθηγητής Ματσούκας δόξασε το Πανεπιστήμιο αλλά βλέπετε κάποιοι ανίκανοι τον χτύπησαν κάτω απο τη μέση»*!



Συμφωνα με δηλώσεις του καθηγητή σεισμολογίας, στην δική του περίπτωση, έφτασαν στο σημείο μέσα στη γενική συνέλευση που συζητείτο το θέμα ίδρυσης ανεξάρτητου σεισμολογικού κέντρου κάτω από το Πανεπιστήμιο σύμφωνα με το νέο νόμο, να πουν *«δε χρειάζονται τόσοι σεισμολογικού σταθμοί, ας τους κλείσετε»*. Πληροφορίες αναφέρουν πως την συγκεκριμένη θέση έλαβε ο καθηγητής Γεωλογίας και υποψήφιος Ευρωβουλευτής με τους Ανεξάρτητους Ελληνες **Αβραάμ Ζελιλίδης**.

ΔΕΛΤΙΟ ΤΥΠΟΥ

15ο Συνέδριο Ιατρικής Χημείας – Απολογισμός

Τιμή σε έναν μεγάλο Ερευνητή και Φιλέλληνα
Ομιλία του Νομπελίστα Καθηγητή Ιατρικής Harald zur Hausen για το Πρώτο Αντικαρκινικό Εμβόλιο
Ομιλία της Καθηγήτριας Βάσως Αποστολοπούλου για την πρόοδο στην Αντικαρκινική Έρευνα

Στην κατάμεστη κεντρική αίθουσα του Συνεδριακού και Πολιτιστικού Κέντρου του Πανεπιστημίου Πατρών, πραγματοποιήθηκε με μεγάλη επιτυχία το **15ο Συνέδριο Ιατρικής Χημείας** στις **10 Απριλίου 2014.** Το 15ο Συνέδριο χαιρέτισαν με Συγχαρητήρια Μηνύματα ο Πρόεδρος του Συμβουλίου Ιδρύματος του Πανεπιστημίου Πατρών, **κ. Χαράλαμπος Γαβράς**, ο Πρύτανης του Πανεπιστημίου, **κ. Γεώργιος Παναγιωτάκης**, ο **Andrew V. Schally**, βραβευμένος με Nobel Ιατρικής και Φυσιολογίας και η **Ada Yonath**, βραβευμένη με Nobel Χημείας. Τα συγχαρητήρια μηνύματα αναφέρονταν επίσης στην επέτειο για τα 50 χρόνια του Πανεπιστημίου Πατρών.

Κεντρικός ομιλητής ήταν ο **Harald zur Hausen**, Καθηγητής Ιατρικής στο Πανεπιστήμιο Χαϊδελβέργης της Γερμανίας, ο οποίος βραβεύθηκε με **Nobel Ιατρικής και Φυσιολογίας** το 2008, για την έρευνά του στο ρόλο του ιού των ανθρωπίνων θηλωμάτων (HPV) και των λοιμώξεων στην καρκινογένεση. Στην ομιλία του, περιέγραψε με γλαφυρότητα την έρευνά του, η οποία οδήγησε στο πρώτο αντικαρκινικό εμβόλιο για τον καρκίνο του τραχήλου της μήτρας.

Ο Καθηγητής **Harald zur Hausen** αναγορεύθηκε **Επίτιμος Διδάκτορας** του Τμήματος Ιατρικής του Πανεπιστημίου Πατρών. Η αναγόρευση έγινε την Πέμπτη, 10 Απριλίου 2014, στις 10:00, στην Αίθουσα Τελετών του Πανεπιστημίου Πατρών και πραγματοποιήθηκε από την Κοσμήτορα της Σχολής Επιστημών Υγείας, κα Βενετσάνα Κυριαζοπούλου. Την τελετή χαιρέτισαν με ομιλίες τους ο Πρόεδρος του Τμήματος Ιατρικής, Καθηγητής κ. Παναγιώτης Γκούμας και ο Καθηγητής του Τμήματος Ιατρικής κ. Παναγιώτης Παπαθανασόπουλος, ο οποίος στην παρουσίαση του τιμώμενου, τον χαρακτήρισε "Ευεργέτη της Γυναίκας και της Ανθρωπότητας".

Στην παρουσίαση κατά την Αναγόρευση υπογραμμίστηκε ότι ο Καθηγητής **Hausen** διακρίνεται από φιλελληνικά αισθήματα, καθώς πρωτοστάτησε στην υποστήριξη της Ελλάδας και των Ελληνικών Πανεπιστημίων, αποστέλλοντας επιστολή στην Ευρωπαϊκή Ηγεσία, με τίτλο **"Support for Greece".** Την επιστολή, που δημοσιεύτηκε στο Science, συνυπέγραψαν 24 Νομπελίστες, μεταξύ των οποίων και οι **James D. Watson, Andrew V. Schally και Jean-Marie Lehn,** προσκεκλημένοι επίσης του ΜΠΣ **«Ιατρική Χημεία»** και του Πανεπιστημίου Πατρών σε προηγούμενα Συνέδρια του Μεταπτυχιακού Προγράμματος.

Στο Συνέδριο συμμετείχε και η διακεκριμένη ερευνήτρια, Καθηγήτρια Ανοσολογίας στο Πανεπιστήμιο Victoria της Αυστραλίας, **κα Βάσω Αποστολοπούλου**, η οποία αναφέρθηκε στην έρευνα για την ανάπτυξη **Αντικαρκινικού Εμβολίου στην προστασία Ωοθηκών και Μαστού.** Στην ομιλία της αναφέρθηκε ειδικότερα στη γνώση που έχει αποκτηθεί τα τελευταία χρόνια στην ανάπτυξη εμβολίων και στα αποτελέσματα κλινικών δοκιμών του αντικαρκινικού εμβολίου CVac (Cancer Vaccine). Το προϊόν, αποτέλεσμα της έρευνάς της στην Αυστραλία, έχει ήδη ελεγχθεί με επιτυχία σε κλινικές δοκιμές Φάσης I, II και III και έχει εγκριθεί σαν θεραπευτικό εμβόλιο σε συγκεκριμένες χώρες. Η κα Αποστολοπούλου αναφέρθηκε επίσης στη συνεργασία της με Ερευνητές των Τμημάτων Χημείας και Ιατρικής του Πανεπιστημίου Πατρών, στην έρευνα που στοχεύει στην ανάπτυξη ανοσοθεραπευτικού εμβολίου για τη Σκλήρυνση κατά Πλάκας.

Ο Διευθυντής του Μεταπτυχιακού Προγράμματος, Καθηγητής Χημείας κ. **Κλεομένης Μπάρλος** αναφέρθηκε στην ομιλία του στη Σύνθεση καινοτομικών παραγώγων της Ινσουλίνης στην Έρευνα για τον Διαβήτη. Ο Καθηγητής Χημείας κ. **Γιάννης Ματσούκας**, η συνεργάτης του Διδάκτωρ κα **Μαριλένα Ανδρούτσου** και η Ερευνήτρια κα **Lesley Probert** του Ινστιτούτου Pasteur αναφέρθηκαν στην πρόοδο των προκλινικών δοκιμών της Ελμυελίνης που στοχεύει στη θεραπεία της Σκλήρυνσης κατά Πλάκας. Στο Συνέδριο συμμετείχαν επίσης Ερευνητές, οι οποίοι σε σύντομες και επικεντρωμένες στον ερευνητικό στόχο ομιλίες παρουσίασαν την πρόοδο, τα αποτελέσματα και τις εφαρμογές των μελετών τους. Οι Ομιλητές ήταν οι κ.κ. **Δ. Βλαχάκος, Θ. Χριστόπουλος, Θ. Μαυρομούστακος, K. Akinosoglou, Α. Τζάκος, Ε. Μαργιωλάκη, Γ. Ρασσιάς, Σ. Χατζηκακού.**

Μετά τις ομιλίες του Καθηγητή Hausen και της κας Αποστολοπούλου, ακολούθησε ένα θαυμάσιο μουσικό διάλειμμα με μελωδίες του διακεκριμένου συνθέτη **Μίμη Πλέσσα** από τη Χορωδία του Πανεπιστημίου Πατρών υπό τη Διεύθυνση της **Λίνας Γερονίκου** και με τη συμμετοχή των ερμηνευτών **Σπύρου Κλείσσα, Κωνσταντίνας Φαλίδα** και του **Νάσσου Σωπύλη** στα πλήκτρα. Ο Μίμης Πλέσσας με ιδιαίτερη χαρά και ενθουσιασμό συμμετέχει ανελλιπώς στα Συνέδρια Ιατρικής Χημείας τα τελευταία χρόνια.

Στη συνέχεια, απενεμήθη από το Διευθυντή του Προγράμματος **κ. Κλεομένη Μπάρλο** και εκ μέρους του Πρύτανη του Πανεπιστημίου, Δίπλωμα Τιμής στον Καθηγητή **Hausen** για την προσφορά του στην Επιστήμη και στην Κοινωνία. Αναμνηστικά Διπλώματα δόθηκαν επίσης στην κα **Αποστολοπούλου** και στον κ. **Πλέσσα**.

Το Μεταπτυχιακό Πρόγραμμα «Ιατρική Χημεία» έχει προσκαλέσει παγκοσμίου κύρους ερευνητές ως κεντρικούς ομιλητές στα ετήσια συνέδριά του, μεταξύ των οποίων και οι κάτοχοι Nobel, **James D. Watson** (Ανακάλυψη Διπλής Έλικας DNA), **Andrew V. Schally**, **Jean-Marie Lehn** και **Ada Yonath**. Ο **Harald zur Hausen** είναι ο πέμπτος κατά σειρά κάτοχος Nobel που προσκαλείται από το Μεταπτυχιακό Πρόγραμμα.

John Matsoukas

From: John Matsoukas [imats@upatras.gr]
Sent: Παρασκευή, 13 Ιουνίου 2014 3:07 μμ
To: 'tovima@upatras.gr'
Cc: 'rector@upatras.gr'; 'upcouncil@upatras.gr'
Subject: Απόρριψη Πρότασης Ομοτιμοποίησης – Αγωγή

ΠΑΝΕΠΙΣΤΗΜΙΑΚΗ ΕΝΗΜΕΡΩΣΗ
Προς Ακαδημαϊκή Κοινότητα

Υπόψη: Πρύτανης, Πρόεδρος και Μέλη Συμβουλίου Ιδρύματος

Θέμα: Απόρριψη Πρότασης Ομοτιμοποίησης – Αγωγή

Συνάδελφοι,

Η Γενική Συνέλευση του Τμήματος Χημείας στις 10 Ιουνίου 2014 – σε μια μελανή διαδικασία για την ιστορία του Τμήματος – απέρριψε Πρόταση Ομοτιμοποίησής μου, η οποία ήταν υπογεγραμμένη από τον Πρύτανη του Πανεπιστημίου Πατρών και δύο διακεκριμένους συναδέλφους.

Για την ιστορία θα ήθελα να γνωρίσω στην Πανεπιστημιακή Κοινότητα τα εξής:

- **Η Ομοτιμοποίησή μου είναι το λιγότερο που με ενδιαφέρει.** Το Έργο μου και η Προσφορά μου στο Ελληνικό Δημόσιο Πανεπιστήμιο είναι γνωστά στην Πανεπιστημιακή Κοινότητα και στην ευρύτερη κοινωνία και δεν αποτιμώνται με τίτλους.

- **Εκείνο που με ενδιαφέρει**, και είναι αγωνία και των συνεργατών μου, είναι η συνέχεια ενός Έργου, το οποίο τιμά το Πανεπιστήμιό μας και το οποίο συνδέεται με την Κοινωνία και την Ανάπτυξη στην Χώρα. Αυτό το Έργο δυστυχώς κάποιοι θέλουν βίαια να διακόψουν.

- Με την έναρξη της συζήτησης της Πρότασης στην Γενική Συνέλευση του Τμήματος, οι κ.κ. Καλλίτσης και Καραμάνος κατέθεσαν αντίγραφο αγωγής που υποβλήθηκε εναντίον μου στις 29 Μαΐου 2014, για φανταστική στιχομυθία στις 17 Οκτωβρίου 2013. Την αγωγή κατέθεσαν οι κ.κ. Κουμπιάς, Καραμάνος, Καλλίτσης, Μπούρας.

- Η αγωγή, η οποία έγινε με καθυστέρηση επτά μηνών με στόχο την αποτροπή της προφανούς και αυτονόητης Ομοτιμοποίησής μου, στηρίχθηκε σε **ΨΕΥΔΗ** και **ΑΝΥΠΑΡΚΤΑ** στοιχεία και σε **ΦΑΝΤΑΣΤΙΚΗ** στιχομυθία, που δεν έγινε ποτέ. Ο απώτερος στόχος των – με προφανή την εμπάθεια στο πρόσωπό μου – ήταν η εκδίωξή μου από το Πανεπιστήμιο και η ακύρωση του Έργου μου.

- Η συζήτηση στη Γενική Συνέλευση επί της Ομοτιμοποίησής μου **δεν στηρίχτηκε στο Ερευνητικό Έργο, το Βιογραφικό και την Προσφορά μου**, αλλά αντίθετα η όλη συζήτηση εξετράπη σε **λασπολογία** εις βάρος μου από συγκεκριμένα μέλη ΔΕΠ του Τμήματος, που οδήγησε στην απόρριψη.

- Ο κ. Καραμάνος, ο οποίος έχει επιλεγεί ως υποψήφιος Αντιπρύτανης της κας Κυριαζοπούλου, θα κληθεί στο δικαστήριο, προκειμένου να εξηγήσει τις πράξεις και τις ενέργειές του εναντίον μου.

- Προφανώς, τον λόγο έχει πλέον η **ΔΙΚΑΙΟΣΥΝΗ**, προκειμένου να προστατευθούν η Αξιοπρέπεια του Πανεπιστημίου και το Έργο της ερευνητικής μου ομάδας, που είναι και Έργο του Πανεπιστημίου.

Συνάδελφοι, οι κρίσεις δικές σας.

Στο ακόλουθο link θα βρείτε την Πρόταση Ομοτιμοποίησης και Περίληψη Ακαδημαϊκών Δραστηριοτήτων.
http://goo.gl/2AI94t

Γιάννης Ματσούκας
Καθηγητής Χημείας

John Matsoukas

From: John Matsoukas [imats@upatras.gr]
Sent: Παρασκευή, 27 Ιουνίου 2014 1:04 μμ
To: 'tovima'
Subject: Κριτήρια για Ομοτιμοποίηση Καθηγητών – Πρόταση

Πανεπιστημιακή Ενημέρωση

Σας γνωρίζω επιστολή μου στον Πρύτανη, σχετικά με τα Κριτήρια Ομοτιμοποίησης, όπως ισχύουν διεθνώς.

Γιάννης Ματσούκας

Πρύτανη Πανεπιστημίου Πατρών
Κύριο Γεώργιο Παναγιωτάκη

Υπόψη: Επιτροπή Οργανισμού, Αναπληρωτές Πρύτανη, Κοσμήτορες, Συμβούλιο Ιδρύματος

Θέμα: Σχέδιο Οργανισμού Πανεπιστημίου Πατρών 2014 – Κριτήρια για Ομοτιμοποίηση Καθηγητών (Άρθρο Ε17, σελ. 45) – Πρόταση

Κύριε Πρύτανη,

Στα πλαίσια της διαβούλευσης για τον Οργανισμό του Πανεπιστημίου, προτείνονται τα ακόλουθα για το άρθρο Ε17 που αφορά τα κριτήρια Ομοτιμοποίησης Καθηγητών του Πανεπιστημίου.

Η Ομοτιμοποίηση πρέπει να γίνεται με Ακαδημαϊκά Κριτήρια, όπως ισχύει διεθνώς και όπως έχουν σωστά θεσπιστεί σε Απόφαση της Σχολής Θετικών Επιστημών για την Ομοτιμοποίηση Καθηγητών.

Συγκεκριμένα, στην απόφαση της ΣΘΕ, έχουν θεσπιστεί τα ακόλουθα κριτήρια:

- Η ευδόκιμη ολοκλήρωση της θητείας του υποψηφίου, με θετική συμβολή στο ακαδημαϊκό κύρος του Τμήματος και του Πανεπιστημίου.
- Η διαρκής παρουσία στο Τμήμα και η ενεργή συμβολή στην ανάπτυξη, λειτουργία, και διοίκησή του.
- Η διαρκής και ενεργή συμβολή στο διδακτικό έργο του Τμήματος και του Πανεπιστημίου. Η αξιολόγηση του υποψηφίου κατά την τελευταία πενταετία εκ μέρους των φοιτητών δεν θα πρέπει να είναι κατώτερη από το μέσο όρο εκείνης των μελών του Τμήματός του.
- Το διεθνώς αναγνωρισμένο επιστημονικό έργο (όπως τεκμηριώνεται από δημοσιεύσεις σε διεθνή περιοδικά και σε πρακτικά συνεδρίων υψηλού κύρους με σύστημα κριτών, ετεροαναφορές, συμμετοχή σε συμβούλια επιστημονικών περιοδικών, συνεδρίων, εκδόσεων κ.ά.). Πιο συγκεκριμένα, πρέπει ο αριθμός των εργασιών του υποψηφίου που έχουν δημοσιευθεί σε διεθνή επιστημονικά περιοδικά και σε πρακτικά συνεδρίων υψηλού κύρους (με σύστημα κριτών), καθώς και ο αριθμός των ετεροαναφορών του, να είναι υψηλότεροι από τους αντίστοιχους μέσους όρους των καθηγητών του Τμήματος ή τους μέσους όρους των καθηγητών του ιδίου επιστημονικού πεδίου σε αντίστοιχα Τμήματα Ελληνικών Πανεπιστημίων.
- Η καθοδήγηση ικανού αριθμού υποψηφίων διδακτόρων στο Τμήμα.

Η Γ.Σ. ενός Τμήματος δεν είναι Λαϊκό Δικαστήριο.
Λαμβάνοντας υπόψη το κλίμα πίεσης που μπορεί να δημιουργηθεί στις χαμηλότερες βαθμίδες μελών ΔΕΠ ενός Τμήματος, θα πρέπει οι Προτάσεις Ομοτιμοποίησης που υπογράφονται από τρία μέλη ΔΕΠ, να αξιολογούνται από επταμελή επιτροπή με τη συμμετοχή εξωτερικών μελών, όπως γίνεται πλέον με τις

εξελίξεις των Μελών ΔΕΠ. Ακολούθως, η αξιολόγηση και η εισήγηση θα εγκρίνεται από την Κοσμητεία και τη Σύγκλητο.

Γιάννης Ματσούκας
Καθηγητής Χημείας

PROFESSOR JOHN M. MATSOUKAS

UNIVERSITY OF PATRAS

DEPARTMENT OF CHEMISTRY

CURRICULUM VITAE

2014

Curriculum Vitae

NAME: John Minas Matsoukas
CITIZENSHIP: Greece
MARITAL STATUS: Married, 3 children
ADDRESS: Department of Chemistry, University of Patras, Patras 26500, Greece (Office) –
Zisimopoulou 28, Agios Vasilios, Patras, Greece (Home)
TELEPHONE: (+30) 2610 911546, (+30) 2610 997180, 6932410564 (Mobile)
FAX: (+30) 2610 911545
E-mail: imats@chemistry.upatras.gr
WEBSITE: www.johnmatsoukas.gr, www.medicinalchemistry.gr, www.chemistry.upatras.gr

DEGREES:

B.Sc Honours, Chemistry, 1971, University of Patras, Greece
M.Sc Chemistry, 1975 University of New Brunswick, Canada - Ph.D. Chemistry, 1978 University of Patras, Greece

PROFESSIONAL EXPERIENCE:

- Postdoctoral Fellow, 1981 – 82, Department of Chemistry, University of New Brunswick, Fredericton NB, Canada
- Postdoctoral Fellow, 1982-84, Division of Pharmacology and Therapeutics, Faculty of Medicine, University of Calgary, Alberta, Canada
- Lecturer, 1984-85, Department of Chemistry, University of Patras, Greece
- Assistant Professor, 1985-1990, Department of Chemistry, University of Patras, Greece
- Associate Professor, 1990-1995, Department of Chemistry, University of Patras, Greece
- Professor, 1995 – today, Department of Chemistry, University of Patras, Greece
- Visiting and Adjunct Professor 1995, Division of Pharmacology and Therapeutics, Department of Medicinal Biochemistry, Faculty of Medicine, University of Calgary, Alberta, Canada
- Honorary Visiting Professor, Immunology and Vaccine Laboratory, Macfarlane Burnet Institute for Medical Research and Public Health, Melbourne, Australia, 2008
- Visiting and adjunet Professor 2009, Department of Immunology, Old Dominion University Virginia, U.S.A
- Sabbatical 1989-1990, Division of Pharmacology and Therapeutics, Department of Medical Biochemistry, Faculty of Medicine, University of Calgary, Alberta, Canada/Department of Chemistry and Natural Products, University of Hawaii, U.S.A.
- Constant Exchange and Visits for Lectures and Collaboration with Universities in several countries of Europe, U.S.A., Canada, Australia 1984-2008 (more than 200 lectures)

ADMINISTRATION EXPERIENCE:

- Head of Organic Chemistry, Biochemistry and Natural Products Division, 1997-1999, Department of Chemistry, University of Patras, GreeceVice
- Head of Department of Chemistry, 1999-2001, Department of Chemistry, University of Patras, Greece
- Acting Head of Department of Chemistry, 2001, Department of Chemistry, University of Patras, Greece
- Head of Department of Chemistry, 2005-2007, Department of Chemistry, University of Patras, Greece
- Member of the Rectorate, 1999-2001, 2005-2007, University of Patras, Greece
- Co-ordinator of International Biomedical Network in Drug Design (Thirty groups)
- Director and Head of Postgraduate Program Medicinal Chemistry: Drug Discovery and Design (1997-Present)

FUNDING of Professor Matsouka's research in Drug Discovery and Design:

- European Funds 1.500.000 €
- National Funds 6.000.000 €
  (Ministries of Development, Education, Health)
- Industry Funds 3.000.000 €

TOTAL: 10.500.000 €

AWARDS:

- Alberta Heritage Foundation for Medical Research, Fellowship Award, 1982-1984 • Medical Research Council (MRC) Canada Scholarship, 1989 • Bristol Myers Squibb Fellowship, 1990 • European Commission Award, 1994 • BACHEM Investigator's Award, 1998 • Academy of Athens Award (Award by Head of State, Premier Constantinos Stephanopoulos), 1999 • Leonidas Zervas Foundation Award, 2000 • Myelin European Network Co-ordinator, 2000 • Pharmaceutical Corporation ELPEN Award, 2003 • Ministry of Research and Development Award (Award by Minister of Development, Mr. Dimitrios Sioufas), 2004 • Patent Award, Patent Office Athens (Award by Minister of Development, Mr. Dimitrios Sioufas), 2004 • Achaia Prefecture State Award, Award by Governor of Achaia Prefect State Mr Dimitrios Catsicopoulos), 2004 • Patras City Council Award by Patras Mayor Mr Andrew Fouras, 2009 • Melbourne Conference Investigator's Award, 2005 • Member of the Journal Board, Review of Clinical Pharmacology and Pharmacokinetics (International Edition), 2000-2008 • Member of the University of Patras Rectorate, 2005-2007 • Who is Who Distinction 2009 • Du Pre Grant Award, Multiple Sclerosis, International Foundation, U.K. 2007 • Award for Multiple Sclerosis Research, Australia, 2009 • Distinguished Scientist Award, Magazine Best, March 30 2008 • ECTN Excellence Award, Athens, 2010 • Promitheas association, Award for Academic Contribution, 2010 • Synergasia Award, 2011 • Med. Chem. Graduate Conference Distinctions (James Watson), Ministry of Education, 2011 • Excellence Award for Med. Chem. Activities, Ministry of education, 2012 • "Greece Innovates", Award for Innovation in Multiple Sclerosis Research, Eurobank and Hellenic Federation of Enterprises, 2012 • "Greece Innovates", Award for Innovation in Hypertation, Eurobank and Hellenic Federation of Enterprises, 2012

- **Recent Awards- Achievements-Distinctions:**
  1) Medicinal Chemistry Program, coordinated by Prof. Matsoukas, has been evaluated by Ministry of Education, as a **Centre of Excellence** in Greece (2012).
  2) Medicinal Chemistry Program, coordinated by Prof. Matsoukas, has been evaluated by the European ECTN expert committee as a **Centre of Excellence** in Greece, awarded with the title of **Euromaster**, the first in the Country (2010).
  3) A Cooperation grant application (Industry-University), under his coordination, for the development of Elmyelin towards Phase I, II clinical trial, was evaluated with high marking 92/100, ranked third, and **awarded with the highest budget 3.000.000€,** among all 620 submitted proposals (2011).
  4) Professor Matsoukas is a Member of a Centre of Excellence for Structure-based **drug** Target Characterization: Strengthening the Research Capacity of **S**outh-**E**astern **E**urope» awarded with 3,586,420 euros in the framework of the European Program of Excellence FP7-regpot-2011-12.
  5) Two R&D proposals, under his coordination, regarding the development of Elmyelin (as vaccine drug in the immunotherapy of Multiple Sclerosis) and Elsartan (as transdermal drug in the treatment of Hypertention) were evaluated and **selected in the top 10 best proposals** among 320 submitted from all over Greece and **awarded** for their innovation in a National Contest of Applied Research and Innovation, organised by the Greek Enterprises Association and Eurobank (2011) (http://www.kainotomeis.gr).
  6) Prof. Matsoukas **was invited twice** in 2010 in the Greek Parliament to present his research findings and the social-economic perspectives. Work was considered of great importance (Press Release by the Greek Parliament) (2010).
  7) Prof. Matsoukas **has invited Nobel Laureate James D. Watson** (Double Helix DNA discovery) in the 12th Medicinal Chemistry Conference as the Guest Scientist. His historical lecture on the discovery of Double Helix was attended by more than 2.500 people from all over Greece (Watson Press Release, Minutes). His participation was a great honour for the University of Patras. Professor Matsoukas has invited also Nobel Laureates **Andrew Schally** (11th Medicinal Chemistry Conference) and **Jean Marie Lehn** (9th Medicinal Chemistry Conference) warmly accepted the Honor and the collaboration.
  8) Professor Matsoukas has incorporated in 2007 a spin off Company, ELDRUG, for the development of two potential drugs, Elsartan (antihypertensionsive transdermal drug) and Elmyelin (Multiple Sclerosis vaccine drug) towards phase I and II clinical evaluation. The Company so far has attracted investments by VIANEX (3.000.000€), SYNERGASIA- GSRT (3.000.000€) and Ministry of Development (720.000€)

SHORT CV

Professor J. Matsoukas (married with three children, two sons, one daughter) was born, June 1st 1946, in Patras, Greece where he grew up. In 1966 he entered University of Patras where he studied Chemistry for four years, graduating with a Honors B.Sc. degree. During the period 1971-73 he served his country as a military officer. In 1973 he entered University of New Brunswick in Canada and graduated in 1978 with a M. Sc. Degree in Chemistry. His dissertation was in the Total Synthesis of Natural Products (Ramulosin). In the period 1976-9 he carried out his Ph.D studies in the University of Patras, Greece under the supervision of Professor D. Theodoropoulos in the Synthesis and Conformational Studies of peptide hormone ANG II and its active fragments. In 1979 joined the Department of Chemistry, University of Patras as Research NMR and Synthesis Specialist. In 1981 joined the University of Calgary, Alberta, Canada after he has been offered a post doctoral scholarship to work with Professor G. Moore. He worked for three years 1981-4 at the Medical Biochemistry and Pharmacology and Therapeutics Departments of the University on the Synthesis and Conformational Analysis of Angiotensin II and analogues and returned in Patras as lecturer at the Department of Chemistry, University of Patras, Greece. His collaboration with Professor Moore resulted in important findings for Science, among them a Conformational Model of the Peptide Hormone Angiotensin revealing mechanism of action for non peptide drug design appeared in highly regarded journals (JBC, JMC, CMC). From 1985 till presently, he yearly visited the University of Calgary, collaborating with Professor Moore in a number of projects towards the rational design of non-peptide mimetics for important peptides, protein active sequences and epitopes such as Angiotensin, ANG II (Hypertension Research), Thrombin Receptor Activating Peptides, TRAP (Angiogenesis and Cancer Research) Gonadotropin Releasing Hormone, GnRH (Infertility and Cancer) and Myelin Proteins MBP, PLP, MOG (Multiple Sclerosis Research). He is a full Professor in this University since 1995 and has been elected as Head of the Department of Chemistry for the period 2005-2007.

SCIENTIFIC LEADERSHIP PROFILE

SELF EVALUATION:

In recent years, Professor Matsoukas has propelled the field of Drug Discovery and Design to new hights. His outstanding achievements include the discovery of Sarmesin as the first type II Angiotensin II peptide antagonist, following after the type I antagonist Sarilesin, as well as methodology and the rational design and synthesis of an array of non-peptide mimetics and novel cyclic peptides, most of which exhibit important biological properties. Cyclic peptides, compared to linear peptides, have greater potential as therapeutic agents due to their increased chemical and enzymatic stability, receptor selectively and improved pharmacodynamic properties. His strategies (using a combination of advanced Nuclear Magnetic Resonance and Molecular Modeling techniques, together with novel acid sensitive resins for appropriate cyclization as well as for clean/large scale protein synthesis) has proved to be the cornerstone in the rational drug design of cyclic peptide and non-peptide mimetics, considered the new and the next generation of drugs. His rational design methodology consists of the following steps: 1. Peptide (The tool), 2. Peptide Model (The ligand-receptor interaction), 3. Cyclic Peptide (The drug lead), 4. Non-peptide Mimetic (The drug), [Moore and Matsoukas U.S.A. Patent 07/1458, 926, 1992, Matsoukas et.al. J. Biol. Chem. 1994]. Professor Matsoukas has devised important design and synthetic strategies which were introduced and applied in physiologically important peptides such as Angiotensin, Gonadotropin Releasing Hormone, Thrombin Receptor Activating Peptides and Myelin Peptides, implicated in Hypertension, Infertility, Cancer and Multiple Sclerosis. Novel lead drugs have resulted which in preclinical investigations promise therapies. For example, myelin cyclic mimetics now in the final preclinical stage, are the frontrunners in these studies carried out in research institutions across the world (Australia, U.S.A. Europe) for the treatment of Multiple Sclerosis. His novel methods in mimetic design can be also applied in other peptides or proteins regulating important biochemical systems, thus providing a platform for general use in the treatment of several diseases whenever peptides or proteins are involved. *In summary*, Professor Matsoukas has made significant contributions to the art and science of peptide mimetics and related technologies and his work has made a major impact in drug discovery in particular Myelin based pharmaceuticals.

STATEMENTS OF DISTINGUISHED SCIENTISTS ABOUT THE RESEARCH WORK OF PROFESSOR MATSOUKAS:

- **Aristidis Patrinos** (Synthetic Genomics, U.S.A.):
  "It is a great honor for me to cooperate with your research group and the Department of Chemistry, University of Patras",(2006)
- **Kyriakos Nikolaou** (Scripps Research Institute, U.S.A.):

"My deep congratulations for all your excellent work and activities and for your great contribution in the progress of Chemistry in Greece"(2007)

- **Vasso Apostolopoulos** (Austin Research Institute, Australia):
  "Congratulations on your creditable effort and your great work. You are an Ambassador for all the Students and the Researchers in Greece"(2007)
- **Dimiris Nanopoulos** (Texas AM University U.S.A.):
  "My warmest congratulations to you and your research group for the international recognition of your research work". (2009)

STATEMENTS OF DISTINGUISHED SCIENTISTS IN THE FIELD ABOUT FINDINGS IN THE MYELIN PROJECT (Co-ordinator Professor John Matsoukas)

Dear John, "Bioassay results for your Cyclic MBP1-11 peptides first time to be reported in transgenic models, are stunning". **Prof. D. Wraith, Dept. of Pathology, University of Bristol, U.K.** *Dear John*, "You have one of the most interesting MBP-derivatives of the world The cyclised peptide are as potent as the linear one!! To my Knowledge, this is the first time, that a cyclised peptide binds to the MHC. As the cyclic peptide is surely more stable than the open one, the therapeutic approach for treatment of Multiple Sclerosis is quite realistic....".**Prof. H. Kalbacher, University of Tubingen, Germany,** *Dear John*, "I am thrilled by findings in this network and congratulations to this team for excellent work. I think we can try the cyclo-MBP peptide in normal humans and then try Multiple Sclerosis patients....".**Prof. V. Apostolopoulou**, Austin Research Institute, Australia

IMPACT – CONTRIBUTION:

Professor Matsoukas is a visiting Professor at the University of Calgary and the Immunology and Vaccine Laboratory, Melbourne Burnet Institute for Medicinal Research and Public Health as a result of his continuing fruitful collaboration with two Universities in Canada and Australia. Professor Matsoukas is the coordinator of an International Biomedical Network (twelve countries, Europe, U.S.A. Canada, Australia) in the Drug Discovery and Design of new and novel therapeutics in Multiple Sclerosis. He has been invited for lectures from many Universities and Institutions across the world with more than 200 lectures in Greece and Abroad, presenting his findings on Drug Design. Professor Matsoukas has supervised so far eighteen MSc and twenty PhD graduate students and more than one hundred in undergraduate research Diploma projects. He has more than 500 Publications (Publications in High Stand Journals, Book Chapters, full Articles in Conference Proceedings and Abstracts). Professor Matsoukas has been the Guest Editor of sixteen books on Drug Design including Conference Proceedings and since 1993 the Organizer and Co-ordinator of fourteen International Conferences in Drug Design and Discovery, held in Patras, which attracted leading scientists in the field all over the world. Professor Matsoukas has served as Guest Editor in the following Scientific Journals and Books, Current Medicinal Chemistry, Letters in Peptide Science (twice), Review of Clinical Pharmacology and Therapeutics (twice), Biomedical and Health Research, Books of IOS Press (thrice) The issue in Current Medicinal Chemistry (Vol. 12, 2005) was dedicated to his research on Myelin Peptides towards Immune Disease Therapy. Professor Matsoukas teaches Organic Chemistry and Advanced NMR Spectroscopy at the Department of Chemistry of University of Patras, Greece. Professor Matsoukas has many Distinctions and has been honored for his work by Scientific and Civil Authorities in his country. Among them, by the Academy of Athens and by Country Head of State, President Costis Stefanopoulos with the National Award for his Research and Innovation in Drug Discovery and Design, by the Minister of Development Mr. Dimitrios Sioufas for excellent research work in Drug Design and Hypertension Research, by the Achaia Prefect State Governor Mr. D. Katsikopoulos, by City of Patras Mayor Mr Andrew Fouras and by the Rector of University of Patras Professor C. Xatzitheodorou for excellent work in Drug Design and Hypertension Research. Recently he has been a candidate for the Best Scientist Award of the University of Patras.

Since 2000 Professor Matsoukas is the Co-ordinator and Director of the Leading Postgraduate Program "Medicinal Chemistry: Drug Discovery and Design" of the Departments of Chemistry and Pharmacy of the University of Patras evaluated by experts and commities as one of the best in Greece among all graduate programs in research activities. 200 students have graduated from the Program with a Master's Degree and 20 students with a PhD Degree. All of them continuing with successful academic and processional carriers. This Program is in evaluation procedures to be the first one in Greece awarded with the title of EuroMaster. Professor Matsoukas and his group is collaborating with more than fifty research groups around the world. In the eleven International Conferences in Drug Discovery and Design, held in Patras since 2000 by the Postgraduate Program Medicinal Chemistry (2000-2008) which he directs, he has invited world leading scientists. Research in Drug Discovery and Design of Professor Matsoukas has been supported with grants from National, European and Investment Funds totaling

7.500.000€. Applied findings of his research resulted in an investment of 1.000.000€ (plus toxicity costs) by VIANEX the Pharmaceutical Company in Greece for the development of Elsartans, which are a new generation of Antihypertensives with multiple advantages and properties including diadermal delivery. Recently VIANEX invested another 1.000.000€ (plus toxicity costs) for Multiple Sclerosis potential drugs, towards clinical investigation. This investment was the biggest in Greece for a University Research team by a Pharmaceutical Company. Result of the investment was a spin off unit under the name ELDRUG incorporated three years ago for the large production of Elsartan towards Phase I and II clinical evaluation. Presently, Professor Matsoukas is co-ordinating an International Biomedical Network in Drug Design and Discovery of Myelin based pharmaceuticals towards Immunotherapy of Multiple Sclerosis. Leading scientists in Centres of Excellence from several countries Europe, Australia, U.S.A. Canada participate in the Network. Findings and potential drugs – linear and cyclic MBP, PLP, MOG potent epitope analogues conjugated with mannan – are protected by Patent Applications submitted to Greek Patent Office (GPO), United Kingdom Patent Office (UKPO), European Patent Office (EPO) and PCT. Professor Matsoukas has proposed to the Ministry of Education in Greece and introduced in 1998 the Postgraduate Program "Medicinal Chemistry: Drug Discovery and Design" as a new direction of training and education considered and evaluated in Greece as one of the best graduate programs. Graduates of Medicinal Chemistry Postgraduate Program under the Co-ordination and leadership of Professor Matsoukas. Masters: 200, PhD:22. All with successful careers: (Harvard, U.S.A.), (Cambridge,U.K.), (Thomas Jefferson, U.S.A.), (Austin, Australia). Graduates under the supervision of Professor John Matsoukas: Total so far 45, all with successful careers.

PhD **and** MSc Graduates under the Supervision of Professor John Matsoukas (1995-2010) Total: **45**

PhD DEGREES – SUPERVISOR, JOHN MATSOUKAS (1995-2013):

1. Ioannis Hondrelis, 1995
2. Euthymia Theodoropoulou, 1997
3. Konstantinos Alexopoulos, 1999
4. Ioanna Ntaliani, 2001
5. Dimitrios Panayiotopoulos, 2001
6. George Agelis, 2001
7. Panayiota Roumelioti, 2001
8. Theodore Tselios, 2001
9. Elisabeth Matsouka, 2001
10. Maria Keramida, 2002
11. Maria Zervou, 2002
12. Spyros Deraos, 2003
13. Panayiotis Fatseas, 2003
14. Panayiotis Zoumpoulakis, 2004
15. Anastasia Zoga, 2004
16. Euthymia Mantzourani, 2007
17. George Deraos, 2007
18. Maria-Eleni Androutsou, 2008
19. Maria Katsara, 2008
20. Eiriri Fryliggou, 2009
21. Amalia Resvani, 2010
22. Konstantinos Kelaidonis, 2010
23. Theodora Katsila, 2011
24. Dimitrios Dountaniotis, 2012
25. Pigi Katsougraki, 2013
26. Mihaila Mihalatou, 2014

M. Sc. DEGREES – SUPERVISOR, JOHN MATSOUKAS (2000-2013)

1. Spyros Deraos, 2000
2. Anastasia Zoga, 2000
3. Nektarios Giatas, 2000
4. Athina Lepenioti, 2001
5. Maria- Eleni Androutsou, 2002
6. George Deraos, 2002
7. Konstantinos Kelaidonis, 2003
8. Theodore Tselios, 2004
9. Panagiota Roumelioti, 2004
10. Maria Anastasopoulou, 2004
11. Maria Katsara, 2004
12. Loukas Synodinos, 2004
13. John Papanastasiou, 2004
14. Amalia Resvani, 2005
15. Eirini Friliggou, 2005
16. Aspasia Choleva, 2006
17. Evi Stavrinou , 2006
18. Paschalina Kepa, 2007
19. Andrew Dais, 2007
20. Despoina Lemou, 2007
21. Michaela Michalatou, 2008
22. Nick Zacharias, 2009
23. Eythymios Neroutsos, 2010
24. Panazidou G., 2011
25. Vera Chrysa, 2012
26. Panagiotis Plotas, 2012
27. Pinelopi Kolokotroni, 2013
28. Kyriaki Mayridaki, 2013
29. Alexia Karagianni, 2014
30. Constantina Christopoulou, 2014
31. Eirini Panayiotopoulou, 2014
32. Ioannis Stauropoulos, 2014

Guest Editor in International Journals and Books

1. **Letters in Peptide Science** (LIPS), Vol.3, 1996
   (Special issue dedicated to network research)
   Guest Editor-J. Matsoukas
2. **Current Medicinal Chemistry** (I.F. 4.95)
   Bioactive Peptides for Immune Disease Therapy
   Bentham Science Publishers LTD, Vol. 12, 2005
   Guest Editor-J. Matsoukas
3. **Bioactive Peptides in Drug Discovery and Design**
   IOS press, Holland 1999, Vol. 22
   (Special issue)
   (Eds Matsoukas J. and Mavromoustakos T.)
4. **Drug Discovery and Design: Medical Aspects**
   IOS press, Holland 2002, Vol. 55 (Special issue)
5. **Review of Clinical Pharmacology Pharmacokinetics**, International Edition Vol. 9, 1998Guest Editor-J. Matsoukas (Eds Matsoukas J. and Mavromoustakos T.)
6. **Review of Clinical Pharmacology and Pharmacokinetics,** International Edition V 20 (3)/2006 Guest Editor, I. Matsoukas.
7. **Review of Clinical Pharmacology and Pharmacokinetics,** International Edition V 21 (2)/2007 Guest Editor, I. Matsoukas.
8. **Review of Clinical Pharmacology and Pharmacokinetics,** International Edition V 26 (1) 2008, Guest Editor, I. Matsoukas.
9. **Review of Clinical Pharmacology and Pharmacokinetics,** International Edition V 2009, Guest Editor, I. Matsoukas.
10. **Review of Clinical Pharmacology and Pharmacokinetics,** International Edition V 2010, Guest Editor, I. Matsoukas.
11. **Review of Clinical Pharmacology and Pharmacokinetics,** International Edition V 2011, Guest Editor, I. Matsoukas.

Editor, Conference Proceedings

Total: 21

Books:

- **1st BIOMED Conference 1993**, Proceedings of Biomedical and Health Research Conference in Drug Discovery and Design, Patras, Greece, Oct. 14-16, 1993.
- **2nd BIOMED Conference 1994**, Proceedings of Biomedical and Health Research Conference in Drug Discovery and Design, Patras, Greece, Nov. 17-19, 1994.
- **3rd BIOMED Conference 1995**, Proceedings of Biomedical and Health Research Conference in Drug Discovery and Design, Patras, Greece, Nov. 23-25, 1995.
- **Rev. Clin. Pharmacol. Pharmacokinet**. Int. Ed., Vol. 9, 1995.
- **Letters in Peptide Science** (LIPS) Vol. 3, 1996, ESCOM.
- **T. Mavromoustakos, J.M. Matsoukas. NMR**. Application of Nuclear Magnetic Resonance in Medicine and Food Industry.
- Editors: **J. Matsoukas**, S.T. Plessas, C.T. Plessas. Peptides in Biomedical Research
  Revew of Clinical Pharmacology and Farmakokinetics, 1997. International Edition.
- Editors: **J. M. Matsoukas and T. Mavromoustakos.** Bioactive Peptides in Drug Discovery and Design: Medical Aspects.
  IOS Press, Holland, **1999**.
- Editors: **J. M. Matsoukas and T. Mavromoustakos**. Bioactive Peptides in Drug Discovery and Design: Medical Aspects.
  IOS Press, Holland, **2002**.
- **Current Medicinal Chemistry**.
  Bioactive Peptides for Immune Disease Therapy, Bentham Science Publishers LTD, Vol. 12, **2005**.
- **1st Medicinal Chemistry: Drug Discovery and Design Conference**, Conference and Cultural Center,Patras, Greece, **1-3/3/2000**. Guest of Honor, Professor Vasso Apostolopoulos

- **2nd Medicinal Chemistry: Drug Discovery and Design Conference**, Conference and Cultural Center, Patras, Greece,**1-3/3/2001**. Guest of Honor, Professor Thanassis Giannis
- **3rd Medicinal Chemistry: Drug Discovery and Design Conference**, Conference and Cultural Center, Patras, Greece,**7-9/3/2002**. Guest of Honor, Professor Chris Platsoukas
- **4th Medicinal Chemistry: Drug Discovery and Design Conference**, Conference and Cultural Center, Patras, Greece,**8-10/3/2003**. Guest of Honor, Professor Michael Maragoudakis
- **5th Medicinal Chemistry: Drug Discovery and Design Conference**, Conference and Cultural Center, Patras, Greece,**9-11/3/2004**. Guest of Honor, Professor Konstantinos Sekeris
- **6th Medicinal Chemistry: Drug Discovery and Design Conference**, Conference and Cultural Center, Patras, Greece,**10-12/3/2005**. Guest of Honor, Professor Haralampos Gavras
- **7th Medicinal Chemistry: Drug Discovery and Design Conference**, Conference and Cultural Center, Patras, Greece,**8-11/3/2006**. Guest of Honor, Professor Aris Platsoukas
- **8th Medicinal Chemistry: Drug Discovery and Design Conference**, Conference and Cultural Center, Patras, Greece,**14-17/3/2007**. Guest of Honor, Professor Kyriakos Nikolaou
- **9th Medicinal Chemistry: Drug Discovery and Design Conference**, Conference and Cultural Center, Patras, Greece,**26-28/3/2008**. Guest of Honor, Professor Jean Marie Lehn, Nobel in Chemistry
- **10th Medicinal Chemistry: Drug Discovery and Design Conference**, Conference and Cultural Center, Patras, Greece, **17-19/3/2009**. Guest of Honor, Professor Dimitris Nanopoulos
- **11th Medicinal Chemistry: Drug Discovery and Design Conference**, Conference and Cultural Center, Patras, Greece, **25-28/4/2010**. Guest of Honor, Professor Andrew Schally, Nobel in Medicine
- **12th Medicinal Chemistry: Drug Discovery and Design Conference**, Conference and Cultural Center, Patras, Greece, **12-15/04/2011.** Guest of Honor, Professor James D. Watson, Nobel in Medicine
- **13th Medicinal Chemistry: Drug Discovery and Design Conference**, Conference and Cultural Center, Patras, Greece, **9-10/05/2012.** Guest of Honor, Professor Kleomenis Barlos.
- **14th Medicinal Chemistry: Drug Discovery and Design Conference**, Conference and Cultural Center, Patras, Greece, **13-15/05/2013.** Guest of Honor, Professor Ada Yonath, Nobel in Chemistry

Conference Coordinator, John Matsoukas

Total: 14

1. 1st Biomedical and Health Research in Drug Design, Patras, Greece November 11-13, 1993
2. 2nd Biomedical and Health Research in Drug Design, Patras, Greece November 19-21, 1994
3. 3rd Biometical and Health Research in Drug Design, Patras, Greece November 14-16, 1995

Conferences organized by post-Graduate Program "Medicinal Chemistry: Drug Discovery and Design", University of Patras, Coordinator , John Matsoukas

4. 1st Medicinal Chemistry: Drug Discovery and Design Conference, Conference and Cultural Center, Patras, Greece, **1-3/3/2000**.
5. 2nd Medicinal Chemistry: Drug Discovery and Design Conference, Conference and Cultural Center, Patras, Greece,**1-3/3/2001**.
6. 3rd Medicinal Chemistry: Drug Discovery and Design Conference, Conference and Cultural Center, Patras, Greece,**7-9/3/2002**.
7. 4th Medicinal Chemistry: Drug Discovery and Design Conference, Conference and Cultural Center, Patras, Greece,**8-10/3/2003**.
8. 5th Medicinal Chemistry: Drug Discovery and Design Conference, Conference and Cultural Center, Patras, Greece,**9-11/3/2004**.
9. 6th Medicinal Chemistry: Drug Discovery and Design Conference, Conference and Cultural Center, Patras, Greece,**10-12/3/2005**.
10. 7th Medicinal Chemistry: Drug Discovery and Design Conference, Conference and Cultural Center, Patras, Greece,**8-11 /3/2006**.

11. 8th Medicinal Chemistry: Drug Discovery and Design Conference, Conference and Cultural Center, Patras, Greece,**15-17/3/2007**
12. 9th Medicinal Chemistry: Drug Discovery and Design Conference, Conference and Cultural Center, Patras, Greece,**26-28/3/2008**
13. 10th Medicinal Chemistry: Drug Discovery and Design Conference, Conference and Cultural Center, Patras, Greece, **17-19/3/2009**
14. 11th Medicinal Chemistry: Drug Discovery and Design Conference, Conference and Cultural Center, Patras, Greece, **26-28/4/2010**
15. 12th Chemistry: Drug Discovery and Design Conference, Conference and Cultural Center, Patras, Greece, **12-15/04/2011**
16. 13th Chemistry: Drug Discovery and Design Conference, Conference and Cultural Center, Patras, Greece, **9-10/05/2012**
17. 14th Chemistry: Drug Discovery and Design Conference, Conference and Cultural Center, Patras, Greece, **13-15/05/2013**

Citations: Over 2000

Funding (1995-2014) of Matsoukas' Research

Total: 10.591.760,08 Euro

1087	BIOMED	DG XII	1995	220.000 €
0984	ERB-CIPD-CT93-0158 Angiotensin antagonists	DG XII European Union	1997	100,000 €
1082	CIPA-CT94-0239 (DGXII) Angiotensin antagonists	COPERNICUS European Union	1998	33277,27 €
1827	MEDICINAL CHEMISTRY	EPEAEK MINISTRY OF EDUCATION	1998	700.000 €
1469	SYNTHESIS AND BIOLOGY IN POTENTIAL	PENED '95 MINISTRY OF DEVELOPMENT	1998	11737,99 €
1728	INHIBITION IN ANGIOGENESIS	MINISTRY OH HEALTH	1999	8804,1 €
1825	LABORATORY CHEMISTRY	MINISTRY OF EDUCATION	1999	8804,5 €
0.020.011	MEDICINAL CHEMISTRY	EPEAEK MINISTRY OF EDUCATION	1999	83.000 €
1881	THROMBIN & MIMETICS	O.PA.P. MINISTRY OF CULTURE	1999	14673,51 €
2027	PEPTIDE MIMETICS NEW GENERATION OF DRUGS	EPET II MINISTRY OF DEVELOPMENT	2000	821716,8 €
2029	96SYN17-SYSNTHESIS OF GnRH ANTAGONISTS	MINISTRY OF DENELOPMENT	2000	29347,02 €
2102	SYNTHESIS OF NEW DRUGS	SPONSORS	2001	25907,94 €
2616	CONFERENCE:DRUG DISCOVERY & DESIGN	SPONSORS	2001	23542,36 €
2771	KARATHEODORIS PROGRAM	UNIVERSITY OF PATRAS	2001	23477,62 €
3163	PRAXE 114:DEVELOPMENT OF POTENTIAL DRUGS	PRAXE MINISTRY OF DEVELOPMENT	2002	44000 €
6519	FK665/BMH-CT92-0038 Hypertension Research	FUNDING MINISTRY OF DEVELOPMENT	2002	8985,32 €
6520	FK.984/CIPD-CT93-0158 Hypertension Research	FUNDING MINISTRY OF DEVELOPMENT	2002	13152,25 €
6521	FK.1082/CIPA-CT94-0239 Hypertension Research	FUNDING MINISTRY OF DEVELOPMENT	2002	9877,4 €
A. 011.002	MEDICINAL CHEMISTRY	EPEAEK MINISTRY OF EDUCATION	2003	149000 €
B. 050	GREECE-AUSTRALIA (2005): IMMUNOTHERAPY OF MS	MINISTRY OF DEVELOPMENT	2003	59850 €
B. 051	YB 76:TOWARDS MS IN IMMUNOTHERAPY	EPAN MINISTRY OF DEVELOPMENT	2003	400000 €
B. 238.049	DESIGN, SYNTHESIS AND BIOLOGICAL EVALUATION	EPEAEK MINISTRY OF EDUCATION	2003	33206 €
B. 321	YB 84:HERCULES DOUBLE ACTION DRUGS	EPAN MINISTRY OF DEVELOPMENT	2003	440000 €
19008	RESEARCH AND DENELOPMENT OF ANTIHYPERTENSIVE ANALOGUES OF ELSARTAN	PRAXE B VIANEX	2006	1.000.000 €
19008	RESEARCH AND DENELOPMENT OF ANTIHYPERTENSIVE ANALOGUES OF ELSARTAN	PRAXE B΄ FUNDING MINISTRY OF DEVELOPMENT	2006	720.000 €
	REASERCH AND DEVELOPMET OF MYELIN MIMETICS	PENED MINISTRY OF DEVELOPMENT	2006	180.000€
	REASERCH AND DEVELOMENT OF ELMYELIN	VIANEX	2010	1.000.000€
	TOXICITY ELSARTAN, ELMYELIN	VIANEX	2010	1.000.000€
	FINAL PRECLINICAL STUDIES OF ELMYELIN: POTENTIAL VACCINE	MINISTRY OF DEVELOPMENT	2011	3.000.000€
	BIOLOGICAL EVALUATION OF SARTANS	IRAKLEITOS II MINISTRY OF EDUCATION	2011	45.000 €
	A NOVEL COMBINED APPROACH FOR THE IMMUNOTHERAPY OF MULTIPLE SCLEROSIS	GREECE- ISRAEL COOPERATION GSRT, MINISTRY OF EDUCATION	2014	384.400 €

Total: **10.591.760,08 €**

Patents:

- **G. Moore And J. Matsoukas**
  U.S. Patent 07/1458,926,1992
  Methods for modeling tertiary structures of ligands and for modeling agonists and antagonists (86 pages, 17 figures)
- **G. Moore And J. Matsoukas**
  International Patent 91901261. 7/August 10,1992.
  Methods for modeling tertiary structures of biologically active ligands including agonists and antagonists thereto and novel synthetic antagonists based on Angiotensin II.
- **G. Moore, J. Habibi, J. Matsoukas**
  International Patent No PCT/CA92/00281/July 2,1994.
  Non-desensitizing analogs of GnRH and otherbiologically active ligands.
- **G. Moore, J. Smith, J. Matsoukas**
  U.K. Patent No 94 16 895,2, August 20,1994.
  Angiotensin II Receptor Antagonists.
- **M. Hollenberg, J. Matsoukas, G. Moore**
  U.S. Patent No 5, 516, 889, May 14, 1996.
  Synthetic Thrombin Receptor Peptides.
- **J. Matsoukas And P. Roumelioti**
  Application No 20000100281, August 17, 2000.
  Angiotensin Receptor Antagonists and Synthetic Methods in the Treatment of Hypertension and Cardiovascular Diseases.
- **J. Matsoukas, M. Maragoudakis, D. Vlahakos And K. Alexopoulos**
  Application No 20000100283, August 17, 2000.
  Thrombin Receptor Non-Peptide Mimetics in the Treatment of Angiogenesis, Cancer, Thrombosis and Cardiovascular Diseases.
- **J. Matsoukas, V. Apostolopoulos And T. Tselios**
  GPO AGIK 38/17, CO7K 14/47, 09/05/2002/M.S. Patent Office/ U.S.A. Patent
  Myelin Basic Protein Epitope Peptides in Treatment of Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis.
- **J. Matsoukas, D. Vlahakos, M. Maragoudakis**
  Greek Patent Office: 20070100312,24/5/2007
  United Kingdom Patent: 0714603.8, 2007
  EPO and PCT Patent Pending
  Angiotensin II receptor antagonists based on 4(5) Substituted Imidazoles, synthetic methods and transdermal delivery in the treatment of hypertension and cardiovascular diseases.
- **J. Matsoukas, C. Gavras, D. Vlahakos, M. Maragoudakis**
  Greek Patent Office: 20070100650, 24/10/2007
  United Kingdom Patent: 0714995.8, 2008
  EPO and PCT Patent Pending
  Angiotensin II receptor antagonists based on histamine with sympathetic suppressant and synthetic methods in the treatment of hypertension and cardiovascular diseases.
- **J. Matsoukas, T. Tselios, G. Deraos, N. Grigoriadis, A. Lourbopoulos, M. Katsara, V. Apostolopoulos**
  Greek Patent Office: 20070100695, 20/11/2007
  EPO and PCT Patent Pending
  Immunotherapy of Multiple Sclerosis using MBP_{83-99} peptide analogues and mannan.
  United Kingdom Patent Office (Submitted)
- **J. Matsoukas, T. Tselios, V. Apostolopoulos, L. Probert, V. Tseveleki, M. Katsara**
  International Patent Application 2008
  Immunotherapy of Multiple Sclerosis using mannosylated peptides as Therapeutic Vaccines.
  Greek Patent Office
  United Kingdom Patent Office (Submitted)
  EPO and PCT Patent Pending

Publications in Peer Reviewed Journals

(i) Ph. D. Thesis., **J. Matsoukas**
Synthesis and conformational properties of N-alkylamido derivatives of the C-terminal tripeptide of oxytocin, [β-Ala^{9}]-oxytocin and N-Trt-α-benzyl derivatives of glutamine and asparagine.
University of Patras, Greece, 1978.
(ii) M. Sc. Thesis., **J. Matsoukas**
Total Synthesis of Epi-ramulosin.
University of New Brunswick, Canada, 1976.
1. Synthesis of d, l-Epiramulosin and the Configuration of Ramulosin./ J. Findlay, **J. Matsoukas** and J. Krepinsky./ **Canadian Journal of Chemistry** 54, 3419-3423, 1976. [Impact Factor:1.260]
2.Synthesis of L-Prolyl-L-Leucylglycine Alkylamides./**J. Matsoukas**, P. Cordopatis and D. Theodoropoulos./ **Journal of Organic Chemistry** 42, 2105-2108, 1977. [Impact Factor: 3.217]
3.Synthesis and Proposed Conformations of L-Prolyl-L-Leucul-β-Alanine Alkylamides./P. Anagnostaras, P. Cordopatis, **J. Matsoukas**, G. Stavropoulos and D. Theodoropoulos./**Tetrahedron** 34, 973-975, 1978. [Impact Factor: 2.897]
4.Synthesis of N^{4}-Dialkyl-Asparagine and N^{5}-Dialkyl-L-Glutamine Derivatives./ Th. Caplaneris, P. Cordopatis, **J. Matsoukas** and D. Theodoropoulos./**Tetrahedron** 34, 969-972, 1978. [Impact Factor: 2.897]
5.Contribution of the Trityl Group to Magnetic Assymetry in N-Trityl Amino Acid Benzyl Ester./**J. Matsoukas** and D. Theodoropoulos./**Organic Magnetic Resonance** 12, 393-395, 1979.[IF: 2.438]
6.Synthesis and Biological Activities of [β-Malyl^{1}] and [β-Malyl^{1}], [Leu^{8}],-Angiotensin II Analogues./P. Cordopatis, **J. Matsoukas**, A. Michel, J. Janen and D. Theodoropoulos./**Experientia** 39, 353-355, 1983.
7.A Convenient Method for the Isolation of Free Amino Acids from Marine Invertebrates.
J. Matsoukas, Y.E. Moharir and J.A. Findlay.
Journal of Natural Products (Llyodia), 46, 582-585, 1983. [Impact Factor: 2.843]
8.^{13}C-NMR Studies of Malic Acid Derivatives.
J. Matsoukas, J. Burnell and D. Theodoropoulos.
Spectroscopy Letters, 16, 933-943, 1983.
9.Synthesis and Conformation of N-Trt-Dipeptide Derivatives.
J. Matsoukas, T. Tsegenidis, P. Cordopatis and D. Theodoropoulos.
Tetrahedron, 40, 1869-1972, 1984. [Impact Factor: 2.897]
10. ^{13}C-NMR Study of the Cis-Trans Isomerism Around the Urethane and Amide Bond of Sarcosine Derivatives.
J. Matsoukas.
Spectroscopy Letters, 17, 21-31, 1984.
11. A Cyclic Angiotensin Antagonist: [Cys^{1,8}] Angiotensin II.
J. Matsoukas, M.N. Scanlon,G.J. Moore.
Journal of Medicinal Chemistry, 27, 404-406, 1984. **[Impact Factor: 5. 2]**
12. A New Approach to Angiotensin Antagonists: Methylation of the Tyrosine Hydroxyl in Angiotensin II.
M.N. Scanlon, J.M. Matsoukas, K.J. Franklin, G.J. Moore.
Life Sciences, 34, 317-321, 1984. [Impact Factor: 2.583]
13. Some constituents of the Sea Cucumber Cucumaria Frondosa.
J.A. Findlay, A. Daljeet, J. Matsoukas and Y.E. Moharir.
Journal of Natural Products, 47, 560-561, 1984. [Impact Factor: 2.843]
14. NMR Studies of Angiotensin II: Histidine and Phenylalanine Ring Stacking and Biological Activity.
J. Matsoukas and J. Moore.
Biophysical and Biochemical Research Communications, 122, 434-438, 1984. [Impact Factor: 2.935]
15. Synthesis and Biological Activities of Analogues of Angiotensin II and III Containing O-Methyl Tyrosine and D-Tryptophan.
J.M. Matsoukas, M.H. Goghari, M.N. Schanlon, K.J. Franklin and G.J. Moore.
Journal of Medicinal Chemistry, 28, 780-783, 1985. **[Impact Factor: 5. 2]**
16. Angiotensin as a Model for Hormone-Receptor Interactions.
J. Moore and **J. Matsoukas**.
Bioscience Reports (Journal of the Chemical Society), 5, 407-416, (1985). [Impact Factor: 2.525]
17. Proton Magnetic Resonance Studies of Angiotensin II Conformation: Cis-Trans Isomerism in Sarcosine^{7}-Containing Analogs.
J.M. Matsoukas, G.J. Moore.
Archives of Biochemistry and Biophysics, 248, 419-423, 1986. [Impact Factor: 2.626]

18. Structures of two N-t-Boc-Amino Acid Phenacyl Esters.
M. Vlassi, G. Germain, **J. Matsoukas**, C. Psachoulia, S. Voliotis.
Acta Cryst. C43, 2173-2175, 1987.
19. Synthesis and Pharmacological Properties of [Aib^1, Leu^8] and [N^4, N^4-Dipropyl-Asn^1, Leu^8]-Angiotensin II Analogues.
P. Cordopatis, A. Michel, **J. Matsoukas**, J. Zanen.
Gazzeta Chimica Italiana 117, 287-289, 1987.
20. Importance of the N-Terminal Domain of the Type II Angiotensin Antagonist Sarmesin for Receptor Blockade.
J. Matsoukas, P. Cordopatis, U. Belte, M. Gophari, R. Ganter, K. Franklin and G. Moore.
Journal of Medicinal Chemistry 31, 1418-1421, 1988. [Impact Factor: 5. 2]
21. NMR and MASS Spectroscopic Studies of the Competitive Angiotensin II Antagonist "Sarmesin".
J. Matsoukas and G. Moore.
Spectroscopy Letters, 21 (5), 477-491, 1988.
22. Isolation and Identification of Free Aminoacids as Crystaline N-t-Butyloxy, o-Phenacyl Derivatives.
G. Lonergan, C. Psachoulia, V. Marmaras, J. Hondrelis, C. Sanida, **J. Matsoukas***.
Analytical Biochemistry 176, 368-372, 1989. [Impact Factor: 3.088]
23. Structure of N-tert-Butyloxycarbonyl-L-tyrosine 4-Bromophenacyl Ester.
J. Matsoukas, M. Semertzidis, J. Hondrelis, V. Nastopoulos, S. Voliotis and I. Leban.
Acta Cryst. C45, 690-692, 1989.
24. Structure of N-(tert-Butyloxycarbonyl) Glycine.
M. Semertzidis, **J. Matsoukas**, V. Nastopoulos, J. Hondrelis, S. Voliotis and I. Leban.
Acta Cryst. C45, 1474-1475, 1989.
25. A Simple Preparation of l-Methyl-L-Histidine.
K. Barlos, J. Hondrelis, G. Lonergan, **J. Matsoukas** and C. Sanida.
Annalen, 387-388, 1989.
26. Preparation of New Acid Labile Resins from sec. Alcohol Type and their Application in Peptide Synthesis.
K. Barlos, D. Gatos, J. Hondrelis, **J. Matsoukas**, G. Moore, W. Schafer and P. Sotiriou.
Annalen, 951-955, 1989.
27. ^{1}H-NMR Studies of [N-MeAib^1, Tyr (Me)^4] ANG II and [N-MeAib^1, Tyr (Me)^4, Ile^8] ANG II in Dimethylsulfoxide by Nuclear Overhauser Effect (NOE) Enhancement Spectroscopy: Cis-Trans Isomerism of the His-Pro Bond.
J. Matsoukas*, P. Cordopatis, R. Yamdagni and G. Moore.
Collect. of Czech. Chem. Commun., 55, 1106-1111 1990.
28. One Pot Synthesis and Conformation of N-t-Butyloxycarbonyl, O-Phenacyl Derivatives of Proline and Other Secondary Amino Acids.
J. Hondrelis, G. Lonergan, S. Voliotis and **J. Matsoukas***.
Tetrahedron, 46, 565-576, 1990. [Impact Factor: 2. 897]
29. ^{1}H-NMR Studies of [Sar^1] Angiotensin II Conformation by Nuclear Overhauser Effect Spectroscopy in the Rotating Frame (ROESY): Clustering of the Aromatic Rings in Dimethylsulfoxide.
J. Matsoukas*, G. Bigam, N. Zhou and G. Moore.
Peptides, 11, 359-366, 1990. [Impact Factor: 2.565]
30. ^{1}H-NMR Studies of Sarmesin and Des^1-Sarmesin Conformation in Dimethylsulfoxide by Nuclear Overhauser Effect (NOE) Enhancement Spectroscopy: Folding of the N-and C-terminal domains.
J. Matsoukas*, R. Yamdagni, G. Moore.
Peptides, 11, 367-374, 1990. [Impact Factor: 2.565]
31. Tyrosinate Flyorescence Life Times for Oxytocin and Vasopressin in Receptor Simulating Environments: Relationship to Biological Activity and ^{1}H-NMR Data.
R.J. Turner, **J.M. Matsoukas**, G.J. Moore.
Bioch. Bioph. Res. Commun., 171, 996-1001, 1990. [Impact Factor: 2.935]
32. Synthesis and Biological Activities of Angiotensin II and Sarmesin Analogues Containing Cyclohexylalanine.
J. Hondrelis, **J. Matsoukas***, P. Cordopatis, R. Ganter, K. Franklin and G.J. Moore.
Int. J. Peptide Protein Res., 37 (1), 21-26, 1991.
33. Fluorescence Properties of Angiotensin II Analogues in Receptor-Simulating Environments: Relationship between Tyrosinate Fluorescence Lifetime and Biological Activity.
R. J. Turner, **J.M. Matsoukas** and G.J. Moore.
Biochimica et Biophysica Acta, 1065, 21-28, 1991. [Impact Factor: 3.011]
34. Influence of Polyfluorination of the Phenylalanine Ring of Angiotensin II on Conformation and Biological Activity.

P.R. Bovy, D.P. Getman, **J.M. Matsoukas** and G.J. Moore.
Biochimica et Biophysica Acta, 1079, 23-28, 1991. [Impact Factor: 3.011]

35. Conformational Studies of Angiotensin II and Analogues in Dimethyl Sulfoxide by ^{1}H-NMR: Lability and Intramolecular interactions of the Tyrosine Hydroxyl and Histidine Imidazole NH Protons.
J. Matsoukas*, G. Bigam, R. Yamdagni and G.J. Moore.
Collect. Czech. Chem. Commun., 56, 1348-1357, 1991.

36. The Crystal and Molecular Structure of N-tert-Butoxycarbonyl-1-Azetidine-2-Carboxylic Acid.
V. Nastopoulos, M. Gikas, **J. Matsoukas** and O. Dideherg.
Zeitschrift fur Kristallographie, 199, 149-155, 1992.

37. Structure of N-tert-Butoxycarbonyl-L-Phenylalanine Benzyl Ester.
M. Gikas, G. Agelis, **J. Matsoukas***, G.J. Moore, L. Dupond and S. Englebert.
Acta Crystallographica C48, 216-217, 1992.

38. Isolation NMR Studies, and Biological Activities of Onomordopicrin from Centaurea Sonchifolia.
G. Lonergan, E. Routsi, T. Georgiadis, G. Agelis, J. Hondrelis, K. Larsen, F. Caplan and **J. Matsoukas***.
J. Nat. Prod., 55, 225, 1992. [Impact Factor: 2.843]

39. Synthesis and Biological Activities of Angiotensin II, Sarilesin and Sarmesin Analogues Containing Aze or Pip at Posotion 7: Conformational Properties of [Sar^1, Aze^7] ANG II Determined by Nuclear Overhauser Effect (NOE) Enhancement Spectroscopy.
J. Matsoukas, G. Agelis, J. Hondrelis, R. Yamdagni, Q. Wu, R. Ganter, D. Moore and G.J. Moore.
Journal of Medicinal Chemistry, 36, 904-911, 1993. [Impact Factor: 5. 2]

40. Imidazole Based Non-Peptide Angiotensin II Receptor Antagonists: An Investigation of the Effect of the Orientation of the Imidazole Ring on Biological Activity.
A Wahhab, J.R. Smith, R.C. Ganter, D.M. Moore, J. Hondrelis, **J. Matsoukas** and G.J. Moore.
Drug Research, 43, 1157-1168, 1993.

41. Role of the NH_2-terminal Domain of Angiotensin II (ANG II)and [Sar1] Angiotensin II on Conformation and Activity.
J. Matsoukas, J. Hondrelis, M. Keramida, T. Mavromoustakos, A. Makriyannis, R. Yamdagni, Q. Wu and G.J. Moore.
J. Biol. Chem., 269, 5303-5311, 1994. [Impact Factor 7.715].

42. Novel Synthesia of Cyclic Amide-Linked Analogues of Angiotensins II and III.
J. Matsoukas, J. Hondrelis, G. Agelis, K. Barlos, R. Ganter, D. Moore and G.J. Moore.
Journal of Medicinal Chemistry, 37, 2958-2969, 1994. [Impact Factor: 5. 2]

43. Receptor Interactions of the Position 4 Side Chains of Angiotensin II Analogues: Importance of Aromatic Ring Quadrupole.
G.J. Moore, R.C. Ganter, **J.M. Matsoukas**, J. Hondrelis, G. Agelis, K. Barlos, S. Wilkinson, J. Sandall and P. Fowler.
J. Mol. Rec., 7, 251-256, 1994. [Impact Factor: 3.16]

44. ^{1}H-NMR Conformational Studies in Water of Angiotensin II Analogues Modified at the N-and C-Termini: Interactions of the Aromatic Side-Chains and Folding of the N-Terminal Domain.
J. Hondrelis, **J. Matsoukas***, G. Agelis, P. Cordopatis, N. Zhou, H. Vogel and G.J. Moore.
Collect. Czech. Chem. Commun., 59, 2523-2532, 1994.

45. Use of Molecular Modeling to Study Superimposition of Angiotensin II with its Non-Peptide Receptor Antagonists.
Th. Mavromoustakos, E. Theodoropoulou, **J.M. Matsoukas**, G. Moore and J. Smith.
Rev. Clin. Pharmacol. Pharmacokinetics, 8, 137-142, 1994.

46. Design and Pharmacology of Peptide Mimetics.
G. Moore, J. Smith, B. Baylis, **J. Matsoukas**.
Advances in Pharmacology, 33, 91-141, 1995.

47. Differences in Backbone Structure between Angiotensin II Agonists and Type I Antagonists.
J. Matsoukas, G.Agelis, A. Wahhab, J. Hondrelis, D. Panagiotopoulos, R. Yamdagni, Q. Wu, T. Mavromoustakos, H. Maia, R. Ganter and G. Moore.
J. Med. Chem., 38, 4660-4669, 1995. [Impact Factor: 4.898]

48. A New Generation of Antihypertensives: Non Peptide Angiotensin II Receptor Antagonists.
J. Smith, A. Wahhab, J. Hondrelis, R. Ganter, D. Moore and **J. Matsoukas**.
Rev. Clin. Pharmacol. Pharmacokin. Int. Ed., 9, 75-79, 1995.

49. Designing Peptides Mimetics.
G. Moore and **J. Matsoukas**.

Rev. Clin. Pharmacol. Pharmacokin. Int. Ed., 9, 53-58, 1995.

50. Type I Angiotensin II Antagonists.

G. Agelis, A. Wahhab, J. Hondrelis, R. Yamdagni, Q. Wu, R. Ganter, J. Smith, G.J. Moore and **J.M. Matsoukas.**

Rev. Clin. Pharmacol. Pharmacokin. Int. Ed., 9, 59-61, 1995.

51. Cyclic Thrombin Receptor Derived Peptide Analogues.

M. Panagiotopoulos, **J.M. Matsoukas**, M. Keramida, S. Deraos, H.L.S. Maia, R. Yamdagni, Q. Wu, P. Redstone, G.J. Moore, A.A. Laniyonu, M Saifeddine and M.D. Hollenberg.

Rev. Clin. Pharmacol. Pharmacokin. Int. Ed., 9, 63-65, 1995.

52. Gonatotropin-Releasing Hormone (GnRH) Analogues Containing Tyr (OMe) at Position 5.

M Keramida, **J.M. Matsoukas**, G. Agelis, D. Panagiotopoulos, J. Cladas, H.L.S. Maia, R. Yamdagni, Q. Wu, D. Pati, G.J. Moore and H.R. Habibi.

Rev. Clin. Pharmacol. Pharmacokin. Int. Ed., 9, 67-69, 1995.

53. From Angiotensin to Non-Peptide Angiotensin II Receptor Antagonists.

J. Hondrelis, J. Smith, A. Wahhab, R. Ganter, D. Moore, G. Moore and **J. Matsoukas**.

Rev. Clin. Pharmacol. Pharmacokin. Int. Ed., 9, 71-73, 1995.

54. Advances in Antihypertensive Therapy: Non-Peptide Angiotensin II Receptor Antagonists as Potent Therapeutic Agents.

J. Smith, A. Wahhab, J. Hondrelis, R. Ganter, D. Moore, **J.M. Matsoukas** and G.J. Moore.

Letters in Peptide Science (LIPS), 3, 169-174, 1996, (Guest Editor of Special Issue). [Impact Factor: 1.69]

55. Design and Synthesis of a Gonadotropin-Releasing Hormone (GnRH) Analogue, [Tyr(Ome)^{5}, D-Glue^{6}, Aze^{9}] GnRH: Receptor Binding, Gonadotropin Release and Ovulation Studies.

M. Keramida, **J.M. Matsoukas**, D. Panagiotopoulos, K. Alexopoulos, E. Matsoukas, J. Cladas, V.A. Tzingounis, E. Kardamakis, H.L.S. Maia, D. Pati and H.R. Habibi.

Letters in Peptide Science (LIPS), 3, 257-262, 1996, (Guest Editor of Special Issue). [Impact Factor: 1.69]

56. Influence of Sarmesin on the Cardiac and Vascular Actions of Angiotensin II.

S. Mihailescu, **J. Matsoukas**, F.L. Abei, V. Nestianu, E. Romanescu and C. Alecu-Parvu.

Letters in Peptide Science (LIPS), 3, 181-184, 1996, (Guest Editor of Special issue). [Impact Factor: 1.69]

57. Influences of Sarmesin on Some Dopamine-Related Behaviours.

V. Georgiev, **J. Matsoukas**, D. Georgieva, J. Tchekalarova and L. Todorov.

Letters in Peptide Science (LIPS), 3, 185-190, 1996, (Guest Editor of Special Issue). [Impact Factor: 1.69]

58. Biological Activity of the Novel Cyclic Angiotensin II Analogues [Sar^{1}, Lys^{3}, Glu^{5}] ANG II.

D.V. Vlahakos, **J.M. Matsoukas**, J. Ancans, G.J. Moore, E.K. Iliodromitis, K.P. Marathias and D.Th. Kremastinos.

Letters in Peptide Science (LIPS), 3, 191-194, 1996, (Guest Editor of Special Issue). [Impact Factor: 1.69]

59. Superimposition of Potent Non-Peptide AT_1 Receptor Antagonists with Angiotensin II.

E. Theodoropoulou, Th. Mavromoustakos, D. Panagiotopoulos, **J. Matsoukas** and J. Smith.

Letters in Peptide Science (LIPS), 3, 209-215, 1996, (Guest Editor of Special Issue). [Impact Factor: 1.69]

60. Interactions of Angiotensin II with Membranes Using a Combination of Differential Scanning Calorimetry and ^{31}P NMR Spectroscopy.

Th. Mavromoustakos, E. Theodoropoulou, Ch. Dimitriou, **J. Matsoukas**, D. Panagiotopoulos and A. Makriyannis.

Letters in Peptide Science (LIPS), 3, 175-180, 1996, (Guest Editor of Special Issue). [Impact Factor: 1.69]

61. Inhibition of TRAP-Induced Angiogenesis by the Tripeptide Phe-Pro-Arg, a Thrombin Receptor-Derived Peptide Analogue.

M. E. Maragoudakis, E. Pipili-Synetos, E. Sakkoula, D. Panagiotopoulos,N. Craniti and **J.M. Matsoukas**.

Letters in Peptide Science (LIPS), 3, 227-232, 1996, (Guest Editor of Special Issue). [Impact Factor: 1.69]

62. Synthesis and Activity of Cyclic Thrombin-Receptor-Derived Analogues of the Ser^{42}-Phe-Leu-Leu-Arg^{46} Motif Sequence Containing D-Phe and/orD-Arg.

D. Panagiotopoulos, **J.M. Matsoukas**, K. Alexopoulos, A. Zebeki, Th. Mavromoustakos, M. Saifeddine and M.D. Hollenberg.

Letters in Peptide Science (LIPS), 3, 233-240, 1996, (Guest Editor of Special Issue). [Impact Factor: 1.69]

63. Novel Synthesis and Biological Activities of Cyclic Thrombin Receptor Peptides.

J.M. Matsoukas, D. Panagiotopoulos, M. Keramida, G. Moore, M. Saifeddeine and M. Hollenberg.

Journal of Medicinal Chemistry, 39, 3585-3591, 1996. [Impact Factor: 5. 2]

64. Conformational Analysis of the Thrombin Receptor Agonist Peptides SFLLR and SFLLR-NH_2 by NMR: Evidence for a Cyclic Bioactive Conformation.

J. Matsoukas, M.D. Hollenberg, T. Mavromoustakos, D. Panagiotopoulos, K. Alexopoulos, R. Yamdagni, Q. Wu and G.J. Moore.

J. Prot.Chem., 16(2), 113-131, 1997. [Impact Factor: 1.290]

65. Structure Elucidation and Conformational Analysis of Gonadotropin Releasing Hormone and its Novel Synthetic Analogue [Tyr(Ome)^5, D-Lys^6,Aze^9 NHEt]GnRH: The importance of Aromatic Clustering in the Receptor Binding Activity.
J. Matsoukas, M. Keramida, D. Panagiotopoulos, T. Mavromoustakos, H.L.S. Maia, G. Bigam, D. Pati, H.R. Habibi and G.J. Moore.
Eur. J. Med. Chem., 32, 927-940, 1997. [Impact Factor: 2.882]
66. Structure, Elucidation and Conformational Properties of the Immunomodulator Linomide.
T. Mavromoustakos, E. Theodoropoulou, M. Zervou, D. Panagiotopoulos, **J. Matsoukas**, D. Karussis.
Journal of Pharmaceutical and Biomedical Analysis, 16, 741-751, 1998. [Impact Factor: 2.629]
67. Recognition of the Encephalitogenic Myelin Basic Protein (74-85) Peptide by the Immune System: Importance of Conformation.
J.M. Pires, **J.M. Matsoukas** and G.J. Moore.
Proc. West. Pharmacol. Soc. 41: 193-195, 1998.
68. Synthesis and Activity of Tyr(Ome)^5-Gonadotropin-Releasing Hormone (GnRH) Analogues with Modifications at Position 6,9 and 10.
M. Keramida, **J. Matsoukas**, G. Agelis, D. Panagiotopoulos, J. Cladas, H.L.S. pati, G.J. Moore and H.R. Habibi.
Letters in Peptide Science 5: 305-315, 1998. [Impact Factor: 1.69]
69. Design and Synthesis of Small Semi-Mimetic Peptides with Immunomodulatory Activity Based on Myelin Basic Protein.
T. Tselios, L. Probert, G. Kollias, E. Matsoukas, P. Roumelioti, K. Alexopoulos, G.J. Moore, **J. Matsoukas.**
Amino Acids, 14:333-341, 1998. [Impact Factor: 4.132]
70. A Comparative SAR Study of Thrombin Receptor Derived Non-Peptide Mimetics: Importance of Phenyl/Quanidino Proximity for Activity.
K. Alexopoulos, **J. Matsoukas**, T. Tselios, P. Roumelioti, T. Mavromoustakos, K. Holada.
Amino Acids, 15, 211-220, 1998. [Impact Factor: 4.132]
71. Design and Synthesis of a Potent Cyclic Analogue of the Myelin Basic Protein Epitope MBP$_{72-85}$: Importance of the Ala^{81} Carboxyl Group and of a Cyclic Conformation for Induction of Experimental Allergic Encephalomyelitis (E.A.E.).
T. Tselios, L Probert, I. Daliani, E. Matsoukas, A. Troganis, I. Gerothanassis, T. Mavromoustakos, G. Moore and **J. Matsoukas**.
Journal of Medicinal Chemistry, 42, 170-1177, 1999. [Impact Factor: 5. 2]
72. An Effort to Understand the Molecular Basis of Hypertension Through the Study of Conformational Analysis of Losartan and Sarmesin Using a Combination of Nuclear Magnetic Resonance Spectroscopy and Theoretical Calculations.
T. Mavromoustakos, A. Kolocouris, M. Zervou, P. Roumelioti, **J. Matsoukas**, R. Weisemann.
Journal of Medicinal Chemistry, 42, 1714-1722, 1999. [Impact Factor: 5. 2]
73. Design and Synthesis of Thrombin Receptor-Derived Non-Peptide Mimetics Utilizing a Piperazine Scallold.
K. Alexopoulos, P. Fatseas, E. Melissari, D. Vlahakos, J. Smith, T. Mavromoustakos, M. Saifeddine, G. Moore, M. Hollenberg, **J. Matsoukas**.
Bioorganic and Medicinal Chemistry, 7, 1033-1041, 1999. [Impact Factor: 3.075]
74. Role of Myelin Basic Protein Epitope MBP$_{74-85}$ in Experimental Autoimmune Encephalomyelitis: Elaboration of Agonist and Antagonist Motifs.
J.M. Pires, T.V. Tselios, **J. M. Matsoukas** and G.J. Moore.
Drug Development Research 48: 1-5, 1999. [Impact Factor: 1.375]
75. Effects of Peptide and Non-Peptide Antagonists of Angiotensin II Receptors on Drinking Behavior in Rats.
L. Alova, S. Stancheva, **J. Mat**soukas, V. Giorgiev.
J. Physiology, 93, 219-224, 1999. [Impact Factor: 3.1]
76. The Bioactive Conformation of Angiotensin II. The Design and Synthesis of a Potent Angiotensin II Cyclic Analogue Confirms the Ring Cluster Receptor Conformation of the Hormone.
J. Matsoukas, J. Ancans, T. Mavromoustakos, P. Roumelioti, D.V. Vlahakos, R. Yamdagni, Q. Wu, G.J. Moore.
Bioorg. Med. Chem., 8, 1-10, 2000. [Impact Factor: 3.075]
77. Structural Comparison Between Type I and Type II Antagonists: Possible Implications in the Drug Design of AT1 Antagonists.
P. Roumelioti, T. Tselios, K. Alexopoulos, T. Mavromoustakos, A. Kolocouris, G. Moore, **J. Matsoukas**.
Bioorg. Med. Chem. Letters, 10, 1-4, 2000. [Impact Factor: 2.531]
78. Treatment of Experimental Allergic Encephalomyelitis (EAE) Induced by Guinea Pig Myelin Basic Epitope MBP$_{72-85}$ with a Human MBP$_{87-99}$ Analogue and effects of Cyclic Peptides.

T. Tselios, I. Daliani, S. Deraos, E. Matsouka, S. Roy, J. Pires, G. Moore, **J. Matsoukas**.
Bioorg. Med. Chem. , 8, 1903-1909, 2000. [Impact Factor: 3.075]

79. Treatment of Experimental Allergic Encephalomyelitis (EAE) by rationally designed cyclic analogue of Myelin Basic Protein (MBP) epitope 72-85.
T. Tselios, I. Daliani, S. Deraos, S. Thymianou, E. Matsouka, A. Troganis, I. Gerothanassis, A. Mouzaki, T. Mavromoustakos, L. Probert and **J. Matsoukas**.
Bioorg. Med. Chem. Let.,10, 2713-2717, 2000. [Impact Factor: 2.531]

80. Design, Synthesis and Modeling of Novel Cyclic Thrombin Receptor-Derived Peptide Analogues of the Ser^{42}-Phe-Leu-Leu-Arg^{46} Motif Sequence with Fixed Conformations of Pharmacophoric Groups:: Importance of a Phe/Arg/NH_2 Cluster for Receptor Activation and Implications in the Design of Non-Peptide Thrombin Receptor Mimetics.
K. Alexopoulos, D. Panagiotopoulos, T. Mavromoustakos, P. Fatseas, M.C. Paredes-Carbajal, D. Mascher, S. Mihailescu, **J. Matsoukas**.
Journal of Medicinal Chemistry, 44, 328-339, 2001. [Impact Factor: 5. 2]

81. Modulation of Angiogenesis and Progelatinase A by Thrombin Receptor Mimetics and Antagonists.
M. Maragoudakis, N. Kraniti, E. Giannopoulou-Missirlis, K. Alexopoulos and **J. Matsoukas**.
Endothelium, 8, 185-195, 2001. [Impact Factor: 1.929]

82. Antihypertensive Drugs that act on Renin-Angiotensin System with Emphasis in AT_1 Antagonists.
T. Mavromoustakos, V. Apostolopoulos, **J. Matsoukas**.
Mini Reviews in Med. Chem., 1, 207-217, 2001. [Impact Factor: 3.132]

83. Designing Peptide Mimetics for the Treatment of Multiple Sclerosis.
J. Matsoukas, V. Apostolopoulos, T. Mavromoustakos.
Mini Reviews in Med. Chem., 1, 273-282, 2001. [Impact Factor: 3.132]

84. Synthesis and Study of a Cyclic Angiotensin II Antagonist Analogue Reveals the Role of π^*-π^* Interactions in the C-terminal Aromatic Residue for Agonist Activity and its Structure Resemblance with AT_1 Non-peptide Antagonists.
L. Polevaya, T. Mavromoustakos, P. Zoumboulakis, S. Crdadolnik, P. Roumelioti, N. Giatas, I Mutule, D. Vlahakos, E. Iliodromitis, D. Kremastinos and **J. Matsoukas**.
Bioorganic and Medicinal Chemistry, 9, 1639-1647, 2001. [Impact Factor: 3.075]

85. Structure Elucidation and Conformational Properties of Eprosartan a Non Peptide Angiotensin II AT_1 Antagonist.
P. Zoumboulakis, S. Grdadolnik, **J. Matsoukas**, T. Mavromoustakos.
J. Pharm. and Biomed. Analysis., 28, 125-135, 2002. [Impact Factor: 2.629]

86. Applications of Peptide Mimetics in Cancer.
V. Apostolopoulos , **J. Matsoukas**, M. Plebanski, T. Mavromoustakos.
Current Med. Chem., 9: 411-420, 2002. [Impact Factor: 4.823]

87. Antagonistic Effects of Human Cyclic MBP_{87-99} Altered Peptide Ligands in Experimental Allergic Encephalomyelitis (EAE)and Human T-Cell Proliferation.
T. Tselios, V. Apostolopoulos, I. Daliani, S. Deraos, S. Grdadolnik, T. Mavromoustakos, M. Melachrinou, S. Thymianou, L. Probert, A. Mouzaki, **J. Matsoukas**.
Journal of Medicinal Chemistry, 45, 275-283, 2002. [Impact Factor: 5. 2]

88. Design, Synthesis and Biological Evaluation of Cyclic Angiotensin II Analogues with 3,5 Side-Chain Bridges: Role of C-Terminal Aromatic Residue and Ring Cluster for Activity and Implications in the Drug Design of AT_1 Non Peptide Antagonists.
P. Roumelioti, L. Polevaya, P. Zoumpoulakis, N. Giatas, I. Mutule, T. Keivish, A. Zoga, D. Vlahakos, E. Iliodromitis, D. Kremastinos, S. Crdadolnik, T. Mavromoustakos, **J. Matsoukas**.
Bioorg. Med. Chem. Let., 12, 2627-2636, 2002 [Impact Factor: 3.075].

89. Conformational and Biological Studies for a Pair of Novel Synthetic AT1 Antagonists: Stereoelectronic Requirements for Antihypertensive Efficacy.
P. Zoumpoulakis, A. Zoga, P. Roumelioti, N. Giatas, S.G.Grdadolnik, E. Iliodromitis, D. Vlahakos, D. Kremastinos, **J. Matsoukas**, T. Mavromoustakos.
Journal of Pharmaceutical and Biomedical Analysis 31, 833-844, 2003 [Impact Factor: 2.629].

90. The Effects of Sarmesin, an Angiotensin II Analogue of Seizure Susceptibility, Memory Retention and Nociception.
J. Tchekalarova, D. Pechlivanova, T. Kambourova, **J. Matsoukas** and V. Georgiev.
Regulatory Peptides, 111, 191-197, 2003. [Impact Factor: 2.276].

91. Synthetic peptides mapping epitopes of the extracellular domain of the IL-2 receptor (IL-2R) beta chain as putative inhibitors of T-cell activation.

T. Parissi, K. Chatzantoni, S. Deraos, **J. Matsoukas** , A. Mouzaki.
Immunology Letters 87, 299-300, 2003. [Impact Factor: 2.858]

92. Design and synthesis of novel biologically active thrombin receptor non-peptide mimetics based on the pharmacophoric cluster Phe/Arg/NH_2 of the Ser_{42}-Phe-Leu-Leu-Arg_{46} Motif sequence: Platelet aggregation and relaxant activities.

K. Alexopoulos, P. Fatseas, E. Melissari, D. Vlahakos, P. Roumelioti, T. Mavromoustakos, S. Mihailescu, M. C. Paredes-Carbajal, D. Mascher and **J. Matsoukas.**

Journal of Medicinal Chemistry, 47, 3338-3352, 2004 [Impact Factor 5. 2].

93. Conformation and Bioactivity. Design and Discovery of Novel Antihypertensive Drugs.

T. Mavromoustakos, M. Zervou, P. Zoumpoulakis, I. Kyrikou, L. Polevaya, P. Roumelioti, N. Giatas A. Zoga, P.M. Minakakis, A. Kolocouris, D. Vlahakos, S. Golic Grdadolnik, **J. Matsoukas**.

Current Topics in Medicinal Chemistry, 4, 385-401, 2004 [Impact Factor 4.823].

94. Hematocrit-lowering effect following inactivation of Renin-Angiotensin-System with angiotensin converting enzyme inhibitors and angiotensin receptor blockers.

K.P. Marathias, B. Agroyannis, T. Mavromoustakos, **J. Matsoukas**, D.V. Vlahakos.

Current Topics in Medicinal Chemistry, 4, 483-486, 2004 [Impact Factor 4.823]

95. Immunotherapy for Multiple Sclerosis: Basic insights for new clinical strategies

A. Mouzaki, T. Tselios, P. Papathanassopoulos, **J. Matsoukas** and K. Chatzantoni.

Current Neurovascular Research, 1 (4): 325-340, 2004 [Impact Factor 3.571].

96. NMR and MD Studies of an Autoimmune MBP Peptide and its /antagonist. Structural Implications for the MHC II (I-Au) Peptide Complex through Docking Calculations.

A. Tsakos, F. Patric, van Nuland Nico, A. Troganis, T. Tselios, S. Deraos, **J. Matsoukas**, I. Gerothanasis, B. Alexandre.

European Journal of Biochemistry, 399-3413, 2004 [Impact Factor 3.6].

97. Animal models of central nervous system immune-mediated diseases: Therapeutic interventions with Bioactive Peptides and Mimetics. Special Issue-Bioactive Peptides in Immune Disease Terapy.

N. Grigoriadis, S. Deraos, T. Tselios, A. Orologas, **J. Matsoukas**.

Current Medicinal Chemistry, 12, 1513-1519, 2005 [Impact Factor 4.823].

98. Structure-Function Relationships of the Myelin Proteins: Current Status and Perspectives. Special Issue-Bioactive Peptides in Immune Disease Therapy.

A. Tzakos, A. Troganis, V. Theodorou, T. Tselios, C. Svarnas, **J. Matsoukas**, V. Apostolopoulos and I. Gerothanassis.

Current Medicinal Chemistry, 12, (13) 1569-1587, 2005 [Impact Factor 4.823].

99. Structural Requirements for Binding of Myelin Basic Protein (MBP) Peptides to MHC II: Effects on Immune Regulation.

E.D. Mantzourani, T.M. Mavromoustakos, J.A. Platts, **J.M. Matsoukas**, T.V. Tselios.

Current Medicinal Chemistry 12, (13), 1569-1587, 2005 [Impact Factor 4.823].

100. Enhanced Stability and Biological Properties of Myelin Basic Protein Epitope 87-99 cyclic mimics render them a potentially new class of Immunomodulators.

J. Matsoukas, V. Apostolopoulos, H. Kalbacher, A.M. Papini, T. Tselios, K. Chantzantoni, T. Biagioli, F. Lolli, S. Deraos, P. Papathanassopoulos, T. Mavromoustakos, L. Probert, A. Mouzaki.

Journal of Medicinal Chemistry, 10, 48 (5) 1470-80, 2005 [Impact Factor 5. 2].

101. Synthesis and Study of the electrophoretic behavior of mannan conjugates with cyclic peptide analogue of Myelin Basic Protein using lysine-glycine linker.

T. Tselios, F. Lamari, I. Karathanasopoulou, M. Katsara, V. Apostolopoulos, G. Pietersz, **J. Matsoukas**, N. Karamanos.

Analytical Biochemistry 1, 347 (1), 121-128, 2005 [Impact Factor 3.088].

102. A putative bioactive conformation for the altered peptide ligand of Myelin Basic Protein and inhibitor of experimental autoimmune incephalomyelitis [Arg^{91}, Ala^{96}] MBP_{87-99}.

E. Mantzourani, T. Tselios, S. Grdadolnik, A. Brancale, J. Platts, **J. Matsoukas**, T. Mavromoustakos.

Journal of Molecular Graphics and Modelling, 25 (1), 17-29, 2006 [Impact Factor 2.347].

103. Design, Synthesis and Molecular Modelling of a novel amide linked cyclic GnRH analogue cyclo (4-9) [Lys^4, D-Trp^6, Glu^9] GnRH: Stimulation of gonadotropin gene expression.

M. Keramida, T. Tselios, E. Mantzourani, K. Papazisis, T. Mavroumoustakos, C. Claussen, G. Agelis, S. Deraos, H. Habibi, **J. Matsoukas**.

Journal of Medicinal Chemistry 49 (1), 105-110, 2006 [Impact Factor 5. 2]

104. Structure elucidation and conformational study of V8, A vonel synthetic non peptide AT_1 antagonist.
P. Zoumpoulakis, A. Politi, S. Golic Grdadolnik, **J. Matsoukas**, T. Mavromoustakos.
Journal of Pharmaceutical and Biomedical Analysis 40, 1097-1104, 2006 [Impact Factor 2.629].

105. Round and round we go : Cyclic Peptides in Disease
Katsara M., Tselios T., Deraos S., Deraos G., Matsoukas M., Lazoura E., **Matsoukas** J., Apostolopoulos V.
Current Medicinal Chemistry, Vol. 13, Number 19, August 2006, pp. 2221-2232(12) [Impact Factor 4.823].

106. Comparison of Proposed Putative Active Conformations of Linear Altered Peptide Ligands with Myelin Basic Protein Epitope 87-99 Linear Altered Peptide Ligands by Spectroscopic and Modelling Studies: The Role of Positions 91 and 96 in T-Cell Receptor Activation.
E. Mantzourani, T. Tselios, S. Grdadolnik, J. Platts, A. Brancale, G. Deraos, **J. Matsoukas**, T. Mavromoustakos.
Journal of Medicinal Chemistry, 49, 6683-6691, 2006 [Impact Factor 5. 2].

107. Emerging therapeutic approaches multi-targeting receptor tyrosine kinases and g protein-coupled receptors in cardiovascular disease.
Flordellis C, Papathanasopoulos P, Lymperopoulos A, Matsoukas J, Paris H.
Cardiovasc Hematol Agents Med Chem. 2007 5(2), 133-45). [Impact Factor 5.05].

108. Putative Bioactive Conformations of Amide Linked Cyclic Myelin Basic Protein Peptide Analogues Associated with Experimental Autoimmune Encephalomyelitis.
Spyranti Z.,Dalkas G.A., Spyroulias G.A., Mantzourani E.D., Mavromoustakos T., Friligou I., **Matsoukas J.M.**, Tselios T.V.
Journal of Medicinal Chemistry, 50, 50(24): 6039-6047, 2007, [Impact Factor 5. 2].

109. Solid Phase Synthesis of a Glycopeptide analogue using the acid sensitive 4-Methoxybenzhydryl bromide resin.
Tselios T., Kelaidonis K., Resvani A., Prousalis K., **Matsoukas J.**, Tsegenidis T.
Protein & Peptide Letters, 15, 1-5, 2008. [Impact Factor 1.281]

110. A combined NMR and molecular dynamics simulation study to determine the conformational properties of agonists ans antagonists against experimental autoimmune encephalomyelitis.
E. D. Mantzourani, K. Blokar, T. V. Tselios, **J. M. Matsoukas**, J. A. Platts, T. M. Mavromoustakos, S. G. Grdadolnik.
Bioorganic & Medicinal Chemistry, 16, 2171 – 2182, 2008 [Impact Factor 3.075]

111. Design of novel cyclic altered peptide ligands of myelin basic protein MBP_{83-99} modulate immune responses in SJL/J mice.
M. Katsara, G. Deraos, T. Tselios, **J.M. Matsoukas**, V. Apostolopoulos
Journal of Medicinal Chemistry, 51 (13), 3971-8, 2008 [Impact Factor 5. 2]

112. Mannosylation of mutated MBP_{83-99} peptides diverts immune responses from Th1 to Th2.
M. Katsara, E. Yuriev, P. A. Ramsland, G. Deraos, T. Tselios, **J. M. Matsoukas**, V. Apostolopoulos
Molecular Immunology, 45, 3661-3670, 2008 [Impact Factor 3.555]

113. Towards immunotherapeutic drugs and vaccines against mulriple sclerosis
M. Katsara, **J. Matsoukas**, G. Deraos, V. Apostolopoulos
Acta Biochim Biophys Sin, 2008, Vol. 40, Issue 7(pp 636-642) [Impact Factor 1.086]

114. *In vivo* evaluation and *in vitro* metabolism of leuprolide in mice – mass spectrometry – based biomarker measurement for efficacy and toxicity
Z.D. Sofianos, T. Katsila, N. Kostomitsopoulos, V. Balafas, **J. Matsoukas**, T. Tselios, and C. Tamvakopoulos Pharmacokinetics and In Vitro Metabolism of Leuprolide in Mice - Mass Spectrometry Based Evaluation of Efficacy and Toxicity.
Journal of Mass Spectroscopy, 43, 1381-1392, 2008 [Impact Factor 3.5].

115. A double mutation of MBP_{83-99} peptide induces IL-4 responses and antagonizes IFN-g responses.
M. Katsara, E. Yuriev, P.R. Ramsland, G. Deraos, T. Tselios, **J. Matsoukas** and V. Apostolopoulos
Journal of Neuroimmunology, 200, 77-89, 2008 [Impact Factor 3,159].

116. Citrullination of Myelin Basic Protein (MBP_{87-99}) epitopes elicits a Th1 polarized immune response in cells Isolated from multiple sclerosis patients and may trigger diserase: The Role of His^{88} in T-Cell Receptor Activation.
G. Deraos, K. Chatzantoni, M.T. Matsoukas, T. Tselios, S. Deraos, P. Papathanasopoulos, D. Vynios, V. Apostolopoulos, A. Mouzaki, **J. M. Matsoukas**
Journal of Medicinal Chemistry, 51 (24), 7834-7842, 2008 [Impact Factor 5. 2].

117. Design and synthesis of a cyclic double mutant (cyclo(87- 99)$[A^{91}]MBP_{87-99}$)

induces altered responses in mice after conjugation to mannan: implications in the immunotherapy of MS.
Katsara, M., Deraos, G., Matsoukas, **J., Matsoukas**, MT., Friligou, I., Tselios T. and Apostolopoulos, V.
Journal of Medicinal Chemistry, 52 (1), 214-218, 2009 [Impact Factor 5. 2].

118. Altered peptide ligands of myelin basic protein (MBP_{87-99}) conjugated to reduced mannan modulate immune responses in mice.
Katsara, M., Yuriev, E., Ramsland, P.R., Tselios, T., Deraos, G., Lourbopoulos, A., Grigoriadis, N., Matsoukas, J. and **Apostolopoulos, V**.
Immunology, 128:521-533, 2009 [Impact Factor 3.398].

119. NMR structural elucidation of myelin basic protein epitope 83-99 implicated in multiple sclerosis.
Z. Spyranti, T. Tselios, G. Deraos, **J. Matsoukas**, G. A. Spyroulias
Amino Acids, 2010, 38 (3: 929-936) [Impact Factor: 4.132]

120. Design, synthesis and biological evaluation of non-peptide PAR_1 thrombin receptor antagonists based on small bifunctional templates: arginine and phenylalanine side chain groups are keys for receptor activity.
M-E Androutsou, M. Saifeddine, M. D. Hollenberg, **J. Matsoukas**, G. Agelis
Amino Acids, 2010, *38*: 985-990 [Impact Factor: 4.132].

121. An efficient synthesis of a rationally designed 1,5 disubstituted imidazole AT1 angiotensin II receptor antagonist: Reorientation of imidazole pharmacophore groups in losartan reserves high receptor affinity and confirms docking studies.
G. Agelis, P. Roumelioti, A. Resvani, S. Durdagi, M-E Androutsou, K. Kelaidonis, D. Vlahakos, T. Mavromoustakos, **J. Matsoukas**
Journal of Computer-Aided Molecular Design, 2010, 24:749-758 [Impact Factor: 3.1]

122. Remitting–relapsing multiple sclerosis patient refractory to conventional treatments and bone marrow transplantation who responded to natalizumab"
A. Mouzaki, M. Koutsokera, Z. Dervilli, M. Rodi, D. Kalavrizioti, N. Dimisianos, **J. Matsoukas** and P. Papathanasopoulos
International Journal of General Medicine, 2010,3:313-20

123. Towards non-peptide ANG II AT1 receptor antagonists based on urocanic acid: Rational design, synthesis and biological evaluation.
G. Agelis, A. Resvani, M.-T. Matsoukas, T. Tselios, K. Kelaidonis, D. Kalavrizioti, D. Vlahakos and **J. Matsoukas**
Amino Acids 40,411-420, 2011[Impact Factor: 4.132].

124. Microwave-assisted solid-phase peptide synthesis of the 60-110 domain of human pleiotrophin on 2-chlorotrityl resin.
Friligou I., Papadimitriou E., Gatos D., **Matsoukas J**., Tselios T.
Amino Acids (2011) 1430-1440) [Impact Factor: 4.132].

126. Evaluation of a stable gonadotropin releasing hormone analogue in mice for the treatment of endocrine disorders and prostate cancer.
T. Katsila, E. Balafas, G. Liapakis, P. Limonta, M. Montagnani Marelli, K. Gkountelias, T. Tselios, N. Kostomitsopoulos, **J. Matsoukas**, C. Tamvakopoulos.
Journal of Pharmacology and Experimental Therapeutics, 336, 613-623, 2011[Impact Factor: 4.17].

127. Conformational studies of immunodominant myelin basic protein 1-11 analogues using NMR and molecular modeling
D. Laimou, E. Lazoura, A. N. Troganis, M.- T. Matsoukas, S. N. Deraos, M. Katsara, **J. Matsoukas**, V. Apostolopoulos, T. V. Tselios
Journal Comput Aided Mol Des. , 25(11),1019-32,2011

128. Crucial role of granulocytic myeloid-derived suppressor cells in the regulation of central nervous system autoimmune disease.
M. Ioannou, T. Alissafi, I. Lazaridis, G. Deraos, **J. Matsoukas**, A. Gravanis, V. Mastorodemos, A. Plaitakis, A. Sharpe, D. Boumpas and P. Verginis
Journal of Immunology, 188(3),1136-1146,2012, (**Impact Factor 5.8**).

129. Recognition Pliability is Coupled to Structural Heterogeneity: a Calmodulin - Intrinsically Disordered Binding Region Complex
Malini Nagulapalli[1], Giacomo Parigi[1], Jing Yuan[1], Joerg Gsponer,[2,3] George Deraos,[4] Vladimir V. Bamm,[5] George Harauz,[5] ***John Matsoukas****,[4] Maurits RR de Planque,[6] Ioannis P. Gerothanassis,[7] M. Madan Babu,[2] Claudio Luchinat,[1*] & Andreas G. Tzakos[7*]*
Structure, 20(3), 522-533, 2012 (**Impact Factor 6. 4**)

130. The Discovery of New Potent non-peptide Angiotensin II AT1 Receptor Blockers: A Concise Synthesis, Molecular Docking Studies and Biological Evaluation of N-substituted 5-Butylimidazole Derivatives.
G. Agelis, A. Resvani, S. Dulgagi, K. Spyridaki, T. Tumova, J. Slaninova, P. Giannopoulos, D. Vlahakos, G. Liapakis, T. Mavromoustakos, **J. Matsoukas,**
Eur. J. Med. Chem., 55 (2012) 358 -374

131. Rationally designed cyclic analogues of luteinizing hormone-releasing hormone: Enhanced enzymatic stability and biological properties. D. Laimou, T. Katsila, **J. Matsoukas**, A. Schally, K. Gkountelias, G. Liapakis, C. Tamvakopoulos, T. Tselios.
European Journal of Medicinal Chemistry, 58, 237–247, 2012

132. Rational Design, Efficient Syntheses and Biological Evaluation of *N,N´*- symmetrically bis-substituted butylimidazole analogs as a new class of potent Angiotensin II Receptor Blockers, G. Agelis, A. Resvani, C. Koukoulitsa, T. Tůmová, J. Slaninová, D. Kalavrizioti, K. Spyridaki, A. Afantitis, G. Melagraki, A. Siafaka, E. Gkini, G. Megariotis, S. Golic Grdadolnik, M. G. Papadopoulos, D. Vlahakos, M. Maragoudakis, G. Liapakis, T. Mavromoustakos**, J. Matsoukas, European Journal of Medicinal Chemistry,** 62, 352-370, 2013**.**

133. Interactions of the potent synthetic AT1 antagonist analog BV6 with membrane bilayers and mesoporous silicate matrices. G. Agelis, A. Resvani, D. Ntountaniotis, P. Chatzigeorgiou, C. Koukoulitsa, M.E. Androutsou, P. Plotas, **J. Matsoukas**, T. Mavromoustakos, T. Čendak, T. Ukmar Godec, G. Mali. **Biochimica et Biophysica Acta (BBA) – Biomembranes**, 1828, (8), 1846–1855, 2013.

134. Facile and Efficient Syntheses of a Series of N-Benzyl and N-Biphenylmethyl Substituted Imidazole Derivatives Based on (E)-Urocanic acid, as Angiotensin II AT1 Receptor Blockers. G. Agelis, K. Kelaidonis, A. Resvani, D. Kalavrizioti , M.E. Androutsou, P. Plotas, D. Vlahakos, C. Koukoulitsa, T. Tselios, T. Mavromoustakos and **J. Matsoukas**. **Molecules** ,18(7), 7510-7532, 2013.

135. Divergent and convergent synthesis of polymannosylated dobranched antigenic peptide of the immunodominant epitope MBP(83-99). I. Friligou, **J. Matsoukas** et al, **Bioorganic& Medicinal Chemistry, 21(21), 6718-6725, 2013**.

136. Immune responses of linear and cyclic PLP139-151 mutant peptides in SJL mice: peptides in their free state versus mannan conjugation., Katsara, M., Deraos, S., Tselios, T.V., Pietersz, G.A., **J. Matsoukas**, J. Apostolopoulos, V. **Immunotherapy (**In Press, 2014)

137. An efficient synthetic method and theoretical calculations of olmesartan methyl ether: Study of biological function of AT1 antagonism. D. Ntountaniotis, G. Agelis, A. Resvani, M. Halabalaki, G. Liapakis, K. Spyridaki, S. Golic Grdadolnik, F. Merzel, S. Kostidis, C. Potamitis, T. Tselios, J. Matsoukas, A. L. Skaltsounis, T. Mavromoustakos. Combinatorial Chemistry & High Throughput Screening. (In Press 2014)

Communications in Journal of Peptide Science

1. K. Alexopoulos, E. Melissari, P. Fatseas, D. Vlahakos, T. Tselios, P. Roumelioti, J. **Matsoukas**. Synthesis and biological activities of thrombin receptor derived peptide mimetics: Importance of phenyl/gouanidino proximity for activation. ***J. Peptide Science***, 1998, 4, 97.(I.F. 1.8).
2. T. Tselios, L. Probert, I. Daliani, E. Matsoukas, P. Roumelioti, K. Alexopoulos, **J. Matsoukas**. Synthesis of novel cyclic analog of the myelin basic protein epitope MBP_{72-85}. *J. Peptide Science*, 1998, 4, 76. (I.F. 1.8).
3. T. Tselios, I. Daliani, L. Probert, S. Deraos, E. Matsoukas, P. Roumelioti, K. Alexopoulos, **J. Matsoukas**. Design and synthesis of potent linear and cyclic analogues of the myelin basic protein epitope MBP_{87-99}. ***J. Peptide Science***, 2000, 6, 186. (I.F. 1.8).
4. K. Alexopoulos, P. Fatseas, A. Zoga, N. Giatas, T. Tselios, P. Roumelioti, E. Melissari, D. Vlahakos, C. Demopoulos, **J. Matsoukas**. The discovery of a non-peptide thrombin receptor antagonist in human and also rabbit platelets: a novel drug lead. ***J. Peptide Science***. 2000, 6, 191. (I.F. 1.8).

5. **J. Matsoukas**, S. Deraos, T. Tselios, I. Daliani, G. Deraos, P. Zoumpoulakis, L. Probert, A. Troganis, T. Mavromoustakos. Design, synthesis and conformation properties of linear analogues based on myelin basic protein epitope MBP_{1-11}. ***J. Peptide Science***. 2002, 8, 157. .(I.F. 1.8).
6. A. Tzakos, P.Fuchs, N. van Nuland, A.Troganis, T. Tselios, S. Deraos, G. Deraos, I. Gerothanassis, A. Bonvin, **J. Matsoukas.** Structural studies and sequence homology investigations of the guinea pig myelin basic protein (MBP) epitope 74-85 analogues. ***Biopolymers, Peptide Science***. 2003, 71(3): P514. .(I.F. 1.8).
7. G.Deraos, S. Deraos, T. Tselios, **J. Matsoukas**, H. Vynios, Citrullination Of EAE Antagonist Analogue, Cyclo(87–99) [Arg^{91}, Ala^{96}] MBP_{87-99} with Peptidylarginine Deiminase (PAD), ***J. Peptide Science***. 2004, H 63. (I.F. 1.8).
8. E. Mantzourani, T. Tselios, **J. Matsoukas**, T. Mavromoustakos. Structural Elucidation and Conformational Analysis of a Potent Altered Peptide Ligand [Arg^{91}, Ala^{96}]MBP_{87-99}, Employing Experimental NOEs Constraints Combined with theoretical Calculations and Molecular Modelling. ***J. Peptide Science***. 2004, H 56. (I.F. 1.8).
9. S. Deraos, T. Parissi, T. Tselios, G. Deraos, M. Matsoukas, K. Chatzantoni, A. Mouzaki, **J. Matsoukas** Solid Phase Synthesis of IL-2 Receptor (IL-2R) Extracellular Domain Beta Chain Epitopes M^{107}-E^{118} and Y^{178}-Q^{199}: Inhibition of T-cell Activation. ***J. Peptide Science***, 2004, 10, 288. (I.F. 1.8)
10. G. Deraos, T. Tselios, S. Deraos, L. Synodinos, A. Papalois, **J. Matsoukas**, Design and Synthesis of a Potent Analogue of Myelin Basic Protein MBP_{87-99} Epitope: Inhibition of Experimental Autoimmune Encephalomyelitis (EAE), ***J. Peptide Science,*** 2004, 10, 288. (I.F. 1.8).
11. Katsara, M., Tselios, T., Deraos, S., Deraos, G., **Matsoukas, J.**, and Apostolopoulos, V. Myelin Basic Protein (MBP) and Proteolipid Protein (PLP)
    Peptides (Linear and cyclic) and Immune responses in animal models. Therapeutic Approaches for Multiple Sclerosis. **Tissue Antigens,** 2005, 66 5): 461-461 325.
12. A. Holeva, I. Friligou, M. Keramida, T. Tselios, **J. Matsoukas**. Design and Synthesis of two Cyclic Analogues of Gonadotropin Releasing Hormone (GnRH) for the Treatment of Canser. ***J. Peptide Science***, 2006, 12, 108 (Th015). (I.F. 1.8).
13. M.Matsoukas, A. Resvani, K. Kelaidonis, D. Lemou, **J. Matsoukas**, T. Tselios. Design, Synthesis and Conformational Analysis of a Potent Angiotensin II Losartan Based Antagonist. ***J. Peptide Science***, 2006, 12, 117 (M049). (I.F. 1.8).
14. M. Androutsou, K. Alexopoulos, S. Mihailescu, T. Tselios, **J. Matsoukas**. Desing and Synthesis of a Novel Non-Peptide Mimetic of PAR-1 Thrombin Receptor with four Pharmacophoric Groups. ***J. Peptide Science***, 2006, 12, 120 (Tu062). (I.F. 1.8).
15. G. N. Deraos, M. Katsara, T. Tselios, S. N. Deraos, V. Apostolopoulos, **J. M. Matsoukas**. Design and Synthesis of Myelin Basic Protein (MBP) Linear and Cyclic Peptide Analogues Complexed with Mannan. Effects in Cytokine Production. ***J. Peptide Science***, 2006, 12, 223 (Th474). (I.F. 1.8).
16. E. D. Mantzourani, T. M. Mavromoustakos, S. Golic-Grdadolnik, J. A. Platts, G. N. Deraos, **J. M. Matsoukas**, T. V. Tselios. Comparison of Proposed Putative Bioactive Conformations of Altered Peptide Ligands of myelin Basic Protein by Spectroscopic and Modelling Studies. ***J. Peptide Science***, 2006, 12, 189 (Tu338). (I.F. 1.8).
17. S. N. Deraos, T. V. Tselios, I. Mylonas, G. N. Deraos, **J. M. Matsoukas**, N. Grigoriadis. A Proteolipid Protein Cyclic Peptide Analogue Reduces the Enchephalitogenicity in EAE Model. ***J. Peptide Science***, 2006, 12, 223 (Tu475) (I.F. 1.8).
18. Drug design on non-peptide mimetics: A new generation of pharmaceutical products
    J. Matsoukas
    Journal of Peptide Science, *Vol. 14, (p.p. 17), Issue No 8,* 2008,**[Impact Factor: 1.8]**
19. Design and synthesis of a non-pepride PAR1 thrombin receptor antagonist, using cyclohexane as template
    M. Androutsou, G. Agelis, G. Magoulas, P. Keppa, M. Saifeddine, M. Holleberg, **J. Matsoukas**
    Journal of Peptide Science, *Vol. 14, (p.p. 144), Issue No 8,* 2008,**[Impact Factor: 1.8]**
20. Modeling studies and biological activities of a non-peptide AT_1 receptor angiotensin II antagonist
    G. Agelis, M. Matsoukas, A. Resvani, K. Kelaidonis, P. Keppa, T. Tselios, D. Vlahakos, **J. Matsoukas**
    Journal of Peptide Science, *Vol. 14,(p.p. 145),Issue No 8,* 2008 **[Impact Factor: 1.8]**
21. Modifications of the Myelin Basic Protein epitope MBP87-99 divert Th2 to Th1: Immune responses in peripheral blood mononuclear cells (PBMC) from Multiple Sclerosis patients.
    G.Deraos, **J. Matsoukas**
    Journal of Peptide Science, *Vol. 14, (p.p. 84), Issue No* 8, 2008 **[Impact Factor: 1.8]**

22. *Efficient microwave-assisted synthesis of myelin epitopes MOG35-55 and MOG97-108 using CLTR-CL resin.*
Friligou, M.E.Androutsou, T.Tselios and **J. Matsoukas.**
Journal of Peptide Science, *Vol. 14, (p.p. 90), Issue No* 8, 2008, **[Impact Factor: 1.8]**

23. A vaccine toward multiple sclerosis.
Katsara, M., Yuriev, E., Ramsland, P.A., Deraos, G., **Matsoukas, J.** and Apostolopoulos, V.
Journal of Peptide Science,*Vol. 14, (p.p 120), Issue No 8,* 2008 **[Impact Factor: 1.8]**

24. Efficient Microwave – Assisted Synthesis of Mitochondrial Signal Peptide using Cltr-Cl and Wang Resin.
Androutsou M-E, Agelis G., **Matsoukas J.**
Journal of Peptide Science,*Vol. 16, (p.p 58), Issue S1,*2010

25. From Peptides to Non Peptide Mimetics: The Examples of Angiotensin II and Myelin.
Matsoukas J.
Journal of Peptide Science,*Vol. 16, (p.p 100), Issue S1,*2010

26. Efficient Synthesis and Biological Evaluation of Substituted Imidazole AT1 ANG II Receptor Antagonists Based on 4(5)-Butylimidazole.
Resvani A., Slaninova J., **Matsoukas J.,** Agelis G.
Journal of Peptide Science,*Vol. 16, (p.p 100), Issue S1,*2010

27. Synthesis and Biological Evaluation of 1-Benzyl and 1-Biphenylmethyl Substituted Imidazole AT1 ANG II Receptor Antagonists.
Kelaidonis K., Kalavrizioti D., **Matsoukas J.** Agelis G.
Journal of Peptide Science, *Vol. 16, (p.p 101), Issue S1,*2010

28. A Concise Synthesis, Docking Studies and Biological Evaluation of *N*-substituted 5-Butylimidazole Analogues as potent Angiotensin II Receptor Blockers
Agelis, A. Resvani, S. Durdagi, T. Tůmová, J. Slaninová, P. Giannopoulos, K. Spyridaki, G. Liapakis, D. Vlahakos, T. Mavromoustakos, **J. Matsoukas**
Journal of Peptide Science, *Vol. 18, (p.p 116),* 2012

29. Rational Design, Efficient Synthesis, Biological Evaluation of New *N,N´*-bis-substituted Butylimidazole analogs as potent Angiotensin Receptor Blockers
G. Agelis, A. Resvani, C. Koukoulitsa, A. Afantitis, G. Melagraki, A. Siafaka, E. Gkini, T. Tůmová, K. Spyridaki, D. Kalavrizioti, M-E. Androutsou, J. Slaninová, G. Liapakis, D. Vlahakos, T. Mavromoustakos, **J. Matsoukas**
Journal of Peptide Science, *Vol. 18, (p.p 123),* 2012

30. Facile and Efficient Syntheses of Structurally Modified *E*-urocanic acid analogs as potent Angiotensin II Receptor Blockers
A. Resvani, C. Nikolis, G. Liapakis D. Vlahakos, C. Koukoulitsa, D. Ntountaniotis, T. Mavromoustakos, **J. Matsoukas**, G. Agelis
Journal of Peptide Science, *Vol. 18, (p.p 120),* 2012

31. Conformational Similarities and Differences of Angiotensin II (AII): AII Acetate vs TFA Salt in Solution
C. Potamitis, A. Resvani, M-E. Androutsou M. Zervou, P. Plotas, G. Agelis, P. Zoumpoulakis, **J. Matsoukas**
Journal of Peptide Science, *Vol. 18, (p.p 161),* 2012

32. Transdermal delivery: New approach in anti-hypertensive therapy
M. Michalatou, M. E. Androutsou, T. Tselios, A. Resvani, G. Agelis, D. Vlahakos, **J. Matsoukas**
Journal of Peptide Science, *Vol. 18, (p.p 129),* 2012

33. Rational Design and Synthesis of linear and cyclic Myelin Epitope Peptides: New Directions in the Immunotherapy of Multiple Sclerosis
John Matsoukas
Journal of Peptide Science *Vol. 18, (p.p 31),* 2012

34. Development and validation of a UPLC- MS analytical method for the control of the conjugation of $[Lys\text{-}Gly]_5\text{-}MOG_{35\text{-}55}$ with mannan
M. E. Androutsou, I. Friligou, **J. Matsoukas,** T. Tselios
Journal of Peptide Science, *Vol. 18, (p.p 195),* 2012

35. Recognition Pliability is Coupled to Stuctural Heterogeneity: a Calmodulin – Intrinsically Disordered Binding Region Complex.
M.Nagulapalli, G. Parigi, J. Yuan, J. Gsponer, G. Deraos, V.V. Bamm, G. Harauz, J. Matsoukas, I.P. Gerothanassis, M. Madan Babu, C. Luchinat, A.G. Tzakos

Journal of Peptide Science, *Vol. 18, (p.p 24)*, 2012

36. A stable gonadotropin releasing hormone analogue for the treatment of endocrine disorders and prostate cancer.
T. Katsila, E. Balafas, G. Liapakis, P. Limonta, M.M. Marelli, K. Gkountelias, T. Tselios, N. Kostomitsopoulos, J. Matsoukas, C. Tamvakopoulos.
Journal of Peptide Science, *Vol. 18, (p.p 135)*, 2012

37. Design and Synthesis of Potent Linear and Cyclic Dirucotide Analogues.
G. Deraos, K. Mauridaki, S. Deraos, T. Tselios, A. Mouzaki, J. Matsoukas
Journal of Peptide Science, *Vol. 18, (p.p 138)*, 2012

38. Enhanced stability and biological properties of rationally designed cyclic analogues of Luteinizing Hormone – Releasing Hormone.
D.Laimou,T. Katsila, J. Matsoukas, A. Schally, K. Gkountelias, G. Liapakis, C. Tamvakopoulos, T. Tselios.
Journal of Peptide Science, *Vol. 18, (p.p 140)*, 2012

Book Chapters

B1 Use of Molecular Modeling to Study Superimposition of Angiotensin II with its Non-Peptide Receptor Antagonists.
Th. Mavromoustakos, E. Theodoropoulou, **J.M. Matsoukas**, G.J. Moore and J. Smith.
Review of Clinical Pharmacology and Pharmacokinetics (International Edition, Guest Editor of Special Issue J. Matsoukas), 8, 137-142, 1994.

B2 A New Generation of Antihypertensives: Non Peptide Angiotensin II Receptor Antagonists.
J. Smith, A. Wahhab, J. Hondrelis, R. Ganter, D. Moore and **J.M. Matsoukas**.
Review of Clinical Pharmacology and Pharmacokinetics (International Edition, Guest Editor of Special Issue J. Matsoukas), 9, 75-79, 1995.

B3 Designing Peptides Mimetics.
G.J. Moore and **J.M. Matsoukas**.
Review of Clinical Pharmacology and Pharmacokinetics (International Edition, Guest Editor of Special Issue J. Matsoukas), 9, 53-58, 1995.

B4 Type I Angiotensin II Antagonists.
G. Agelis, A. Wahhab, J. Hondrelis, R. Yamdagni, Q. Wu, R. Ganter, J. Smith, G.J. Moore and **J.M. Matsoukas**.
Review of Clinical Pharmacology and Pharmacokinetics (International Edition, Guest Editor of Special Issue J. Matsoukas), 9, 59-61, 1995.

B5 Cyclic Thrombin Receptor Derived Peptide Analogues.
M. Panagiotopoulos, **J.M. Matsoukas**, M. Keramida, S. Deraos, H.L.S. Maia, R. Yamdagni, Q. Wu, P. Redstone, G.J. Moore, A.A. Laniyonu, M Saifeddine and M.D. Hollenberg.
Review of Clinical Pharmacology and Pharmacokinetics (International Edition, Guest Editor of Special Issue J. Matsoukas), 9, 63-65, 1995.

B6 Gonatotropin-Releasing Hormone (GnRH) Analogues Containing Tyr (OMe) at Position 5.
M Keramida, **J.M. Matsoukas**, G. Agelis, D. Panagiotopoulos, J. Cladas, H.L.S. Maia, R. Yamdagni, Q. Wu, D. Pati, G.J. Moore and H.R. Habibi.
Review of Clinical Pharmacology and Pharmacokinetics (International Edition, Guest Editor of Special Issue J. Matsoukas), 9, 67-69, 1995.

B7 From Angiotensin to Non-Peptide Angiotensin II Receptor Antagonists.
J. Hondrelis, J. Smith, A. Wahhab, R. Ganter, D. Moore, G.J. Moore and **J.M. Matsoukas**.
Review of Clinical Pharmacology and Pharmacokinetics (International Edition, Guest Editor of Special Issue J. Matsoukas), 9, 71-73, 1995.

B8 Myelin Basic Protein Peptides: Induction and Inhibition of Experimental Allergic Encephalomyelitis.
T. Tselios, S. Deraos, E. Matsoukas, D. Panagiotopoulos, **J.M. Matsoukas**, G.J. Moore, L. Probert, G. Kollias, B. Hilliard, A. Rostami, D. Monos.
Review of Clinical Pharmacology and Pharmacokinetics (International Edition, Guest Editor of Special Issue J. Matsoukas), 11, 60-64, 1997.

B9 Conformational Properties of the Immunomodulator Limodine.
T. Mavromoustakos, E. Theodorou, M. Zervou, D. Karussis, **J.M. Matsoukas**.

Review of Clinical Pharmacology and Pharmacokinetics (International Edition, Guest Editor of Special Issue J. Matsoukas), 11, 70-74, 1997.

B10 Behavioural Effects of Sarmesin.
V. Georgiev, **J.M. Matsoukas**, M. Opitz, D. Georgieva, J. Tchekalarova, T. Kambourova, I. Todorov.
Review of Clinical Pharmacology and Pharmacokinetics (International Edition, Guest Editor of Special Issue J. Matsoukas), 11, 75-79, 1997.

B11 Characteristics of Sarmesin, an Angiotensin II Receptor Blocker.
S. Mihailescu, **J.M. Matsoukas**, F.L. Abel, V. Nestianu, F. Romanescu, Alecu-Parvu Cristina.
Review of Clinical Pharmacology and Pharmacokinetics (International Edition, Guest Editor of Special Issue J. Matsoukas), 11, 80-83, 1977.

B12 Solution Synthesis of a Potent Cyclic Amide-Linked Angiotensin II Analogue, [Sar^1,Lys^3,Glu^5] ANG II.
J. Ancans, G.J. Moore, P. Roumelioti, **J.M. Matsoukas**.
Review of Clinical Pharmacology and Pharmacokinetics (International Edition, Guest Editor of Special Issue J. Matsoukas), 11, 108-112, 1997.

B13 Hypertesnive Responses to Intravenous Infusion of the Novel Cyclic Angiotensin II (ANG II) Analogue [Sar^1,Lys^3,Glu^5]-ANG II in Anesthetized Rabbits.
D. Vlahakos, **J.M. Matsoukas**, J. Ancans, E. Iliodromitis, K. Marathias, D. Kremastinos.
Review of Clinical Pharmacology and Pharmacokinetics (International Edition, Guest Editor of Special Issue J. Matsoukas), 11, 113-115, 1997.

B14 Synthesis and Activities of Cyclic Thrombin Receptor-Derived Peptide Analogues of the Ser_{42}-Phe-Leu-Leu-Arg_{46} Motif Sequence, containing 2,3-Diaminopropionic Acid.
D. Panagiotopoulos, K. Alexopoulos, **J.M. Matsoukas**, T. Mavromoustakos, E. Thedoropoulou, E. Kalatzis, P. Fatseas, M. Saifeddine, M.D. Hollenberg.
Review of Clinical Pharmacology and Pharmacokinetics (International Edition, Guest Editor of Special Issue J. Matsoukas), 11, 128-131, 1997.

B15 Difference in Backbone Structure between the Super Agonist [Sar^1] Angiotensin II and its Type I Antagonist Sarilesin.
J.M. Matsoukas, K. Alexopoulos, T. Tselios, P. Roumelioti, R. Yamdagni, Q. Wu, T. Mavromoustakos, E. Kalatzis, E. Siapi, G.J. Moore.
Review of Clinical Pharmacology and Pharmacokinetics (International Edition, Guest Editor of Special Issue J. Matsoukas), 11, 132-136, 1997.

B16 Charge Transfer Interactions in Peptide Hormones.
G.J. Moore, **J.M. Matsoukas**.
Hellenic Forum on Bioactive Peptides, 161-170, **1997**, *Patras, Greece.*

B17 Conformational Analysis of Peptidic and Peptidomimetic AII Antagonists using a Combination of NMR Spectroscopy and Theoretical Calculations.
A. Kolokouris, M. Zervou, T. Mavromoustakos, P. Roumelioti, T. Tselios, **J.M. Matsoukas**, E. Humpfer.
In Bioactive Peptides in Drug Discovery and Design (Eds. Matsoukas, J.; Mavromoustakos, T.), IOS Press, **1999**, *pp. 3-12.*

B18 The Application of Biophysical Methods to Study Drug: Membrane Interactions.
T. Mavromoustakos, I. Daliani, **J.M. Matsoukas**.
In Bioactive Peptides in Drug Discovery and Design (Eds. Matsoukas, J.; Mavromoustakos, T.), IOS Press, **1999**, *pp. 13-24.*

B19 Advances in Antihypertensive Therapy: Angiotensin Blockade, in "Bioactive Peptides in Drug Design and Development: Medical Applications".
G.J. Moore, **J.M. Matsoukas**, (Editors: J. Matsoukas, T. Mavromoustakos).
In Bioactive Peptides in Drug Discovery and Design (Eds. Matsoukas, J.; Mavromoustakos, T.), IOS Press, **1999**, *pp. 33-39.*

B20 Peptidomimetic Thrombin Receptor Analogs: Effects on Angiogenesis and Metalloproteinase Activation in Endothelial Cells.
E. Missirlis, N. Kraniti, K. Alexopoulos, **J.M. Matsoukas** and M. Maragoudakis.
In Bioactive Peptides in Drug Discovery and Design (Eds. Matsoukas, J.; Mavromoustakos, T.), IOS Press, **1999**, *pp. 71-79.*

B21 Possible Role of the Angiotensin-Like Fragment of Thrombin in Recognition and Binding with Protease-Activated Receptor 1.
L. Polevaya and **J.M. Matsoukas**.

In Bioactive Peptides in Drug Discovery and Design (Eds. Matsoukas, J.; Mavromoustakos, T.), IOS Press, **1999**, *pp. 91-99.*

B22 Structure-Function Relationships in Cyclic and Non-Peptide Thrombin Receptor Mimetics.
S. Mihailescu, **J.M. Matsoukas**, K. Alexopoulos, F.L. Abel, C. Paredes-Carbajal, D. Mascher, F. Romanescu, C. Parvu and V. Nestianu.
In Bioactive Peptides in Drug Discovery and Design (Eds. Matsoukas, J.; Mavromoustakos, T.), IOS Press, **1999**, *pp. 101-109.*

B23 Gonadotropin-Releasing Hormone: Structural and Functional Diversity.
H. R. Habibi and **J.M. Matsoukas**.
In Bioactive Peptides in Drug Discovery and Design (Eds. Matsoukas, J.; Mavromoustakos, T.), IOS Press, **1999**, *pp. 247-254.*

B24 Semi-mimetic Peptides with Immunomodulatory Activity based on Myelin Basic Protein (74-85): Synthesis and Conformational Properties.
T. Tselios, I. Daliani, E. Matsoukas, P. Roumelioti, K. Alexopoulos, L. Probert, J.M. Pires, G.J. Moore, **J.M. Matsoukas**.
In Bioactive Peptides in Drug Discovery and Design (Eds. Matsoukas, J, Mavromoustakos T.), IOS Press, Holland, **1999**, *pp. 255-264.*

B25 Novel Biomedical Products Based on MBP.
J.M. Matsoukas.
Ashley Publications Ltd, **1999**.

B26 Angiotensin Charge Relay System Revisited: Swings or Roundabouts?.
G.J. Moore, J. Pires, P. Roumelioti, **J.M. Matsoukas**.
2nd Hellenic Forum on Bioactive Peptides, (Editor P. Cordopatis),Patras, Greece, April 14-15, **2001**, *pp. 55-64.*

B27 Design and Synthesis of Cyclic Analogues of Gonadotropin-Releasing Hormone (GnRH)
A.Manessi, T. Tselios, M. Keramida, **J.M. Matsoukas**.
2nd Hellenic Forum on Bioactive Peptides, (Editor P. Cordopatis),Patras, Greece, April 14-15, **2001**, *pp.327-334.*

B28 Peptide Conformation and the Design of Mimetics: From Angiotensin to Non-Peptide Receptor Antagonists.
N. Giatas, P. Roumelioti, T. Mavromoutakos, **J.M. Matsoukas**.
2nd Hellenic Forum on Bioactive Peptides, (Editor P. Cordopatis),Patras, Greece, April 14-15, **2001**, *pp. 335-342.*

B29 Design and Synthesis of Linear and Cyclic Analogues of Human Myelin Basic Protein Epitope MBP_{1-11}.
S. Deraos, T. Tselios, I. Daliani, L. Probert, E. Matsoukas, **J.M. Matsoukas**.
2nd Hellenic Forum on Bioactive Peptides, (Editor P. Cordopatis),Patras, Greece, April 14-15, **2001**, *pp. 343-349.*

B30 Thrombin Receptor Analogues: Synthesis and Platelet Aggregation Bioassays.
A. Zoga, N. Giatas, K. Alexopoulos, P. Fatseas, E. Melissari, C. Demopoulos, P. Cordopatis, **J.M. Matsoukas**.
2nd Hellenic Forum on Bioactive Peptides, (Editor P. Cordopatis),Patras, Greece, April 14-15, **2001**, *pp. 351-357.*

B31 Can Nuclear Magnetic Resonance be of aid to treat Hypertension?.
T. Mavromoustakos, M. Zervou, A. Kolocouris, P. Zoumboulakis, S. G. Gardadolnik, P. Roumelioti, **J.M. Matsoukas**.
2nd Hellenic Forum on Bioactive Peptides,(Editor P. Cordopatis), Patras, Greece, April 14-15, **2001**, *pp. 461-466.*

B32 Design, Synthesis and Biological Evaluation of Cyclic Angiotensin II Analogues with 3,5 Side-Chain Bridges: Role of C-Terminal Aromatic Residue and Positions 3,5 for Activity.
L. Polevaya, P. Roumelioti, T. Mavromoustakos, P. Zoumpoulakis, N. Giatas, I. Mutule, T. Keivish, A. Zoga, D. Vlahakos, E. Iliodromitis, D. Kremastinos and **J.M. Matsoukas**.
Drug Discovery and Design: Medical Aspects J. Matsoukas and T. Mavromoustakos (Eds.) IOS Press 55, 3-12, **2002**.

B33 Design, Synthesis and Conformational Properties of Linear Analogues of Human Myelin Basic Protein Epitope MBP_{1-11}.
S. Deraos, T. Tselios, I. Daliani, P. Zoumpoulakis, L. Probert, A. Troganis, P. Papathanassopoulos, T. Mavromoustakos and **J.M. Matsoukas**.

Drug Discovery and Desighn: Medical Aspects J. Matsoukas and T. Mavromoustakos (Eds.) IOS Press, 55, 116-121, **2002**.

B34 ^{1}H and ^{13}C NMR Assignment and Conformational Studies of a Myelin Basic Protein Epitope 74-85 Implicated in Multiple Sclerosis.
A.Tzakos, A. Troganis, T. Tselios, A. Bonvin, N. van Nuland, S. Deraos, **J.M. Matsoukas** and I. Gerothanassis.
Drug Discovery and Desighn: Medical Aspects J. Matsoukas and T. Mavromoustakos (Eds.) IOS Press, 55, 180-187, **2002**.

B35 Effect of Linear and Cyclic Peptide Analogues of Myelin Basic Protein Epitope MBP_{72-85} on Human T-cell Activation.
S. Thymianou, K. Chatzantoni, M. Karakantza, T. Tselios, P. Papathanassopoulos, **J.M. Matsoukas** and A. Mouzaki.
Drug Discovery and Desighn: Medical Aspects J. Matsoukas and T. Mavromoustakos (Eds.) IOS Press, 55, 241-250, **2002**.

B36 Design and Synthesis of Potent Human Cyclic MBP_{87-99} Altered Peptide Ligands: Inhibition of Experimental Allergic Encephalomyelitis (EAE).
T. Tselios, S. Deraos, I. Dalinai, G. Deraos, T. Mavromoustakos, L. Probert, **J.M. Matsoukas.**
3rd Hellenic Forum on Bioactive Peptides,(Editor P. Cordopatis), Patras, Greece, April 14-15, **2003**, *pp. 227-234.*

B37 NMR and Molecular Dynamic Conformational Studies of Two Peptide Analogues of a Myelin Basic Protein Epitope 74-85.
A. Tzakos, A. Troganis, T. Tselios, A. Bonvin, Nico van Nuland, P. Fuchs, S. Deraos, **J.M. Matsoukas**, I. Gerothanassis.
3rd Hellenic Forum on Bioactive Peptides,(Editor P. Cordopatis), Patras, Greece, April 14-15, **2003**, *pp.341-346.*

B38 Structural Resemblance of Angiotensin II Ring Cluster Conformation with AT_1 Non-Peptide Antagonists.
N. Giatas, P. Roumelioti, A. Zoga, M.E. Androutsou, L. Polevaya, I. Mutule, T. Keivish,T. Mavromoustakos, P. Zoumpoulakis, D. Vlahakos, **J.M. Matsoukas**.
3rd Hellenic Forum on Bioactive Peptides,(Editor P. Cordopatis), Patras, Greece, April 14-15, **2003**, *pp.361-366.*

B39 Comparative Conformational Analysis Studies between Losartan Derivatives.
P. Zoumpoulakis, M. Zervou, I. Kyrikou, S. Grdadolnik, P. Roumelioti, A. Zoga, N. Giatas, **J.M. Matsoukas**, T. Mavromoustakos.
3rd Hellenic Forum on Bioactive Peptides,(Editor P. Cordopatis), Patras, Greece, April 14-15, **2003**, *pp.367-370.*

B40 Human Myelin Basic Protein Epitope MBP_{1-11}: Synthesis and Conformational Analysis of Altered Peptide Ligands.
S. Deraos, T. Tselios, I. Daliani, P. Zoumpoulakis, L. Probert, A. Troganis, T. Mavromoustakos, **J.M. Matsoukas**.
3rd Hellenic Forum on Bioactive Peptides,(Editor P. Cordopatis), Patras, Greece, April 14-15, **2003**, *pp.601-605.*

B41 Citrullination of EAE Antagonist, Cyclo (87-99) (Arg^{91}, Ala^{96}) MBP_{87-99} with Peptidylarginine Deiminase (PAD)
G. Deraos, S. Deraos, T. Tselios, **J.M. Matsoukas**, D. Vynios.
4th Hellenic Forum on Bioactive Peptides,(Editors P. Cordopatis, E. Manesi, G. Pairas), Patras, Greece, **2005**, *pp.351-354.*

B42 Structural Elucidation and Conformational Analysis of a Potent Altered Peptide Ligand, [Arg^{91}, Ala^{96}] MBP_{87-99}, Employing Experimental NOEs Constraints Combined with Theoretical Calculations and Molecular Modelling.
E. Mantzourani, T. Tselios, S. Grdadolnik, **J.M. Matsoukas**, T. Mavromoustakos.
4th Hellenic Forum on Bioactive Peptides,(Editors P. Cordopatis, E. Manesi, G. Pairas), Patras, Greece, **2005**, *pp. 321-325.*

B43 Immune Responses of Myelin Basic Protein (MBP) and Proteolipid Protein (PLP) in SJL/J mice: Towards a new Immunotherapeutic approaches of Multiple Sclerosis.
M. Katsara, T. Tselios, S. Deraos, G. Deraos, **J. Matsoukas**, V. Apostolopoulos.
5th Hellenic Forum of Bioactive Peptides, Patra, Greece, May 14-16, ***2006***.

B44 Towards the proposal of a structural Motif for the Bioactive APL of Myelin Basic Protein and Inhibitor of Experimental Autoimmune Encephalomyelitis [Ala^{96}]MBP$_{87-99}$.
E. Mantzourani, T. Mavromoustakos, S. Golic-Grdadolnik, J. Platts, G. Deraos, **J. Matsoukas**, T. Tselios.
5th Hellenic Forum of Bioactive Peptides, Patra, Greece, May 14-16, ***2006.***

B45 Rational Design of Potent Myelin Basic Protein (MBP) Cyclic Analogues: Exploring the Molecular Basis of Experimental Autoimmune Encephalomyelitis (EAE) Inhibition.
T. Tselios, E. Mantzourani, I. Friligou, J. Platts, T. Mavromoustakos, **J. Matsoukas**
5th Hellenic Forum of Bioactive Peptides, Patra, Greece, May 14-16, ***2006.***

B46 Synthesis of Potent Mide Linked Cyclic MBP$_{87-99}$ Analogues: Inhibition of Experimental Autoimmune Encephalomyelitis (EAE).
I. Friligou, V. Tseveleki, M. Emmanouil, L. Probert, **J. Matsoukas**, T.Tselios
Eurocombi 4. First International Symposium on Combinatorial Sciences in Biology, Chemistry, Catalysis and Materials, Firenze Italy, July 15-18, ***2007.***

B47 Design and Synthesis of novel non-peptide antagonists of Part-1 thrombin receptor with two or three pharmacophoric groups mounted upon an indolic template.
P. Keppa, M.E. Androutsou, T.Tselios, **J. Matsoukas**
Eurocombi 4. First International Symposium on Combinatorial Sciences in Biology, Chemistry, Catalysis and Materials, Firenze Italy, July 15-18, ***2007.***

B48 Rational Design and Synthesis of Potent Myelin Cyclic Peptide Analogues with Enchanced Stability and Biological Properties
G. Deraos, S. Deraos, T. Tselios, **J. Matsoukas**
6th Hellenic Forum on Bioavtive Peptides (Editor P. Cordopartis*), Patras, April 2008*

B49 Double action Angiotensin II Receptor Antagonists
M. Michalatou, M.T. Matsoukas, K. Kelaidonis, G. Agelis, **J. Matsoukas**, T. Tselios
6th Hellenic Forum on Bioavtive Peptides (Editor P. Cordopartis*), Patras, April 2008)*

B50 A structural perspective of peptides from myelin basic protein.
Katsara, M., Ramsland, P.A., Tselios, T., **Matsoukas, J**. and Apostolopoulos, V.
Book entitled "Myelin Basic Protein" (In "Intrinsically Disordered Proteins" series edited by Dr. Vladimir Uversky), Nova Science Publisher, Inc, 2008, Chapter V, 87-102

Publications in Conference Proceedings

1. On the Selective Antagonism of Angiotensin Receptors in Smooth Muscle by two Classes of Angiotensin Antagonists.
G.J. Moore, **J.M. Matsoukas,** M.N. Scanlon, K.J. Franklin and M.H. Goghari.
Proceedings of Western Pharmacological Society, Reno, Nevada, U.S.A., February **1984**, *pp. 377-383.*
2. Conformation and Chemistry of Angiotensin II: Evidence for the Existence of a Tyrosine Charge Relay System in Dimethyl-Sulfoxide and Water.
G.J. Moore and **J.M. Matsoukas**.
Proceedings of the 18th European peptide Symposium, Upsala, Sweden, June **1984**, *pp. 615-619.*
3. ^{1}H-NMR Studies of Angiotensin II Conformation: Chemical Shifts of the Aromatic Protons of Selected Analogs in DMSO-d_6 at 400 MHz.
J. Matsoukas, H. Gohpari, G.J. Moore.
Proceedings of the 19th European Peptide Symposium, Porto Carras, Chalkidiki, Greece, Sept. **1986**, *pp. 335-339.*
4. Synthesis and Biological Activities of Analogs of Angiotensin II Containing Cyclohexylalanine.
J. Matsoukas, J. Hondrelis, P. Cordopatis, R. Ganter, K. Franklin and G. Moore.
Proceedings of the 2nd Peptides Forum, Nancy, France, 1-5 May **1988**, *pp. 465-468.*
5. Angiotensin II and III: Conformational Comparison by ^{1}H and ^{13}C NMR and Circular Dichroism.
J. Matsoukas, J. Hondrelis, P. Cordopatis, G. Moore.
20th European Peptide Symposium, Tubingen, Gernamy, Sept. **1988**, *pp. 492-494.*
6. Synthesis and Biological Activity of Sarmesin Analogs with Substitution at Positions 1 and 8.
P. Cordopatis, **J. Matsoukas**, U. Belte, R. Ganter, K.J. Franklin and G.J. Moore.
20th European Peptide Symposium, Tubingen, Germany, Sept. **1988**, *pp. 571-573.*
7. Synthesis and Biological Activities of [Aze^{7}]-ANG II and [Pip^{7}]-ANG II Analogues.

J. Matsoukas, J. Hondrelis, G. Agelis, R. Ganter, R. Yamdagni, G. Moore.
21st European Peptide Symposium, Barcelona, Spain, Sept. 2-10, **1990**, *pp. 589-590.*

8. Nanosecond Time-Resolved Fluorescence Study of Tyrosinate Spesies in Angiotensin II and Analogues.
R. Turner, **J. Matsoukas**, G. Moore.
21st European Peptide Symposium, Barcelona, Spain, Sept. 2-10, **1990**, *pp. 669-670.*

9. Synthesis and Biological Activities of Cyclic Amide-Linked Analogues of Angiotensin II and III.
J. Hondrelis, **J.M. Matsoukas**, G. Agelis, M. Keramida, A. Panagiotopoulos, K. Barlos, R. Ganter, D. Moore and G.J. Moore.
Proceedings of 22nd European Peptide Symposium, Interlaken, Switzerland, Sept. 13-19, **1992**, *pp. 689-690.*

10. The Importance of the Aromatic Ring Quadrupole for Receptor Interactions of the Position 4 Side Chains of Angiotensin II Analogues.
G.J. Moore, R.C. Ganter, **J.M. Matsoukas**, J. Hondrelis, G. Agelis, K. Barlos, S. Wilkinson, J. Sandall and P. Fowler.
Peptides 1993. Proceedings of the Thirteenth American Peptide Symposium, June 20-25, **1993**, *Edmonton, Alberta, Canada. (Eds. Robert S. Hodges and J. A. Smith).*

11. Type I Angiotensin II Antagonists.
G. Agelis, A. Wahhab, J. Hondrelis, R. Yamdagni, Q. Wu, R. Ganter, J. Smith, G.J. Moore and **J.M. Matsoukas**.
Proceedings of Biomedical & Health Research Euroworkshop, Patras, October 14-15, **1993** *Greece, pp. 15-19.*

12. Cyclic Thrombin Receptor Derived Peptide Analogues.
D. Panagiotopoulos, **J.M. Matsoukas**, M. Keramida, S. Deraos, H.L.S. Maia, R. Yamdagni, Q. Wu, P. Redstone, G.J. Moore, A.A. Laniyonu, M. Saifeddine and M.D. Hollenberg.
Proceedings of Biomedical & Health Research Euroworkshop, Patras, October 14-15, **1993** *Greece, pp. 19-22.*

13. Gonadotropin-Releasing Hormone (GnRH) Analogues Containing Tyr (OMe) at Position 5.
M. Keramida, **J.M. Matsoukas**, G. Agelis, D. Panagiotopoulos, J. Cladas, H.L.S. Maia, R. Yamdagni, Q. Wu, D. Pati, G.J. Moore and H.R. Habibi.
Proceedings of Biomedical & Health Research Euroworkshop, Patras, October 14-15, **1993** *Greece, pp. 23-26.*

14. Synthesis and Activities of Type I Angiotensin II Antagonists.
G. Agelis, **J.M. Matsoukas**, A. Wahhab, J. Hondrelis, R. Yamdagni, Q. Wu, R. Ganter, M. Rebello, H.L.S. Maia, J. Smith and G.J. Moore.
Peptides **1994**. *Proceedings of 23rd European Peptide Symposium Braga, Portugal. H. Maia (Ed*) **1994** *ESCOM. pp. 365-366.*

15. Cyclic Thrombin Receptor-Derived Peptide Analogues Containing D-PHR and D- ARG.
D. Panagiotopoulos, **J.M. Matsoukas**, M. Keramida, D. Gatos, L Monteiro, H. Maia, R. Yamdagni, Q. Wu, P. Redstone, G.J. Moore, A.A. Laniyonou, M Saifeddine and M.D. Hollenberg.
Peptides **1994**. *Proceedings of 23rd European Peptide Symposium Braga, Portugal. H. Maia (Ed)* **1994** *ESCOM. pp. 359-360.*

16. Synthesis and Activity of Gonadotropin-Releasing Hormone (GnRH) Analogues Containing Tyr (OMe) and Aze at Positions 5 and 9.
M. Keramida, **J.M. Matsoukas**, G. Agelis, D. Panagiotopoulos, J. Cladas, H.L.S. Maia, R. Yamdagni, Q. Wu, D. Pati, G.L. Moore and H.R. Habibi.
Peptides **1994**. *Proceedings of 23rd European Peptide Symposium Braga, Portugal. H. Maia (Ed)* **1994** *ESCOM. pp. 613-614.*

17. Designing Peptide Mimetics.
G.J. Moore and **J.M. Matsoukas**.
Proceedings of Biomedical and Health Research Conference.
University of Patras, Patras-Greece, Oct. 14-15, **1993**, *pp. 1-14.*

18. From Angiotensin to Non-Peptide Angiotensin II Receptor Antagonists.
J. Hondrelis, J. Smith, A. Wahhab, R. Ganter, D. Moore, G. Moore, **J. Matsoukas**.
Proceedings of Biomedical and Health Research Conference.
University of Patras, Patras-Greece, Oct. 14-15, **1993**, *pp. 27-31.*

19. A New Generation of Antihypertensives: Non-Peptide Angiotensin II Receptor Antagonists.
J. Smith, A Wahhab, J. Hondrelis, R. Ganter, D. Moore, G. Moore, **J. Matsoukas**.

Proceedings of Biomedical and Health Research Conference.
University of Patras, Patras-Greece, Oct. 14-15, **1993**, *pp.32-35.*

20. Inhibition of Angiogenesis by the Tripeptide Phe-Pro-Arg a Thrombin Receptor Derived Peptide Analogue.
M Maragoudakis, E. Pipili, D. Panagiotopoulos and **J. Matsoukas**.
Proceedings of Biomedical and Health Research Conference in Drug Design.
University of Patras, Patras-Greece, Nov. 17-19, **1994**, *pp. 59-62.*

21. Peptide Conformation and the Design of Peptide Mimetics.
G.J. Moore, J.R. Smith, B.W. Baylis and **J. Matsoukas**.
Proceedings of Biomedical and Health Research Conference in Drug Design.
University of Patras, Patras-Greece, Nov. 17-19, **1994**, *pp.1-8.*

22. Synthesis of a Potent Cyclic Amide-Linked Angiotensin II Analogue, [Sar^{1}, Lys^{3}, Clu^{5}] Ang II.
J. Ancans, G.J. Moore and **J.M. Matsoukas**.
Proceedings of Biomedical and Health Research Conference in Drug Design.
University of Patras, Patras-Greece, Nov. 17-19, **1994**, *pp.31-35.*

23. Angiotensin II: A Multifunctional Molecule.
D.V. Vlahakos, E.K. Iliodromitis, J. Ancans and **J.M. Matsoukas**.
Proceedings of Biomedical and Health Research Conference in Drug Design.
University of Patras, Patras-Greece, Nov. 17-19, **1994**, *pp.63-67.*

24. Superimposition of Angiotensin II with Potent Non-Peptide AT-1 Receptor Antagonists.
T. Mavromoustakos, E. Theodoropoulou, **J. Matsoukas**, G. Moore, J. Smith.
Proceedings of Biomedical and Health Research Conference in Drug Design.
University of Patras, Patras-Greece, Nov. 17-19, **1994**, *pp.74-80.*

25. Advances in Antihypertensive Therapy: Non-Peptide Angiotensin II Receptor Antagonists as Potent Therapeutic Agents.
J. Smith, Q. Wahhab, J. Hondrelis, R.Ganter, D. Moore, G. Moore and **J. Matsoukas.**
Proceedings of Biomedical and Health Research Conference in Drug Design.
University of Patras, Patras-Greece, Nov. 17-19, **1994**, *pp. 103-107.*

26. Cyclic Thrombin Receptor Derived Peptide Analogues of the S^{42} FLLR^{46} Motif: Novel Synthesis and Biological Activities.
D. Panagiotopoulos, **J.M. Matsoukas**, M. Keramida, T. Mavromoustakos, H.L.S. Maia, R. Yamdagni, Q.Wu, G.J. Moore, M. Saifeddine and M.D. Hollenberg.
Proceedings of Biomedical and Health Research Conference in Drug Design.
University of Patras, Patras-Greece, Nov. 17-19, **1994**, *pp.108-111.*

27. A Potent Gonadotropin-Releasing Hormone (GnRH) Analogue, [Tyr(OMe)^{5}, D-Glu^{6}, Aze^{9}] GnRH: Synthesis and Activities.
M. Keramida, **J.M. Matsoukas**, D. Panagiotopoulos, H.L.S. Maia, D. Pati, H. Hoang, G.J. Moore and H.R. Habibi.
Proceedings of Biomedical and Health Research Conference in Drug Design.
University of Patras, Patras-Greece, Nov., 17-19, **1994**, *pp.112-113.*

28. Myelin Basic Protein Peptides: Induction and Inhibition of Experimental Allergic Encephalomyelitis.
S. Deraos, T. Tselios, E. Matsoukas, D. Panagiotopoulos, **J. Matsoukas**, G.J. Moore, L. Probert, G. Kollias, B. Hilliard, A. Rostami and D. Monos.
In Matsoukas J. (Ed.), Aminoacids-Peptides-Proteins in Drug Discovery and Design, Proceedings of Biomedical and Health Research, University of Patras, Greece, **1995**, *pp. 7-13.*

29. The Conformational Properties of the Immunomodulator Linomide.
T. Mavromoustakos, M. Bensaia, E. Theodoropoulou, M. Zervou, D. Karussis and **J. Matsoukas**.
In Matsoukas J. (Ed.), Aminoacids-Peptides-Proteins in Drug Discovery and Design, Proceedings of Biomedical and Health Research, University of Patras, Greece, **1995**, *pp. 23-30.*

30. Behavioural Effects of Sarmesin.
V. Georgiev, **J. Matsoukas**, M. Opitz, D. Georgieva, J. Tchekalarova, T. Kambourova and I. Todorov.
In Matsoukas J. (Ed.), Aminoacids-Peptides-Proteins in Drug Discovery and Design, Proceedings of Biomedical and Health Research, University of Patras, Greece, **1995**, *pp.31-37.*

31. Characteristics of Sarmesin, an Angiotensin II Receptor Blocker.
S. Mihailescu, **J. Matsoukas**, F.L. Abel, V. Nestianu, F. Romanescu, Alecu-Parvu Cristina.
In Matsoukas J. (Ed.), Aminoacids-Peptides-Proteins in Drug Discovery and Design, Proceedings of Biomedical and Health Research, University of Patras, Greece, **1995**, *pp.38-44.*

32. Hypertensive Responses to Intravenous Infusion of the Novel Cyclic Angiotensin II (ANG II) Analogue [Sar^1, Lys^3, Glu^5] ANG II in Anesthetized Rabbits.
D.V. Vlahakos, **J.M. Matsoukas**, J. Ancans, K. Iliodromitis, K.P. Marathia and D.Th. Kremastinos.
In Matsoukas J. (Ed.), Aminoacids-Peptides-Proteins in Drug Discovery and Design, Proceedings of Biomedical and Health Research, University of Patras, Greece, **1995**, *pp.84-88.*

33. Use of Molecular Modeling to Study Superimposition of the Thrombin Receptor Motif S^{42} $FLLR^{46}$ with its Peptidomimetic Analogs.
T. Mavromoustakos, E. Theodoropoulou, K. Alexopoulos, **J. Matsoukas** and M. Hollenberg.
In Matsoukas J. (Ed.), Aminoacids-Peptides-Proteins in Drug Discovery and Design, Proceedings of Biomedical and Health Research, University of Patras, Greece, **1995**, *pp.102-107.*

34. Synthesis and Activities of Cyclic Thrombin Receptor-Derived Peptide Analogues of the Ser^{42}-Phe-Leu-$Leu-Arg^{46}$ Motif Sequence, Containing 2,3 Diaminopropionic Acid.
D. Panagiotopoulos, K. Alexopoulos, **J.M. Matsoukas**, Th. Mavromoustakos, E. Theodoropoulou, H.L.S. Maia, M. Saifeddine and D. Hollenberg.
In Matsoukas J. (Ed.), Aminoacids-Peptides-Proteins in Drug Discovery and Design, Proceedings of Biomedical and Health Research, University of Patras, Greece, **1995**, *pp.108-113.*

35. Differences in Backbone Structure between the Super Agonist [Sar^1] Angiotensin II and its Type I Antagonist Sarilesin.
J.M. Matsoukas, K. Alexopoulos, T. Tselios, R. Yamdagni, Q. Wu, T. Mavromoustakos and G.J. Moore.
In Matsoukas J. (Ed.), Aminoacids-Peptides-Proteins in Drug Discovery and Design, Proceedings of Biomedical and Health Research, University of Patras, Greece, **1995**, *pp.114-119.*

36. Recognition of the Encephalitogenic Myelin Basic Protein (74-85) by the Immune System: Importance of Conformation.
J.M. Pires, **J.M. Matsoukas**, G.J. Moore.
Proc. West. Pharm. Soc., **1998,** *41, pp. 193-195.*

37. Synthesis of a Novel Cyclic Analogue of the Myelin Basic Protein Epitope MBP_{72-85}.
T. Tselios, L. Probert, G. Kollias, I. Daliani, E. Matsoukas, P. Roumelioti, K. Alexopoulos, **J. Matsoukas**.
Proceedings of the 25th EPS (Ed. Bazush), Budapest, Hungary, Sept. 1-5, **1998**, *pp. 504-505.*

38. Thrombin-Derived Peptides: Design and Synthesis.
L. Polevaya, **J. Matsoukas**, T. Keivish, I. Mutule, I. Mutule.
Proceedings of the 25th EPS (Ed. Bazush), Budapest, Hungary, Sept. 1-5, **1998**, *pp. 620-621.*

39. Synthesis and Biological Activities of Thrombin Receptor Derived Non-Peptide Mimetics: Importance of Phenyl/Guanidino Proximity for Activity.
K. Alexopoulos, E. Melissari, P. Fatseas, D. Vlahakos, T. Tselios, P. Roumelioti, **J. Matsoukas.**
Proceedings of the 25th EPS (Ed. Bazush), Budapest, Hungary, Sept. 1-5, **1998**, *pp. 650-651.*

40. Design and Synthesis of Two Potent Amide Linked Cyclic Analogs of the Hormone Angiotensin II Confirm the Importance of Ring Cluster and Relay System in its Possible Bioactive Conformation.
P. Roumelioti, L. Polevaya, D. Vlahakos, T. Mavromoustakos, A. Kolocouris, T. Tselios and **J. Matsoukas**.
Proceedings of 16th American Peptide Symposium, Minneapolis, U.S.A., June 26-July 1, **1999.** *Edited by G. Fields, J. Tam and G. Barany. . pp. 509-510.*

41. Homology-Based Analysis of Thrombin Receptors.
L. Peloyava and **J. Matsoukas**.
Proceedings of 16th American Peptide Symposium, Minneapolis, U.S.A., June 26-July 1, **1999.** *Edited by G. Fields, J. Tam and G. Barany. pp. 647-680.*

42. The Biological Activity of Amide Linked Angiotensin II (AII) Cyclic Analogues Confirms the Ring Clustering and Charge Relay Bioactive Conformation of AII.
D. V. Vlahakos, E. K. Iliodromitis. E. Bofilis, K. P. Marathias, L. Poleyava, **J. Matsoukas**, P. Roumelioti, D. Th. Kremastinos
European Society of Cardiology, August 28-September 1, **1999** *- Barcelona – Spain.*

43. Design and Synthesis of Potent Linear and Cyclic Analogues of the Myelin Basic Protein Epitope MBP_{87-99}.
T. Tselios, I. Daliani, L. Probert, S. Deraos, E. Matsoukas, P. Roumelioti, K. Alexopoulos, **J. Matsoukas**.
Proceedings of the 26th EPS, Montpellier, France, Sept. **2000**, *pp. 761-762.*

44. The Discovery of a Non-Peptide Thrombin Receptor Antagonist in Human and also Rabbit Platelets: a Novel Drug Lead.
K. Alexopoulos, P. Fatseas, A. Zoga, N. Giatas, T. Tselios, P. Roumelioti, E. Melissari, D. Vlahakos, C. Demopoulos, **J. Matsoukas**.

Proceedings of the 26th EPS, Montpellier, France, Sept. **2000**, *pp. 789-790.*

45. Design and Synthesis of Amide-Linked Angiotensin II Analogues With 3,5 Side Chain Bridges: Structural Resemblance of Ring Cluster Conformation with AT1 Non-Peptide Antagonists.
P. Roumelioti, L. Polevaya, N. Giatas, A. Zoga, I. Mutule, T. Keivish, T. Mavromoustakos, P. Zoumboulakis, D. Vlahakos, and **J. Matsoukas.**
Proceedings of the 2nd International and 17th American Peptide Symposium, San Diego, California, USA, June 9-14, **2001.** *Edited by M. Lebl and R. Houghteen, pp. 656-657.*

46. Design and Biological Activity of Novel Non-Peptide Imidazole Based Angiotensin II Receptor Antagonists.
N. Giatas, P. Roumelioti, A. Zoga, P. Zoumpoulakis, T. Mavromoustakos, D. Vlahakos, E. Iliodromitis, and **J. Matsoukas.**
2nd Conference on Medicinal Chemistry: Drug Discovery and Design, Patras, Greece, March 1-3, **2001**, *pp. 65.*

47. Rational Design and Synthesis of a Potent Amide-Linked Cyclic Analogue of MBP_{87-99} Based on 2D-NMR Studies and Molecular Dynamics.
Daliani, T. Tselios, L. Probert, S. Deraos, T. Mavromoustakos and **J. Matsoukas.**
Proceedings of the Second International and the Seventeenth American Peptide Symposium, San Diego, California, USA, June **2001.** *Edited by M. Lebl and R. Houghteen, pp. 238-239.*

48. Design, Synthesis and Modulation of Angiogenesis by Thrombin Receptor Non-Peptide Antagonists.
K. Alexopoulos, M. Maragoudakis and **J. Matsoukas.**
Proceedings of the Second International and the Seventeenth American Peptide Symposium, San Diego, California, USA, June **2001.** *Edited by M. Lebl and R. Houghteen, pp. 614-615.*

49. Design, Synthesis and Conformation Properties of Linear Analogues Based on Myelin Basic Protein Epitope MBP_{1-11}.
J. Matsoukas, S. Deraos, T. Tselios, I. Daliani, G. Deraos, P. Zoumpoulakis, L. Probert, A. Troganis, T. Mavromoustakos.
Proceedings of 27th EPS, Sorrento, Italy, Aug. 31-Sept. 6. **2002**. *Edited by E. Benedetti.*

50. Potent Cyclic Angiotensin II Analogues Confirm the Ring Cluster Conformation: Implications in the Design of AT1 Non-Peptide Antagonists.
N. Giatas, A. Zoga, M. Androutsou, P. Roumelioti, L. Polevaya, T. Mavromoustakos, P. Zoumpoulakis, D. Vlahakos, **J. Matsoukas.**
27th European Peptide Symposium, Sorrento, Italy, August 31-September 6, **2002**. *Edited by E. Benedetti.*

51. Structural studies and sequence homology investigations of the guinea pig myelin basic protein (MBP) epitope 74-85 analogues.
Tzakos, P.Fuchs, N. van Nuland, A.Troganis, T. Tselios, S. Deraos, G. Deraos, I. Gerothanassis, A. Bonvin, **J. Matsoukas**.
18th American Peptide Sumposium, Boston, USA, July 19-23, **2003**, p943, Editors: M. Chorev and T. Sawyer.

52. Desing and Synthesis of Novel Antihypertensive Drugs.
T. Mavromoustakos, P. Roumelioti, M. Zervou, P. Zoumpoulakis, I. Kyrikou, N. Giatas, D. Gatos, M.E.Androutsou, I. Papanastasiou, A. Zioga, P.M.Minakakis, G. Kokkotos, D. Vlahakos, E. Iliodromitis, **J. Matsoukas**.
18th American Peptide Sumposium, Boston, USA, July 19-23, **2003**, p569, Editors: M. Chorev and T. Sawyer.

53. Structural Studies of Agonist and Antagonist Peptides of the Guinea Pig Myelin Basic Protein Epitope 74-85 in Solution-Docking calculations to the MHC-II receptor site and Implication of Structure-Function Relationships.
Andreas G. Tzakos, Patrick Fuchs, Nico A.J. van Nuland, Anastasios Troganis, Theodore Tselios, Spyros Deraos, **John Matsoukas**, Ioannis P. Gerothanassis and Alexandre M.J.J. Bonvin.
7th European NMR Large Scale Facilities User Meeting, November 21 - 22, **2003**, *Oosterbeek, Netherlands.*

54. Design and Synthesis of a Potent Analogue of Myelin Basic Protein MBP_{87-99} Epitope: Inhibition of Experimental Autoimmune Encephalomyelitis (EAE).
G. Deraos, T. Tselios, S. Deraos, L. Synodinos, A. Papalois and **J. Matsoukas**.
28th European Peptide Symposium, Prague, Chech Republic, Sept. 1-6, **2004**, *Edited by Jirina Slaninova.*

55. Effects of Myelin Basic Protein MBP74-85 mannan complexes on cytokine secretion by peripheral blood mononuclear cells of Multiple Sclerosis patients and controls.

Katsara, M., Tselios, T., Chantzantoni, K., Mouzaki, A., and **Matsoukas J.**
*5th Conference Medicinal Chemistry: Drug Discovery and Design, University of Patras, Patras, Greece, Mar. 10-12, **2004***

56. Citrullination Of EAE Antagonist Analogue, Cyclo(87–99) (Arg91, Ala96) MBP87–99 with Peptidylarginine Deiminase (PAD).
Deraos, S. Deraos, T. Tselios, **J. Matsoukas**, H. Vynios.
*28th European Peptide Symposium, Prague, Chech Republic, Sept. 1-6, **2004**, Edited by Jirina Slaninova.*

57. Solid Phase Synthesis of IL-2 Receptor (IL-2R) Extracellular Domain Beta Chain Epitopes M^{107}-E^{118} and Y^{178}-Q^{199}: Inhibition of T-cell Activation.
Deraos, T. Parissi, T. Tselios, G. Deraos, M. Matsoukas, K. Chatzantoni, A. Mouzaki, **J. Matsoukas**.
*28th European Peptide Symposium, Prague, Chech Republic, Sept. 1-6, **2004**, Edited by Jirina Slaninova.*

58. Myelin basic protein peptides (MBP83-99): Immunomodulating therapeutic approaches for multiple sclerosis
Katsara, M., Deraos, G., Tselios, T., Deraos, S., **Matsoukas, J.**, and Apostolopoulos, V.
*Austin Health Research Week, Austin Hospital, Melbourne, Victoria, Australia, Oct. 10-14, **2005** (Highly Commended)*

59. Myelin basic protein (MBP) and proteolipid protein (PLP) peptides (linear and cyclic) and immune responses in animal models.Therapeutic Approaches for multiple sclerosis.
Katsara, M., Tselios, T., Deraos, S., Deraos, G., **Matsoukas, J.**, and Apostolopoulos V.
*35th Australasian Society for Immunology / 14th International HLA and Immunogenetics Work shop, Melbourne, Victoria, Australia, Dec. 4-8, **2005***

60. Myelin basic protein (MBP) and proteolipid protein (PLP) peptides (linear and cyclic) and immune responses in SJL/J mice: Immunotherapeutic approaches for multiple sclerosis,
Katsara, M., Tselios, T., Deraos, S., Deraos, G., **Matsoukas, J.**, and Apostolopoulos, V.
*35th Australasian Society for Immunology / 14th International HLA and Immunogenetics Workshop, Melbourne, Victoria, Australia, Dec. 4-8, **2005***
*1st Australasian Vaccines and Immunotherapeutics Development Meeting (AVID), Melbourne, Victoria, Australia, 31 May-1 June, **2006***

61. Design and Synthesis of two Cyclic Analogues of Gonadotropin Releasing Hormone (GnRH) for the Treatment of Canser.
A. Holeva, I. Friligou, M. Keramida, T. Tselios, **J. Matsoukas**.
*29th European Peptide Symposium, Gdansk, Poland, Sept. 3-8, **2006**, Edited by K. Rolka, P. Rekowski and J. Silberring*

62. Design, Synthesis and Conformational Analysis of a Potent Angiotensin II Losartan Based Antagonist.
M.Matsoukas, A. Resvani, K. Kelaidonis, D. Lemou, **J. Matsoukas**, T. Tselios.
*29th European Peptide Symposium, Gdansk, Poland, Sept. 3-8, **2006**, Edited by K. Rolka, P. Rekowski and J. Silberring*

63. Desing and Synthesis of a Novel Non-Peptide Mimetic of PAR-1 Thrombin Receptor with four Pharmacophoric Groups.
M. Androutsou, K. Alexopoulos, S. Mihailescu, T. Tselios, **J. Matsoukas**.
*29th European Peptide Symposium, Gdansk, Poland, Sept. 3-8, **2006**, Edited by K. Rolka, P. Rekowski and J. Silberring*

64. Design and Synthesis of Myelin Basic Protein (MBP) Linear and Cyclic Peptide Analogues Complexed with Mannan. Effects in Cytokine Production.
G. N. Deraos, M. Katsara, T. Tselios, S. N. Deraos, V. Apostolopoulos, **J. M. Matsoukas**.
*29th European Peptide Symposium, Gdansk, Poland, Sept. 3-8, **2006**, Edited by K. Rolka, P. Rekowski and J. Silberring*

65. Comparison of Proposed Putative Bioactive Conformations of Altered Peptide Ligands of myelin Basic Protein by Spectroscopic and Modelling Studies.
E. D. Mantzourani, T. M. Mavromoustakos, S. Golic-Grdadolnik, J. A. Platts, G. N. Deraos, **J. M. Matsoukas**, T. V. Tselios.
*29th European Peptide Symposium, Gdansk, Poland, Sept. 3-8, **2006**, Edited by K. Rolka, P. Rekowski and J. Silberring*

66. A Proteolipid Protein Cyclic Peptide Analogue Reduces the Enchephalitogenicity in EAE Model.
S. N. Deraos, T. V. Tselios, I. Mylonas, G. N. Deraos, **J. M. Matsoukas**, N. Grigoriadis.

*29th European Peptide Symposium, Gdansk, Poland, Sept. 3-8, **2006**, Edited by K. Rolka, P. Rekowski and J. Silberring*

67. Myelin basic protein MBP83-99 and its novel analogues (linear and cyclic) using CFA or conjugated to reduced mannan: Immune responses in SJL/J mice for multiple sclerosis.
Katsara, M., Deraos, G., **Matsoukas, J.,** and Apostolopoulos, V.
*Alfred Research Week, Alfred Hospital, Melbourne,Victoria, Australia, Oct. 23-27, **2006***

68. Rational Altered peptide ligands of myelin basic protein for immunotherapy of multiple sclerosis.
Katsara, M., Deraos, G., **Matsoukas, J**., and Apostolopoulos, V.
*36th Australasian Society for Immunology / 15th International HLA and Immunogenetics Work shop, Auckalnd, New Zealand, Dec. 3-7, **2006***

69. Design,synthesis and immunological studies of linear and cyclic altered peptide ligands of myelin basic protein MBP87-99 Epitope.
Katsara, M., Tselios, T., **Matsoukas, J**., and Apostolopoulos, V
*36th Australasian Society for Immunology / 15th International HLA and Immunogenetics Work shop, Auckalnd, New Zealand, Dec. 3-7, **2006***

70. Novel Linear and Cyclic GnRH Analogues Inhibit Proliferation Of Human Mammary Tumor Cell Line MCF-7, Katsara, M., Tselios, T., **Matsoukas, J**., and V., Apostolopoulos.
36th Australasian Society for Immunology / 15th International HLA and Immunogenetics Work shop, Auckalnd, New Zealand, Dec. 3-7, **2006**

71. T cell receptor altered peptide ligands of myelin basic protein and proteolipid protein (Linear and Cyclic) can modulate immune responses to SJL/J mice: Bioactive peptides for multiple sclerosis.
Katsara, M., Deraos, G., **Matsoukas, J**., and Apostolopoulos, V.
*4th International Peptide Symposium / 7th Australian Peptide Conference and 2nd Asia-PacificInternational Peptide, Cairns, Queensland, Australia, Oct.21-25, **2007***
*Scientific meeting on "Progress in Multiple Sclerosis", Melbourne, Victoria, Australia, Nov.15-16, **2007***

72. A single or double TCR altered peptide ligands of myelin basic protein and proteolipid protein (Linear and Cyclic) can modulate immune responses to SJL/J mice.
Katsara, M., Tselios, T., **Matsoukas, J**., and Apostolopoulos, V.
Austin Health Research Week, Austin Hospital, Melbourne, Victoria, Australia, Oct. 22-26, **2007**

73. A vaccine toward multiple sclerosis.
Katsara, M., Yuriev, E., Ramsland, P.A., Deraos, G., **Matsoukas, J.,** and Apostolopoulos, V.
*30th European Peptide Symposium", Helsinki, Finland, Europe, 31 Aug.-5 Sept. **2008***
Edited by Hilkka Lankinen

74. Drug design on non-peptide mimetics: A new generation of pharmaceutical products
J. Matsoukas
*30th EPS, Helsinki, Finland, August 31 – September 5, **2008***
Edited by Hilkka Lankinen

75. Design and synthesis of a non-pepride PAR1 thrombin receptor antagonist, using cyclohexane as template
M. Androutsou, G. Agelis, G. Magoulas, P. Keppa, M. Saifeddine, M. Holleberg, **J. Matsoukas**
*30th EPS, Helsinki, Finland, August 31 – September 5, **2008***
Edited by Hilkka Lankinen

76. Modeling studies and biological activities of a non-peptide AT_1 receptor angiotensin II antagonist
G. Agelis, M. Matsoukas, A. Resvani, K. Kelaidonis, P. Keppa, T. Tselios, D. Vlahakos, **J. Matsoukas**
*30th EPS, Helsinki, Finland, August 31 – September 5, **2008***
Edited by Hilkka Lankinen

77. Modifications of the Myelin Basic Protein epitope MBP87-99 divert Th2 to Th1: Immune responses in peripheral blood mononuclear cells (PBMC) from Multiple Sclerosis patients.
G.Deraos, **J. Matsoukas**
*30th EPS, Helsinki, Finland, August 31 – September 5, **2008***
Edited by Hilkka Lankinen

78. *Efficient microwave-assisted synthesis of myelin epitopes MOG35-55 and MOG97-108 using CLTR-CL resin*
I. Friligou, M.E.Androutsou, T.Tselios and **J. Matsoukas.**
*30th EPS, Helsinki, Finland, August 31 – September 5, **2008***
Edited by Hilkka Lankinen

79. Efficient Microwave – Assisted Synthesis of Mitochondrial Signal Peptide using Cltr-Cl and Wang Resin.

Androutsou M-E, Agelis G., Matsoukas J.
31st European Peptide Symposium", Denmark, Copenhagen, Europe, 5-9 Septeber, ***2010,*** Edited by M. Meldal, Knud J. Jensen and T. Hoeg-Jensen

80. From Peptides to Non Peptide Mimetics: The Examples of Angiotensin II and Myelin.
Matsoukas J.
31st European Peptide Symposium", Denmark, Copenhagen, Europe, 5-9 Septeber, ***2010***
Edited by M. Meldal, Knud J. Jensen and T. Hoeg-Jensen

81. Efficient Synthesis and Biological Evaluation of Substituted Imidazole AT1 ANG II Receptor Antagonists Based on 4(5)-Butylimidazole.
Resvani A., Slaninova J., Matsoukas J., Agelis G.
31st European Peptide Symposium", Denmark, Copenhagen, Europe, 5-9 Septeber, ***2010***
Edited by M. Meldal, Knud J. Jensen and T. Hoeg-Jensen

82. Synthesis and Biological Evaluation of 1-Benzyl and 1-Biphenylmethyl Substituted Imidazole AT1 ANG II Receptor Antagonists.
Kelaidonis K., Kalavrizioti D., Matsoukas J. Agelis G.
31st European Peptide Symposium", Denmark, Copenhagen, Europe, 5-9 Septeber, ***2010***
Edited by M. Meldal, Knud J. Jensen and T. Hoeg-Jensen

83. A Concise Synthesis, Docking Studies and Biological Evaluation of *N*-substituted 5-Butylimidazole Analogues as potent Angiotensin II Receptor Blockers
Agelis, A. Resvani, S. Durdagi, T. Tůmová, J. Slaninová, P. Giannopoulos, K. Spyridaki, G. Liapakis, D. Vlahakos, T. Mavromoustakos, J. Matsoukas
32st European Peptide Symposium", Athens, Greece, Augoust 31- Septeber 5, 2012.

84. Rational Design, Efficient Synthesis, Biological Evaluation of New *N,N´*-bis-substituted Butylimidazole analogs as potent Angiotensin Receptor Blockers
G. Agelis, A. Resvani, C. Koukoulitsa, A. Afantitis, G. Melagraki, A. Siafaka, E. Gkini, T. Tůmová, K. Spyridaki, D. Kalavrizioti, M-E. Androutsou, J. Slaninová, G. Liapakis, D. Vlahakos, T. Mavromoustakos, J. Matsoukas
32st European Peptide Symposium", Athens, Greece, Augoust 31- Septeber 5, 2012.

85. Facile and Efficient Syntheses of Structurally Modified *E*-urocanic acid analogs as potent Angiotensin II Receptor Blockers
A. Resvani, C. Nikolis, G. Liapakis D. Vlahakos, C. Koukoulitsa, D. Ntountaniotis, T. Mavromoustakos, J. Matsoukas, G. Agelis
32st European Peptide Symposium", Athens, Greece, Augoust 31- Septeber 5, 2012.)

86. Conformational Similarities and Differences of Angiotensin II (AII): AII Acetate vs TFA Salt in Solution
D.Potamitis, A. Resvani, M-E. Androutsou M. Zervou, P. Plotas, G. Agelis, P. Zoumpoulakis, J. Matsoukas
32st European Peptide Symposium", Athens, Greece, Augoust 31- Septeber 5, 2012.

87. Transdermal delivery: New approach in anti-hypertensive therapy
M. Michalatou, M. E. Androutsou, T. Tselios, A. Resvani, G. Agelis, D. Vlahakos, J. Matsoukas
32st European Peptide Symposium", Athens, Greece, Augoust 31- Septeber 5, 2012.

88. Rational Design and Synthesis of linear and cyclic Myelin Epitope Peptides: New Directions in the Immunotherapy of Multiple Sclerosis
John Matsoukas
32st European Peptide Symposium", Athens, Greece, Augoust 31- Septeber 5, 2012.

89. Development and validation of a UPLC- MS analytical method for the control of the conjugation of $[Lys\text{-}Gly]_5\text{-}MOG_{35\text{-}55}$ with mannan
M. E. Androutsou, I. Friligou, J. Matsoukas, T. Tselios
32st European Peptide Symposium", Athens, Greece, Augoust 31- Septeber 5, 2012.

Abstract – Presentations at International Conferences

1. On the Selective Antagonism of Angiotensin Receptors in Smooth Muscle by two Classes of Angiotensin Antagonists.

G.J. Moore, **J.M. Matsoukas,** M.N. Scanlon, K.J. Franklin and M.H. Goghari.
Proceedings of Western Pharmacological Society, Reno, Nevada, U.S.A., February **1984**, *pp. 377.*

2. Conformation and Chemistry of Angiotensin II: Evidence for the Existence of a Tyrosine Charge Relay System in Dimethyl-Sulfoxide and Water.
G.J. Moore and **J.M. Matsoukas**.
Proceedings of the 18th European peptide Symposium, Upsala, Sweden, June **1984**, *pp. 615.*

3. ^{1}H-NMR Studies of Angiotensin II Conformation: Chemical Shifts of the Aromatic Protons of Selected Analogs in DMSO-d_6 at 400 MHz.
J. Matsoukas, H. Gohpari, G.J. Moore.
Proceedings of the 19th European Peptide Symposium, Porto Carras, Chalkidiki, Greece, Sept. **1986**, *pp. 335.*

4. Synthesis and Biological Activities of Analogs of Angiotensin II Containing Cyclohexylalanine.
J. Matsoukas, J. Hondrelis, P. Cordopatis, R. Ganter, K. Franklin and G. Moore.
Proceedings of the 2nd Peptides Forum, Nancy, France, 1-5 May **1988**, *pp. 465.*

5. Angiotensin II and III: Conformational Comparison by ^{1}H and ^{13}C NMR and Circular Dichroism.
J. Matsoukas, J. Hondrelis, P. Cordopatis, G. Moore.
20th European Peptide Symposium, Tubingen, Gernamy, Sept. **1988**, *pp. 492.*

6. Synthesis and Biological Activity of Sarmesin Analogs with Substitution at Positions 1 and 8.
P. Cordopatis, **J. Matsoukas**, U. Belte, R. Ganter, K.J. Franklin and G.J. Moore.
20th European Peptide Symposium, Tubingen, Germany, Sept. **1988**, *pp. 571.*

7. Synthesis and Biological Activities of [Aze^{7}]-ANG II and [Pip^{7}]-ANG II Analogues.
J. Matsoukas, J. Hondrelis, G. Agelis, R. Ganter, R. Yamdagni, G. Moore.
21st European Peptide Symposium, Barcelona, Spain, Sept. 2-10, **1990**, *pp. 589.*

8. Nanosecond Time-Resolved Fluorescence Study of Tyrosinate Spesies in Angiotensin II and Analogues.
R. Turner, **J. Matsoukas**, G. Moore.
21st European Peptide Symposium, Barcelona, Spain, Sept. 2-10, **1990**, *pp. 669.*

9. Synthesis and Biological Activities of Cyclic Amide-Linked Analogues of Angiotensin II and III.
J. Hondrelis, **J.M. Matsoukas**, G. Agelis, M. Keramida, A. Panagiotopoulos, K. Barlos, R. Ganter, D. Moore and G.J. Moore.
Proceedings of 22nd European Peptide Symposium, Interlaken, Switzerland, Sept. 13-19, **1992**, *pp. 689.*

10. The Importance of the Aromatic Ring Quadrupole for Receptor Interactions of the Position 4 Side Chains of Angiotensin II Analogues.
G.J. Moore, R.C. Ganter, **J.M. Matsoukas**, J. Hondrelis, G. Agelis, K. Barlos, S. Wilkinson, J. Sandall and P. Fowler.
Peptides 1993. Proceedings of the Thirteenth American Peptide Symposium, June 20-25, **1993**, *Edmonton, Alberta, Canada. (Eds. Robert S. Hodges and J. A. Smith).*

11. Type I Angiotensin II Antagonists.
G. Agelis, A. Wahhab, J. Hondrelis, R. Yamdagni, Q. Wu, R. Ganter, J. Smith, G.J. Moore and **J.M. Matsoukas**.
Proceedings of Biomedical & Health Research Euroworkshop, Patras, October 14-15, **1993** *Greece, pp. 15.*

12. Cyclic Thrombin Receptor Derived Peptide Analogues.
D. Panagiotopoulos, **J.M. Matsoukas**, M. Keramida, S. Deraos, H.L.S. Maia, R. Yamdagni, Q. Wu, P. Redstone, G.J. Moore, A.A. Laniyonu, M. Saifeddine and M.D. Hollenberg.
Proceedings of Biomedical & Health Research Euroworkshop, Patras, October 14-15, **1993** *Greece, pp. 19.*

13. Gonadotropin-Releasing Hormone (GnRH) Analogues Containing Tyr (OMe) at Position 5.
M. Keramida, **J.M. Matsoukas**, G. Agelis, D. Panagiotopoulos, J. Cladas, H.L.S. Maia, R. Yamdagni, Q. Wu, D. Pati, G.J. Moore and H.R. Habibi.
Proceedings of Biomedical & Health Research Euroworkshop, Patras, October 14-15, **1993** *Greece, pp. 23.*

14. Synthesis and Activities of Type I Angiotensin II Antagonists.
G. Agelis, **J.M. Matsoukas**, A. Wahhab, J. Hondrelis, R. Yamdagni, Q. Wu, R. Ganter, M. Rebello, H.L.S. Maia, J. Smith and G.J. Moore.
Peptides **1994**. *Proceedings of 23rd European Peptide Symposium Braga, Portugal. H. Maia (Ed*) **1994** *ESCOM. pp. 365.*

15. Cyclic Thrombin Receptor-Derived Peptide Analogues Containing D-PHR and D- ARG.

D. Panagiotopoulos, **J.M. Matsoukas**, M. Keramida, D. Gatos, L Monteiro, H. Maia, R. Yamdagni, Q. Wu, P. Redstone, G.J. Moore, A.A. Laniyonou, M Saifeddine and M.D. Hollenberg.
Peptides **1994**. *Proceedings of 23rd European Peptide Symposium Braga, Portugal. H. Maia (Ed)* **1994** *ESCOM. pp. 359.*

16. Synthesis and Activity of Gonadotropin-Releasing Hormone (GnRH) Analogues Containing Tyr (OMe) and Aze at Positions 5 and 9.
M. Keramida, **J.M. Matsoukas**, G. Agelis, D. Panagiotopoulos, J. Cladas, H.L.S. Maia, R. Yamdagni, Q. Wu, D. Pati, G.L. Moore and H.R. Habibi.
Peptides **1994**. *Proceedings of 23rd European Peptide Symposium Braga, Portugal. H. Maia (Ed)* **1994** *ESCOM. pp. 613.*

17. Designing Peptide Mimetics.
G.J. Moore and **J.M. Matsoukas**.
Proceedings of Biomedical and Health Research Conference.
University of Patras, Patras-Greece, Oct. 14-15, **1993**, *pp. 1.*

18. From Angiotensin to Non-Peptide Angiotensin II Receptor Antagonists.
J. Hondrelis, J. Smith, A. Wahhab, R. Ganter, D. Moore, G. Moore, **J. Matsoukas**.
Proceedings of Biomedical and Health Research Conference.
University of Patras, Patras-Greece, Oct. 14-15, **1993**, *pp. 27.*

19. A New Generation of Antihypertensives: Non-Peptide Angiotensin II Receptor Antagonists.
J. Smith, A Wahhab, J. Hondrelis, R. Ganter, D. Moore, G. Moore, **J. Matsoukas**.
Proceedings of Biomedical and Health Research Conference.
University of Patras, Patras-Greece, Oct. 14-15, **1993**, *pp.32.*

20. Inhibition of Angiogenesis by the Tripeptide Phe-Pro-Arg a Thrombin Receptor Derived Peptide Analogue.
M Maragoudakis, E. Pipili, D. Panagiotopoulos and **J. Matsoukas**.
Proceedings of Biomedical and Health Research Conference in Drug Design.
University of Patras, Patras-Greece, Nov. 17-19, **1994**, *pp. 59.*

21. Peptide Conformation and the Design of Peptide Mimetics.
G.J. Moore, J.R. Smith, B.W. Baylis and **J. Matsoukas**.
Proceedings of Biomedical and Health Research Conference in Drug Design.
University of Patras, Patras-Greece, Nov. 17-19, **1994**, *pp.1.*

22. Synthesis of a Potent Cyclic Amide-Linked Angiotensin II Analogue, [Sar^1, Lys^3, Clu^5] Ang II.
J. Ancans, G.J. Moore and **J.M. Matsoukas**.
Proceedings of Biomedical and Health Research Conference in Drug Design.
University of Patras, Patras-Greece, Nov. 17-19, **1994**, *pp.31.*

23. Angiotensin II: A Multifunctional Molecule.
D.V. Vlahakos, E.K. Iliodromitis, J. Ancans and **J.M. Matsoukas**.
Proceedings of Biomedical and Health Research Conference in Drug Design.
University of Patras, Patras-Greece, Nov. 17-19, **1994**, *pp.63.*

24. Superimposition of Angiotensin II with Potent Non-Peptide AT-1 Receptor Antagonists.
T. Mavromoustakos, E. Theodoropoulou, **J. Matsoukas**, G. Moore, J. Smith.
Proceedings of Biomedical and Health Research Conference in Drug Design.
University of Patras, Patras-Greece, Nov. 17-19, **1994**, *pp.74.*

25. Advances in Antihypertensive Therapy: Non-Peptide Angiotensin II Receptor Antagonists as Potent Therapeutic Agents.
J. Smith, Q. Wahhab, J. Hondrelis, R.Ganter, D. Moore, G. Moore and **J. Matsoukas.**
Proceedings of Biomedical and Health Research Conference in Drug Design.
University of Patras, Patras-Greece, Nov. 17-19, **1994**, *pp. 103.*

26. Cyclic Thrombin Receptor Derived Peptide Analogues of the S^{42} $FLLR^{46}$ Motif: Novel Synthesis and Biological Activities.
D. Panagiotopoulos, **J.M. Matsoukas**, M. Keramida, T. Mavromoustakos, H.L.S. Maia, R. Yamdagni, Q.Wu, G.J. Moore, M. Saifeddine and M.D. Hollenberg.
Proceedings of Biomedical and Health Research Conference in Drug Design.
University of Patras, Patras-Greece, Nov. 17-19, **1994**, *pp.108.*

27. A Potent Gonadotropin-Releasing Hormone (GnRH) Analogue, [Tyr(OMe)^5, D-Glu^6, Aze^9] GnRH: Synthesis and Activities.
M. Keramida, **J.M. Matsoukas**, D. Panagiotopoulos, H.L.S. Maia, D. Pati, H. Hoang, G.J. Moore and H.R. Habibi.

Proceedings of Biomedical and Health Research Conference in Drug Design. University of Patras, Patras-Greece, Nov., 17-19, **1994**, *pp.112.*

28. Myelin Basic Protein Peptides: Induction and Inhibition of Experimental Allergic Encephalomyelitis.
S. Deraos, T. Tselios, E. Matsoukas, D. Panagiotopoulos, **J. Matsoukas**, G.J. Moore, L. Probert, G. Kollias, B. Hilliard, A. Rostami and D. Monos.
In Matsoukas J. (Ed.), Aminoacids-Peptides-Proteins in Drug Discovery and Design, Proceedings of Biomedical and Health Research, University of Patras, Greece, **1995**, *pp. 7.*

29. The Conformational Properties of the Immunomodulator Linomide.
T. Mavromoustakos, M. Bensaia, E. Theodoropoulou, M. Zervou, D. Karussis and **J. Matsoukas**.
In Matsoukas J. (Ed.), Aminoacids-Peptides-Proteins in Drug Discovery and Design, Proceedings of Biomedical and Health Research, University of Patras, Greece, **1995**, *pp. 23.*

30. Behavioural Effects of Sarmesin.
V. Georgiev, **J. Matsoukas**, M. Opitz, D. Georgieva, J. Tchekalarova, T. Kambourova and I. Todorov.
In Matsoukas J. (Ed.), Aminoacids-Peptides-Proteins in Drug Discovery and Design, Proceedings of Biomedical and Health Research, University of Patras, Greece, **1995**, *pp.31.*

31. Characteristics of Sarmesin, an Angiotensin II Receptor Blocker.
S. Mihailescu, **J. Matsoukas**, F.L. Abel, V. Nestianu, F. Romanescu, Alecu-Parvu Cristina.
In Matsoukas J. (Ed.), Aminoacids-Peptides-Proteins in Drug Discovery and Design, Proceedings of Biomedical and Health Research, University of Patras, Greece, **1995**, *pp.38.*

32. Hypertensive Responses to Intravenous Infusion of the Novel Cyclic Angiotensin II (ANG II) Analogue [Sar^1, Lys^3, Glu^5] ANG II in Anesthetized Rabbits.
D.V. Vlahakos, **J.M. Matsoukas**, J. Ancans, K. Iliodromitis, K.P. Marathia and D.Th. Kremastinos.
In Matsoukas J. (Ed.), Aminoacids-Peptides-Proteins in Drug Discovery and Design, Proceedings of Biomedical and Health Research, University of Patras, Greece, **1995**, *pp.84.*

33. Use of Molecular Modeling to Study Superimposition of the Thrombin Receptor Motif S^{42} $FLLR^{46}$ with its Peptidomimetic Analogs.
T. Mavromoustakos, E. Theodoropoulou, K. Alexopoulos, **J. Matsoukas** and M. Hollenberg.
In Matsoukas J. (Ed.), Aminoacids-Peptides-Proteins in Drug Discovery and Design, Proceedings of Biomedical and Health Research, University of Patras, Greece, **1995**, *pp.102.*

34. Synthesis and Activities of Cyclic Thrombin Receptor-Derived Peptide Analogues of the Ser^{42}-Phe-Leu-$Leu-Arg^{46}$ Motif Sequence, Containing 2,3 Diaminopropionic Acid.
D. Panagiotopoulos, K. Alexopoulos, **J.M. Matsoukas**, Th. Mavromoustakos, E. Theodoropoulou, H.L.S. Maia, M. Saifeddine and D. Hollenberg.
In Matsoukas J. (Ed.), Aminoacids-Peptides-Proteins in Drug Discovery and Design, Proceedings of Biomedical and Health Research, University of Patras, Greece, **1995**, *pp.108.*

35. Differences in Backbone Structure between the Super Agonist [Sar^1] Angiotensin II and its Type I Antagonist Sarilesin.
J.M. Matsoukas, K. Alexopoulos, T. Tselios, R. Yamdagni, Q. Wu, T. Mavromoustakos and G.J. Moore.
In Matsoukas J. (Ed.), Aminoacids-Peptides-Proteins in Drug Discovery and Design, Proceedings of Biomedical and Health Research, University of Patras, Greece, **1995**, *pp.114.*

36. Recognition of the Encephalitogenic Myelin Basic Protein (74-85) by the Immune System: Importance of Conformation.
J.M. Pires, **J.M. Matsoukas**, G.J. Moore.
Proc. West. Pharm. Soc., **1998,** *41, pp. 193.*

37. Synthesis of a Novel Cyclic Analogue of the Myelin Basic Protein Epitope MBP_{72-85}.
T. Tselios, L. Probert, G. Kollias, I. Daliani, E. Matsoukas, P. Roumelioti, K. Alexopoulos**, J. Matsoukas**.
Proceedings of the 25th EPS (Ed. Bazush), Budapest, Hungary, Sept. 1-5, **1998**, *pp. 504.*

38. Thrombin-Derived Peptides: Design and Synthesis.
L. Polevaya, **J. Matsoukas**, T. Keivish, I. Mutule, I. Mutule.
Proceedings of the 25th EPS (Ed. Bazush), Budapest, Hungary, Sept. 1-5, **1998**, *pp. 620.*

39. Synthesis and Biological Activities of Thrombin Receptor Derived Non-Peptide Mimetics: Importance of Phenyl/Guanidino Proximity for Activity.
K. Alexopoulos, E. Melissari, P. Fatseas, D. Vlahakos, T. Tselios, P. Roumelioti, **J. Matsoukas.**
Proceedings of the 25th EPS (Ed. Bazush), Budapest, Hungary, Sept. 1-5, **1998**, *pp. 650.*

40. Design and Synthesis of Two Potent Amide Linked Cyclic Analogs of the Hormone Angiotensin II Confirm the Importance of Ring Cluster and Relay System in its Possible Bioactive Conformation.

P. Roumelioti, L. Polevaya, D. Vlahakos, T. Mavromoustakos, A. Kolocouris, T. Tselios and **J. Matsoukas**.
Proceedings of 16th American Peptide Symposium, Minneapolis, U.S.A., June 26-July 1, **1999.** *Edited by G. Fields, J. Tam and G. Barany. . pp. 509.*

41. Homology-Based Analysis of Thrombin Receptors.
L. Peloyava and **J. Matsoukas**.
Proceedings of 16th American Peptide Symposium, Minneapolis, U.S.A., June 26-July 1, **1999.** *Edited by G. Fields, J. Tam and G. Barany. pp. 647.*

42. The Biological Activity of Amide Linked Angiotensin II (AII) Cyclic Analogues Confirms the Ring Clustering and Charge Relay Bioactive Conformation of AII.
D. V. Vlahakos, E. K. Iliodromitis. E. Bofilis, K. P. Marathias, L. Poleyava, **J. Matsoukas**, P. Roumelioti, D. Th. Kremastinos
European Society of Cardiology, August 28-September 1, **1999** *- Barcelona – Spain.*

43. Design and Synthesis of Potent Linear and Cyclic Analogues of the Myelin Basic Protein Epitope MBP_{87-99}.
T. Tselios, I. Daliani, L. Probert, S. Deraos, E. Matsoukas, P. Roumelioti, K. Alexopoulos, **J. Matsoukas**.
Proceedings of the 26th EPS, Montpellier, France, Sept. **2000**, *pp. 761.*

44. The Discovery of a Non-Peptide Thrombin Receptor Antagonist in Human and also Rabbit Platelets: a Novel Drug Lead.
K. Alexopoulos, P. Fatseas, A. Zoga, N. Giatas, T. Tselios, P. Roumelioti, E. Melissari, D. Vlahakos, C. Demopoulos, **J. Matsoukas**.
Proceedings of the 26th EPS, Montpellier, France, Sept. **2000**, *pp. 789.*

45. The Design of Non-Peptide Angiotensin II Mimetics Based on the Ring Cluster Receptor Conformation of the Hormone.
N. Giatas, P. Roumelioti, T. Mavromoustakos, **J. Matsoukas**.
1st Conference on Medicinal Chemistry: Drug Discovery and Design, Patras, Greece, March 1-3, **2000**.

46. Peptide Conformation and the Design of Mimetics: From Angiotensin to Non-Peptide Receptor Antagonists.
P. Roumelioti, P. Zoumboulakis, **J. Matsoukas**.
1st Conference on Medicinal Chemistry: Drug Discovery and Design, Patras, Greece, March 1-3, **2000**.

47. The Design of Myelin Basic Protein as Drugs in the Immunotherapy of Multiple Sclerosis.
T. Tselios, I. Daliani, S. Deraos, L. Probert, P. Roumelioti, **J. Matsoukas**.
1st Conference on Medicinal Chemistry: Drug Discovery and Design, Patras, Greece, March 1-3, **2000**.

48. Conformational Properties of AT_1 Antagonists: A comparative study.
M. Zervou, S.G. Gardadolnik, A. Kolocouris, P. Zoumboulakis, T. Mavromoustakos, P. Roumelioti, **J. Matsoukas.**
1st Conference on Medicinal Chemistry: Drug Discovery and Design, Patras, Greece, March 1-3, **2000**.

49. AT1 Antagonists: From Bench Research to Clinical Application.
D.V. Vlahakos, **J. Matsoukas**.
Conference on Medicinal Chemistry: Drug Discovery and Design, Patras, Greece, March 1-3, **2000**.

50. Peptide Conformation and the Design of Mimetics: from Angiotensin to Non-peptide Receptor Antagonists.
P. Roumelioti, P. Zoumboulakis, **J. Matsoukas**.
1st *Conference on Medicinal Chemistry: Drug Discovery and Design, Patras, Greece, March 1-3,* **2000**.

51. The Design of Myelin Basic Protein Mimetics as Drugs in the Immunotherapy of Multiple Sclerosis.
T. Tselios, I. Daliani, S. Deraos, L. Probert, P. Roumelioti, **J. Matsoukas**.
1st Conference on Medicinal Chemistry: Drug Discovery and Design, Patras, Greece, March 1-3, **2000**.

52. Conformational Properties of AT1 Antagonists: A Comparative Study.
M. Zervou, S.G. Gardadolnik, A. Kolocouris, P. Zoumboulakis, T. Mavromoustakos, P. Roumelioti, **J. Matsoukas**.
1st Conference on Medicinal Chemistry: Drug Discovery and Design, Patras, Greece, March 1-3, **2000**.

53. Design and Synthesis of Novel Biologically Active Thrombin Receptor Non Peptide Mimetics.
K. Alexopoulos, P. Fatseas, A. Zoga, N. Giatas, E. Melissari, D. Vlahakos, **J. Matsoukas**.
1st Conference on Medicinal Chemistry: Drug Discovery and Design, Patras, Greece, March 1-3, **2000**.

54. Design and Synthesis of Amide-Linked Angiotensin II Analogues With 3,5 Side Chain Bridges: Structural Resemblance of Ring Cluster Conformation with AT1 Non-Peptide Antagonists.
P. Roumelioti, L. Polevaya, N. Giatas, A. Zoga, I. Mutule, T. Keivish, T. Mavromoustakos, P. Zoumboulakis, D. Vlahakos, and **J. Matsoukas.**

Proceedings of the 2nd International and 17th American Peptide Symposium, San Diego, California, USA, June 9-14, **2001.** *Edited by M. Lebl and R. Houghteen, pp. 656.*

55. Design and Biological Activity of Novel Non-Peptide Imidazole Based Angiotensin II Receptor Antagonists.
N. Giatas, P. Roumelioti, A. Zoga, P. Zoumpoulakis, T. Mavromoustakos, D. Vlahakos, E. Iliodromitis, and **J. Matsoukas.**
2nd Conference on Medicinal Chemistry: Drug Discovery and Design, Patras, Greece, March 1-3, **2001**, *pp. 65.*

56. Rational Design and Synthesis of a Potent Amide-Linked Cyclic Analogue of MBP_{87-99} Based on 2D-NMR Studies and Molecular Dynamics.
I. Daliani, T. Tselios, L. Probert, S. Deraos, T. Mavromoustakos and **J. Matsoukas.**
Proceedings of the Second International and the Seventeenth American Peptide Symposium, San Diego, California, USA, June **2001.** *Edited by M. Lebl and R. Houghteen, pp. 238.*

57. Design, Synthesis and Modulation of Angiogenesis by Thrombin Receptor Non-Peptide Antagonists.
K. Alexopoulos, M. Maragoudakis and **J. Matsoukas.**
Proceedings of the Second International and the Seventeenth American Peptide Symposium, San Diego, California, USA, June **2001.** *Edited by M. Lebl and R. Houghteen, pp. 614.*

58. Effect of Peptide Analogues of Myelin Basic Protein (MBP) on Human Peripheral Blood (HPB) T Cells of Multiple Sclerosis (MS) Patients and Controls.
K. Hatzantoni, S. Thymianou, T. Tselios, A. Nikoletatou, P. Papathanassopoulos, I. Papapetropoulos, **J. Matsoukas**, A. Mouzaki.
2nd Conference on Medicinal Chemistry: Drug Discovery and Design, Patras, Greece, March 1-3, **2001**.

59. Insights into the Regulation Thrombin-Stimulated Angiogenesis.
L. Polevaya, **J. Matsoukas**.
2nd Conference on Medicinal Chemistry: Drug Discovery and Design, Patras, Greece, March 1-3, **2001**.

60. Antibodies Against the MBP_{72-85} Epitope May Protect the Lewis Rats in the Experimental Allergic Encephalomyelitis (EAE).
A. Lepenioti, T. Tselios, S. Deraos, G. Nezi, **J. Matsoukas**, A. Aletras.
2nd Conference on Medicinal Chemistry: Drug Discovery and Design, Patras, Greece, March 1-3, **2001**.

61. Design and Synthesis of Amide-linked Angiotensin II Analogues with 3,5 side Chain Bridges: Structural Resemblance of Ring Cluster Conformation with AT1 non-Peptide Antagonists.
P. Roumelioti, N. Giata, A. Zoga, L. Polevaya, T. Mavromoustakos, P. Zoumboulakis, D. Vlahakos, E. Iliodromitis, **J. Matsoukas**.
2nd Conference on Medicinal Chemistry: Drug Discovery and Design, Patras, Greece, March 1-3, **2001**.

62. Rational Design and Synthesis of a Potent Amike-Linked Cyclic Analogue of MBP_{87-99} based on 2D-NMR Studies and Molecular Dynamics.
I. Daliani, T. Tselios, L. Probert, S. Deraos, T. Mavromoustakos, **J. Matsoukas**.
2nd Conference on Medicinal Chemistry: Drug Discovery and Design, Patras, Greece, March 1-3, **2001**.

63. Design and Biological Activity of Novel Non-Peptide Imidazole Based Angiotensin II Receptor Antagonists.
N. Giatas, P. Roumelioti, A. Zoga, P. Zoumpoulakis, D. Vlahakos, T. Mavromoustakos, **J. Matsoukas**.
2nd Conference on Medicinal Chemistry: Drug Discovery and Design, Patras, Greece, March 1-3, **2001**.

64. Design, Synthesis and Conformation Properties of Linear Analogues Based on Myelin Basic Protein Epitope MBP_{1-11}.
J. Matsoukas, S. Deraos, T. Tselios, I. Daliani, G. Deraos, P. Zoumpoulakis, L. Probert, A. Troganis, T. Mavromoustakos.
Proceedings of 27th EPS, Sorrento, Italy, Aug. 31-Sept. 6. **2002**. Edited by E. Benedetti.

65. Potent Cyclic Angiotensin II Analogues Confirm the Ring Cluster Conformation: Implications in the Design of AT1 Non-Peptide Antagonists.
N. Giatas, A. Zoga, M. Androutsou, P. Roumelioti, L. Polevaya, T. Mavromoustakos, P. Zoumpoulakis, D. Vlahakos, **J. Matsoukas**.
27th European Peptide Symposium, Sorrento, Italy, August 31-September 6, **2002**. Edited by E. Benedetti.

66. A Very Promising Cyclic MBP Peptide for Multiple Sclerosis.
J. Matsoukas, T. Tselios, S. Deraos, T. Biagioli, C. Ballerini, B. Mazzanti, E. Traggiai, M. Chelli, M. Vergelli, F. Lolli, A.M. Papini.
3rd Conference on Medicinal Chemistry: Drug Discovery and Design, Patras, Greece, March 7-9, **2002**.

67. Effect of Peptide Analogs of Myelin Basic Protein on Cytokine Secretion by Peripheral Blood Mononuclear Cells of Multiple Sclerosis Patients and Controls.

K. Chatzantoni, S. Thymianou, T. Tselios, P. Papathanassopoulos, **J. Matsoukas**, A. Mouzaki.
3rd Conference on Medicinal Chemistry: Drug Discovery and Design, Patras, Greece, March 7-9, **2002**.

68. Conformation and Bioactivity.
T. Mavromoustakos, P. Zoumpoulakis, M. Zervou, N. Zoga, N. Giatas, P. Roumelioti, **J. Matsoukas**.
3rd Conference on Medicinal Chemistry: Drug Discovery and Design, Patras, Greece, March 7-9, **2002**.

69. NMR and Molecular Dynamic Conformational Studies of Two Peptide Analogues of a Myelin Basic Protein Epitope 74-85 Implicated in Multiple Sclerosis.
A. Tzakos, A. Troganis, T. Tselios, A. Bonvin, N. Nuland, S. Deraos, **J. Matsoukas**, I. Gerothanassis.
3rd Conference on Medicinal Chemistry: Drug Discovery and Design, Patras, Greece, March 7-9, **2002**.

70. Effect of non-Peptide Thrombin Receptor Antagonists and RGD-Analogues on Angiogenesis in the Chick Chorioallantoic Membrane.
M. Papakonstantinou, N. Tsopanoglou, Y. Sarigiannis, **J. Matsoukas**, G. Stavropoulos, M. Maragoudakis.
3rd Conference on Medicinal Chemistry: Drug Discovery and Design, Patras, Greece, March 7-9, **2002**.

71. Design and Synthesis of Histamine Derivatives Analogues as Antagonists to the AT1 Receptor of Angiotensin II.
M.E. Androutsou, A. Zoga, N. Giatas, P. Roumelioti, E. Iliodromitis, D. Vlahakos, **J. Matsoukas**.
3rd Conference on Medicinal Chemistry: Drug Discovery and Design, Patras, Greece, March 7-9, **2002**.

72. Design and Synthesis of Linear and Cyclic Analogues Based on Human MBP_{87-99} Epitope: Effects on Healthy Peripheral Blood Cells.
G. Deraos, T. Tselios, S. Deraos, K. Hanziantoni, A. Mouzaki, **J. Matsoukas**.
3rd Conference on Medicinal Chemistry: Drug Discovery and Design, Patras, Greece, March 7-9, **2002**.

73. Design, Synthesis and Conformational Properties of Linear Analogues of Human Myelin Basic Protein Epitope MBP_{1-11}.
S. Deraos, T. Tselios, I. Daliani, P. Zoumpoulakis, L. Probert, A. Troganis, T. Mavromoustakos, **J. Matsoukas.**
3rd Conference on Medicinal Chemistry: Drug Discovery and Design, Patras, Greece, March 7-9, **2002**.

74. Synthesis of Imidazole-based Non-peptide Angiotensin II Receptor Antagonists as Potent Antihypertensives.
N. Giatas, M.E. Androutsou, A. Zoga, P. Roumelioti, P. Zoumpoulakis, T. Mavromoustakos, D. Vlahakos, E. Iliodromitis, **J. Matsoukas**.
3rd Conference on Medicinal Chemistry: Drug Discovery and Design, Patras, Greece, March 7-9, **2002**.

75. Biological Essays of non-Peptide Angiotensin II AT1-Receptor Antagonists.
A. Zoga, N. Giatas, P. Roumelioti, M.E. Androutsou, P. Zoumpoulakis, T. Mavromoustakos, D. Vlahakos, E. Iliodromitis, **J. Matsoukas**.
3rd Conference on Medicinal Chemistry: Drug Discovery and Design, Patras, Greece, March 7-9, **2002**.

76. Conformational and Biophysical Studies of AT1 Non-Peptide Antagonists.
P. Zoumpoulakis, A. Zoga, E. Zervou, N. Giatas, P. Roumelioti, **J. Matsoukas**, T. Mavromoustakos.
3rd Conference on Medicinal Chemistry: Drug Discovery and Design, Patras, Greece, March 7-9, **2002**.

77. Structural studies and sequence homology investigations of the guinea pig myelin basic protein (MBP) epitope 74-85 analogues.
A. Tzakos, P.Fuchs, N. van Nuland, A.Troganis, T. Tselios, S. Deraos, G. Deraos, I. Gerothanassis, A. Bonvin, **J. Matsoukas**.
18th American Peptide Sumposium, Boston, USA, July 19-23, **2003**, p943, Editors: M. Chorev and T. Sawyer.

78. Desing and Synthesis of Novel Antihypertensive Drugs.
T. Mavromoustakos, P. Roumelioti, M. Zervou, P. Zoumpoulakis, I. Kyrikou, N. Giatas, D. Gatos, M.E.Androutsou, I. Papanastasiou, A. Zioga, P.M.Minakakis, G. Kokkotos, D. Vlahakos, E. Iliodromitis, **J. Matsoukas**.
18th American Peptide Sumposium, Boston, USA, July 19-23, **2003**, p569, Editors: M. Chorev and T. Sawyer.

79. Structural Studies of Agonist and Antagonist Peptides of the Guinea Pig Myelin Basic Protein Epitope 74-85 in Solution-Docking calculations to the MHC-II receptor site and Implication of Structure-Function Relationships.
Andreas G. Tzakos, Patrick Fuchs, Nico A.J. van Nuland, Anastasios Troganis, Theodore Tselios, Spyros Deraos, **John Matsoukas**, Ioannis P. Gerothanassis and Alexandre M.J.J. Bonvin.
7th European NMR Large Scale Facilities User Meeting, November 21 - 22, **2003**, Oosterbeek, Netherlands.

80. Conformation and Bioactivity. Design and Discovery of Novel Antihypertensive Drugs.
T. Mavromoustakos, M. Zervou, P. Zoumpoulakis, I. Kyrikou, P. Roumelioti, N. Giatas, A. Zoga, P.M. Minakakis, C. Kamoutsis, D. Dimitriou, A. Pitsas, **J. Matsoukas**.
4th Conference on Medicinal Chemistry: Drug Discovery and Design, Patras, Greece, March 13-14, **2003**.

81. Structural Studies and Sequence Homology Investigations of Agonist and Antagonist Peptides of the Guinea Pig Myelen Basic Protein (MBP) Epitope 74-85: Imlication for Structure-Function Relationships.
Conference on Medicinal Chemistry: Drug Discovery and Design, Patras, Greece, March 13-14, **2003**.

82. Design and Synthesis of Linear and Cyclic Analogues of Human Myelin Basic Protein MBP_{87-99} Epitope: Stability and HLA-binding Studies.
G. Deraos, T. Tselios, S. Deraos, H. Kalbacher, **J. Matsoukas**.
4th Conference on Medicinal Chemistry: Drug Discovery and Design, Patras, Greece, March 13-14, **2003**.

83. Novel Hybrid Imidazole-basid Compounds Against Hypertension and Other Cardiovascular Diseases.
N. Giatas, P. Roumelioti, A. Zoga, M. Anastasopoulou, D. Vlahakos, **J. Matsoukas**.
4th Conference on Medicinal Chemistry: Drug Discovery and Design, Patras, Greece, March 13-14, **2003**.

84. Biological Studies of Angiotensin II Receptor Blockers in *in vivo* Experimental Models.
A. Zoga, N. Giatas, P. Roumelioti, E. Iliodromitis, D. Vlahakos, **J. Matsoukas**.
4th Conference on Medicinal Chemistry: Drug Discovery and Design, Patras, Greece, March 13-14, **2003**.

85. Synthesis and Characterization of Biologically Active Glycopeptides.
K. Kelaidonis, P. Roumelioti, T. Tselios, **J. Matsoukas**, T. Tsegenidis.
4th Conference on Medicinal Chemistry: Drug Discovery and Design, Patras, Greece, March 13-14, **2003**.

86. Design and Synthesis of Thrombin Receptor-Derived Non-Peptide Mimetics.
M. E. Androutsou, N. Giatas, P. Roumelioti, I. Papanastasiou, K. Alexopoulos, **J. Matsoukas**.
4th Conference on Medicinal Chemistry: Drug Discovery and Design, Patras, Greece, March 13-14, **2003**.

87. Synthesis of Peptides which Imitate Specific Amino Acid Sequences of the Extracellular Domain of the beta Chain of the High Affinity I1-2 Receptor (I1-2R) to be Used for the Suppression of t-Cell Activation.
S. Deraos, T. Parissi, K. Chatzantoni, G. Deraos, T. Tselios, **J. Matsoukas**, A. Mouzaki.
4th Conference on Medicinal Chemistry: Drug Discovery and Design, Patras, Greece, March 13-14, **2003**.

88. Design and Synthesis of Two Novel Cyclic GnRH Analogues: Biological and Conformational Studies.
M. Keramida, T. Tselios, H. Habibi, G. Agelis, T. Mavromoustakos, K. Papazisis, **J. Matsoukas**.
4th Conference on Medicinal Chemistry: Drug Discovery and Design, Patras, Greece, March 13-14, **2003**.

89. Design and Synthesis of a Potent Analogue of Myelin Basic Protein MBP_{87-99} Epitope: Inhibition of Experimental Autoimmune Encephalomyelitis (EAE).
G. Deraos, T. Tselios, S. Deraos, L. Synodinos, A. Papalois and **J. Matsoukas**.
28th European Peptide Symposium, Prague, Chech Republic, Sept. 1-6, **2004**, *Edited by Jirina Slaninova.*

90. Citrullination Of EAE Antagonist Analogue, Cyclo(87–99) (Arg91, Ala96) MBP87–99 with Peptidylarginine Deiminase (PAD).
Deraos, S. Deraos, T. Tselios, **J. Matsoukas**, H. Vynios.
28th European Peptide Symposium, Prague, Chech Republic, Sept. 1-6, **2004**, *Edited by Jirina Slaninova.*

91. Solid Phase Synthesis of IL-2 Receptor (IL-2R) Extracellular Domain Beta Chain Epitopes M^{107}-E^{118} and Y^{178}-Q^{199}: Inhibition of T-cell Activation.
S. Deraos, T. Parissi, T. Tselios, G. Deraos, M. Matsoukas, K. Chatzantoni, A. Mouzaki, **J. Matsoukas**.
28th European Peptide Symposium, Prague, Chech Republic, Sept. 1-6, **2004**, *Edited by Jirina Slaninova.*

92. From Angiotensin to Losartan: The Case of Vivartan.
J. Matsoukas.
5th Conference on Medicinal Chemistry: Drug Discovery and Design, Patras, Greece, March 11-13, **2004**.

93. In vitro Effects of Myelin Basic Protein Peptides on Multiple Sclerosis.
K. Chatzantoni, P. Papathanassopoulos, T. Tselios, **J. Matsoukas**, A. Mouzaki.
5th Conference on Medicinal Chemistry: Drug Discovery and Design, Patras, Greece, March 11-13, **2004**.

94. Structure-Function Relationships of the Myelin Proteins: Current Status and Perspectives in the Treatment of Multiple Sclerosis.
A. Tzakos, C. Svarnas, A. Troganis, G. Deraos, S. Deraos, **J. Matsoukas**, V. Apostolopoulos, I. Gerothanassis.
5th Conference on Medicinal Chemistry: Drug Discovery and Design, Patras, Greece, March 11-13, **2004**.

95. Reliase of Hydrophobic Pharmaceuticals from Biopolymers: Targeting the Reduction of Arterial Restenosis in Cardiovascular Diseases.
M. Anastasopoulou, G. Bokias, P. Roumelioti, N. Giatas, Z. Kyriakidis, **J. Matsoukas**.
5th Conference on Medicinal Chemistry: Drug Discovery and Design, Patras, Greece, March 11-13, **2004**.

96. Design and Synthesis of Non-peptide Mimetics as Potential Antagonists of Part 1 Thrombin Receptor.
M. E. Androutsou, P. Roumelioti, K. Alexopoulos, **J. Matsoukas**.
5th Conference on Medicinal Chemistry: Drug Discovery and Design, Patras, Greece, March 11-13, **2004**.

97. Control of the Release of an Angiotensin II AT1 Receptor Antagonist from Biopolymer Films: Influence of the Biopolymer Hydrophilicity.
G. Bokias, M. Anastasopoulou, P. Roumelioti, N. Giatas, Z. Kyriakidis, **J. Matsoukas**.
5th Conference on Medicinal Chemistry: Drug Discovery and Design, Patras, Greece, March 11-13, **2004**.

98. Synthesis of Cyclic Peptides Based on High Affinity Il-2 Receptor (IL-2R) Extracellular Domain Beta Chain Epitopes: Suppression of T-Cell Activation.
S. Deraos, T. Tselios, **J. Matsoukas**, A. Mouzaki.
5th Conference on Medicinal Chemistry: Drug Discovery and Design, Patras, Greece, March 11-13, **2004**.

99. Synthesis and Comparative Modeling Studies of the C-Terminal 145-162 Fragment of *guinea pig* MBP (gpMBP) with the 950-967 Fragment of Vinculin.
G. Deraos, A. Tzakos, C. Svarnas, A. Troganis, C. Moulkioti, S. Deraos, I. Gerothanassis, D. Gatos, **J. Matsoukas**.
5th Conference on Medicinal Chemistry: Drug Discovery and Design, Patras, Greece, March 11-13, **2004**.

100. Effects of Myelin Basic Protein MBP 72-85 – Mannan Complexes in Peripheral Blood Mononuclear Cells (PBMCs): Cytokine Secretion.
M. Katsara, K. Chatzantoni, A. Mouzaki, **J. Matsoukas**.
5th Conference on Medicinal Chemistry: Drug Discovery and Design, Patras, Greece, March 11-13, **2004**.

101. Structural Elucidation and Conformation Properties of [Arg^{91}, Ala^{96}] MBP_{87-99}. An Antagonist Suppressing the Induction of Experimental Autoimmune Encephalomyelitis (EAE).
A. Mantzourani, T. Tselios, **J. Matsoukas**, T. Mavromoustakos.
5th Conference on Medicinal Chemistry: Drug Discovery and Design, Patras, Greece, March 11-13, **2004**.

102. Design and Synthesis of Thrombin Agniotensin Like Peptide (TALP) Mimetics.
I. Papanastasiou, P. Roumelioti, N. Giatas, A. Vlachou, **J. Matsoukas**.
5th Conference on Medicinal Chemistry: Drug Discovery and Design, Patras, Greece, March 11-13, **2004**.

103. Biological Studies of Analogues of Myelin Basic Protein (MBP) in Experimental Autoimmune Encephalomyelitis (EAE).
L. Synodinos, A. Papalois, G. Pairas, G. Deraos, T. Tselios, **J. Matsoukas**.
5th Conference on Medicinal Chemistry: Drug Discovery and Design, Patras, Greece, March 11-13, **2004**.

104. Cellular Activation and Cytokine Expression Profiles in Autoimmune Diseases and Organ Transplantation: Modulation by Therapeutic Peptides, Sparing the Regulatory Cells.
A. Mouzaki, S. Deraos, T. Tselios, **J. Matsoukas**, P. Papathanassopoulos, K. Chatzantoni.
6th Conference on Medicinal Chemistry: Drug Discovery and Design, Patras, Greece, March 10-12, **2005**.

105. From Angiotensin to Sartans, A New Generation of Anti-Hypertensives.
J. Matsoukas.
6th Conference on Medicinal Chemistry: Drug Discovery and Design, Patras, Greece, March 10-12, **2005**.

106. Thrombin-Angiotensin Mimetics: Design of Double Action Mimetics (TALPs: Thrombin Ang II Like Peptides)
I. Papanastasiou, P. Roumelioti, M.E. Androutsou, **J. Matsoukas**.
6th Conference on Medicinal Chemistry: Drug Discovery and Design, Patras, Greece, March 10-12, **2005**.

107. Design and Synthesis of MBP_{83-99} Epitope Conjugated with Mannan for the Immunotherapy of Multiple Sclerosis.
E. Friligou, **J. Matsoukas**, T. Tselios.
6th Conference on Medicinal Chemistry: Drug Discovery and Design, Patras, Greece, March 10-12, **2005**.

108. Design and Synthesis of an Non-Peptide Indole Based Antagonist of Par 1 Trhrombin Receptor.
M. E. Androutsou, K. Alexopoulos, **J. Matsoukas**.
6th Conference on Medicinal Chemistry: Drug Discovery and Design, Patras, Greece, March 10-12, **2005**.

109. Citrullination of EAE Antagonist Analogue, Cyclo(87-99) (Arg^{91}, Ala^{96}) MBP_{87-99} with Peptidylarginine Deiminase (PAD).
G. Deraos, S. Deraos, **J. Matsoukas**, D. Vynios.
6th Conference on Medicinal Chemistry: Drug Discovery and Design, Patras, Greece, March 10-12, **2005**.

110. Development of New Non-Peptide Antagonists for Thrombin Receptor, Par-1: Test of Thrombin-Induced Mobilization of Intracellular CA^{2+}.
N. Zacharakis, N. Tsopanoglou, K. Alexopoulos, M.E. Androutsou, J. Papanastasiou, **J. Matsoukas**.
6th Conference on Medicinal Chemistry: Drug Discovery and Design, Patras, Greece, March 10-12, **2005**.

111. Myelin Basic Protein (MBP) and Proteolipid Protein (PLP) Peptides (Cyclic and Linear, Agonist and Antagonist): Immune Responses in Animal Models for Multiple Sclerosis.
M. Katsara, V. Apostolopoulos, T. Tselios, S. Deraos, G. Deraos, **J. Matsoukas**.
6th Conference on Medicinal Chemistry: Drug Discovery and Design, Patras, Greece, March 10-12, **2005**.

112. Design and Synthesis of Non-Peptide Angiotensin II Receptor Antagonists Based on Urocanic Acid.
A. Resvani, M.E. Androutsou, **J. Matsoukas**.
6th Conference on Medicinal Chemistry: Drug Discovery and Design, Patras, Greece, March 10-12, **2005**.

113. Myelin basic protein (MBP) and proteolipid protein (PLP) peptides (cyclic and linear, agonist and antagonist): Immune responses in animal models for multiple sclerosis.
Katsara, M., Apostolopoulos, V., Tselios, T., Deraos, S., and **Matsoukas, J**.
Autumn Peptide Symposium 2005, University of Melbourne, Melbourne, Victoria, Australia, Apr. 20, **2005.**

114. Design and synthesis of novel linear and cyclic analogues based on myelin basic protein MBP83-99 epitope: Immune responses in animal models for multiple sclerosis.
Katsara M., Deraos G., Tselios T., Deraos S., **Matsoukas J.,** and Apostolopoulos V.
Spring Peptide Symposium 2005, University of Melbourne, Melbourne, Victoria, Australia, Oct. 18, **2005.**

115. Myelin basic protein (MBP) and proteolipid protein (PLP) peptides (linear and cyclic, agonist and antagonist):Immunomodulating therapeutic approaches for multiple sclerosis.
Katsara M., Tselios T., Deraos S., Deraos G., **Matsoukas J**., and Apostolopoulos V.
Austin Health Research Week, Austin Hospital, Melbourne, Victoria, Australia, Oct. 10-14, 2005.

116. Effect of myelin basic protein (MBP) and proteolipid protein (PLP) peptides (linear and cyclic) using CFA or conjugated to reduced mannan in animal models for multiple sclerosis.
Katsara M., Tselios T., Deraos S., Deraos G., **Matsoukas J**., and Apostolopoulos V.
Alfred Research Week, Alfred Hospital, Melbourne, Victoria, Australia, Oct. 24-28, **2005.**

117. Myelin basic protein (MBP) and proteolipid protein (PLP) peptides (liner and cyclic) and immune responses in animal models.Therapeutic approaches for multiple sclerosis.
Katsara M., Tselios T., Deraos S., Deraos G., **Matsoukas J**., and Apostolopoulos V.
35th Australasian Society for Immunology / 14th International HLA and Immunogenetics Work shop, Melbourne, Victoria, Australia, Dec. 4-8, **2005**

118. Design and Synthesis of two Cyclic Analogues of Gonadotropin Releasing Hormone (GnRH) for the Treatment of Canser.
A. Holeva, I. Friligou, M. Keramida, T. Tselios, **J. Matsoukas**.
J. Peptide Science, **2006**, 12, 108 (Th015).

119. Design, Synthesis and Conformational Analysis of a Potent Angiotensin II Losartan Based Antagonist.
M. Matsoukas, A. Resvani, K. Kelaidonis, D. Lemou, **J. Matsoukas**, T. Tselios.
J. Peptide Science, **2006**, 12, 117 (M049).

120. Desing and Synthesis of a Novel Non-Peptide Mimetic of PAR-1 Thrombin Receptor with four Pharmacophoric Groups.
M. Androutsou, K. Alexopoulos, S. Mihailescu, T. Tselios, **J. Matsoukas**.
J. Peptide Science, **2006**, 12, 120 (Tu062).

121. Design and Synthesis of Myelin Basic Protein (MBP) Linear and Cyclic Peptide Analogues Complexed with Mannan. Effects in Cytokine Production.
G. N. Deraos, M. Katsara, T. Tselios, S. N. Deraos, V. Apostolopoulos, **J. Matsoukas**.
J. Peptide Science, **2006**, 12, 223 (Th474).

122. Comparison of Proposed Putative Bioactive Conformations of Altered Peptide Ligands of myelin Basic Protein by Spectroscopic and Modelling Studies.
E. D. Mantzourani, T. M. Mavromoustakos, S. Golic-Grdadolnik, J. A. Platts, G. N. Deraos, **J. Matsoukas**, T. V. Tselios.
J. Peptide Science, **2006**, 12, 189 (Tu338).

123. A Proteolipid Protein Cyclic Peptide Analogue Reduces the Enchephalitogenicity in EAE Model.
S. N. Deraos, T. V. Tselios, I. Mylonas, G. N. Deraos, **J. M. Matsoukas**, N. Grigoriadis.
J. Peptide Science, **2006**, 12, 223 (Tu475).

124. Angiotensin II: A Role in Inflammation and Cancer.
A. Koumarianou, D. Vlahakos, J. Matsoukas, T. Economopoulos.
7th Conference on Medicinal Chemistry: Drug Discovery and Design, Patras, Greece, March 8-11, **2006**.

125. Effect of Myelin Basic Protein Peptides on T-Cell Activation Parameters of the Same Multiple Sclerosis Patient Tested at Presentation and One Year Later.
K. Chatzantoni, P. Papathanassopoulos, T. Tselios, **J. Matsoukas**, A. Mouzaki.

7th Conference on Medicinal Chemistry: Drug Discovery and Design, Patras, Greece, March 8-11, **2006**.

126. The Molecular Basis of Hypertension by the Use of Biophysical Methods.
I. Gerothanassis, A. Tzakos, G. Spyroulias, V. Theodorou, **J. Matsoukas**, P. Cordopatis.
7th Conference on Medicinal Chemistry: Drug Discovery and Design, Patras, Greece, March 8-11, **2006**.

127. From Angiotensin to Losartan and Sartans a New Generation of Anti-Hypertensives.
J. Matsoukas, A. Resvani, M.E. Androutsou, C. Kelaidonis, M.T. Matsoukas.
7th Conference on Medicinal Chemistry: Drug Discovery and Design, Patras, Greece, March 8-11, **2006**.

128. Design, Synthesis and Molecular Modeling Studies of an Non-Peptide Antagonist of Par 1 Thrombin Receptor, Using Piperazine as Template.
M.E. Androutsou, K. Alexopoulos, A. Resvani, K. Kelaidonis, T. Tselios, **J. Matsoukas**.
7th Conference on Medicinal Chemistry: Drug Discovery and Design, Patras, Greece, March 8-11, **2006**.

129. Design, Synthesis and Biological Evaluation of the MBP_{83-99} Epitope Conjugated with Oxidised of Reduced Mannan: A Pilot Study of the in vitro Effects of the Mannan-Peptides on T-Cells Isolated from Multiple Sclerosis (MS) Patients and Controls.
G. Deraos, K. Chatzantoni, P. Papathanassopoulos, E. Friligou, S. Deraos, T. Tselios, **J. Matsoukas**, A. Mouzaki.
7th Conference on Medicinal Chemistry: Drug Discovery and Design, Patras, Greece, March 8-11, **2006**.

130. Immune Responses of Myelin Basic Protein (MBP_{83-99}) Analogues (Alone or Conjugated with Mannan) in SJL/J Mice.
M. Katsara, G. Deraos, T. Tselios, S. Deraos, **J. Matsoukas**, V. Apostolopoulos.
7th Conference on Medicinal Chemistry: Drug Discovery and Design, Patras, Greece, March 8-11, **2006**.

131. A Putative Bioactive Conformation for the APL of Myelin Basic Protein and Inhibitor of Experimental Autoimmune Encephalomyelitis, [Ala^{96}] MBP_{87-99}.
E. Mantzourani, T. Mavromoustakos, S. Grdadolnik, J. Platts, G. Deraos, **J. Matsoukas**, T. Tselios.
7th Conference on Medicinal Chemistry: Drug Discovery and Design, Patras, Greece, March 8-11, **2006**.

132. Design and Conformational Analysis of Potent Angiotensin II, Losartan Based Antagonists.
M. Matsoukas, A. Resvani, K. Kelaidonis, **J. Matsoukas**, T. Tselios.
7th Conference on Medicinal Chemistry: Drug Discovery and Design, Patras, Greece, March 8-11, **2006**.

133. Rational Design and Synthesis AT1 Angiotensin II Receptor Antagonists Based on Imidazole.
A. Resvani, C. Kelaidonis, M.E. Androutsou, T. Tselios, **J. Matsoukas**.
7th Conference on Medicinal Chemistry: Drug Discovery and Design, Patras, Greece, March 8-11, **2006**.

134. Design and Synthesis of a Cyclic Analogue of Gonadotropin-Releasing Hormone (GnRH) for the Treatment of Cancer.
A. Holeva, T. Tselios, I. Friligou, **J. Matsoukas**.
7th Conference on Medicinal Chemistry: Drug Discovery and Design, Patras, Greece, March 8-11, **2006**.

135. Novel linear and cyclic analogues based on myelin basic protein MBP83-99 epitope: Immune responses in SJL/J mice using CFA and reduced mannan-peptide complexes for multiple sclerosis.
Katsara, M., Deraos, G., Tselios, T., Deraos, S., **Matsoukas, J.,** andApostolopoulos, V.
7th Conference Medicinal Chemistry: Drug Discovery and Design, University of Patras, Patras, Greece, Mar. 8-11, **2006.**

136. Myelin basic protein (MBP) and proteolipid protein (PLP) peptides (linear and cyclic) and immune responses in SJL/J mice Immunotherapeutic approaches for multiple sclerosis.
Katsara M., Tselios T., Deraos S., Deraos G., **Matsoukas J**., and Apostolopoulos V.
5th Hellenic Forum of Bioactive Peptides, Patras, Greece, May 14-16, **2006.**

137. Myelin basic protein (MBP) and proteolipid protein (PLP) peptides (linear and cyclic) and immune responses in SJL/J mice: Immunotherapeutic approaches for multiple sclerosis.
Katsara M., Tselios T., Deraos S., Deraos G**., Matsoukas J.,** and Apostolopoulos V.
1st Australasian Vaccines and Immunotherapeutics Development Meeting (AVID), Melbourne, Victoria, Australia, 31 May-1 June, **2006.**

138. Design and synthesis of myelin basic protein (MBP) linear and cyclic peptide analogues complexed with mannan. Effects in cytokine production.
Deraos GN., Katsara M., Tselios T., Deraos SN., Apostolopoulos V. and **Matsoukas JM**.
29th European Peptide Symposium, Gdansk, Poland, Sept. 3-8, **2006.**

139. Immune responses to MBP87-99 (linear and cyclic) and its analogues in SJL/J mice.
Katsara, M., Deraos, G., **Matsoukas, J**., and Apostolopoulos, V.
Immunology Group of Victoria (IgV), Beechworth, Victoria, Australia, Oct. 15-17, **2006.**

140. Myelin basic protein MBP83-99 and its novel analogues (linear and cyclic) using CFA or conjugated to reduced mannan: Immune responses in SJL/J mice for multiple sclerosis.
Katsara, M., Deraos, G., **Matsoukas, J.**, and Apostolopoulos, V.
Alfred Research Week, Alfred Hospital, Melbourne, Victoria, Australia, Oct. 23-27, **2006.**

141. Rational Altered peptide ligands of myelin basic protein for immunotherapy of multiple sclerosis.
Katsara, M., Deraos, G., **Matsoukas, J.**, and Apostolopoulos, V.
36th Australasian Society for Immunology / 15th International HLA and Immunogenetics Work shop, Auckalnd, New Zealand, Dec. 3-7, **2006.**

142. Design,Synthesis and immunological studies of linear and cyclic altered peptide igands of myelin basic protein MBP87-99 Epitope.
Katsara, M., Tselios, T., **Matsoukas, J.,** and Apostolopoulos, V.
36th Australasian Society for Immunology / 15th International HLA and Immunogenetics Work shop, Auckalnd, New Zealand, Dec. 3-7, **2006.**

143. Suppression of chronic experimental autoimmune encephalomyelitis using a novel cyclic peptide: Immunological analysis.
Katsara, M., Deraos, S., Grigoriadis, N., **Matsoukas, J.,** and Apostolopoulos, V.
36th Australasian Society for Immunology / 15th International HLA and Immunogenetics Work shop, Auckalnd, New Zealand, Dec. 3-7, **2006.**

144. Novel Linear and Cyclic GnRH Analogues Inhibit Proliferation Of Human Mammary Tumor Cell Line MCF-7.
Katsara, M., Tselios, T., **Matsoukas, J.**, and Apostolopoulos, V.
36th Australasian Society for Immunology /15th International HLA and Immunogenetics Work shop, Auckalnd, New Zealand, Dec. 3-7, **2006.**

145. Immune Responses to Rational Altered Pepride Ligands of Myelin Basic Protein
(Linear and Cyclic)in
SJL/J Mice.
M. Katsara, G. Deraos, **J. Matsoukas**, V.Apostolopoulou
8th Conference "Medical Chemistry: Drug Discovery and Design", March 15-17, Patras, Greece, **2007.**

146. Higt Liquid Pressure Chromatography (HPLC-MS/MS):Quantitative Analysis of
Bioactive Peptides for the Treatment of Cancer.
T. Katsila, Z. Sofianos, T. Tselios, **J. Matsoukas** and C. Tamvakopoulos.
*8th Conference "Medical Chemistry: Drug Discovery and Design", March 15-17, Patras, Greece,***2007**.

147. Solid Phase Synhesis of Glycopeptide Analogues.
K. Kelaidonis, A. Resvani, K. Prousalis, T. Tselios, **J. Matsoukas** and T. Tsegenidis.

148. Synthesis of Novel Non-Peptide Mimetic of Par-1 Thrombin Receptor with two of
three Pharmacophoric Groups.
Pasxalina Keppa, Maria- Eleni Androutsou, Theodore Tselios and **John Matsoukas.**
8th Conference "Medical Chemistry: Drug Discovery and Design", March 15-17,Patras, Greece, **2007**.

149. In Silico Studies Of Adme Properties of AT1 Receptor Antagonists
C. Koukoylitsa, P. Zoumpoulakis, A. Resvani, **J. Matsoukas,** T. Mauromoustakos.
8th Conference "Medical Chemistry: Drug Discovery and Design", March 15-17, Patras, Greece, **2007**.

150. Synthesis of Peptide Dendrimers in solid and liquid Phase Utilizing the 2-Clorotrityl
Chloride Resin (CLTR-C1).
Andreas Dais, Irene Friligou, Theodore Tselios, **John Matsoukas** and Dimitrios Gatos.
8th Conference "Medical Chemistry: Drug Discovery and Design", March 15-17, Patras, Greece, **2007.**

151. T cell receptor altered peptide ligands of myelin basic protein and proteolipid protein (linear and cyclic) can modulate immune responses to SJL/J mice: Bioactive peptides for multiple sclerosis.
Katsara, M., Deraos, G., **Matsoukas, J.**, and Apostolopoulos, V.
4th International Peptide Symposium / 7th Australian Peptide Conference and 2nd Asia-Pacific International Peptide, Cairns, Queensland, Australia,Oct.21-25 / Scientific meeting on "Progress in Multiple Sclerosis", Melbourne, Victoria, Australia, Nov.15-16, **2007.**

152. A single or double TCR altered peptide ligands of myelin basic protein and proteolipid protein (linear and cyclic) can modulate immune responses to SJL/J mice.
Katsara, M., Deraos, G., **Matsoukas, J.**, and Apostolopoulos, V.
Austin Health Research Week, Austin Hospital, Melbourne, Victoria, Australia, Oct. 22-26, **2007.**

153. Linear and cyclic mutant analogues of self antigens (MBP and PLP) manipulate immune responses in SJL/J mice

Katsara, M., Yuriev, E., Ramsland, P.A., Deraos, G., Tselios, T., Deraos, S., **Matsoukas, J.**, and Apostolopoulos, V.
9th International Conference Medicinal Chemistry: Drug Discovery and Design, University of Patras, Patras, Greece, Mar.26-28, **2008.**

154. Drug design on non-peptide mimetics: A new generation of pharmaceutical products
J. Matsoukas
30th EPS, Helsinki, Finland, August 31 – September 5, **2008.**

155. Design and synthesis of a non-pepride PAR1 thrombin receptor antagonist, using cyclohexane as template
M. Androutsou, G. Agelis, G. Magoulas, P. Keppa, M. Saifeddine, M. Holleberg, **J. Matsoukas**
30th EPS, Helsinki, Finland, August 31 – September 5, **2008**.

156. Modeling studies and biological activities of a non-peptide AT_1 receptor angiotensin II antagonist
G. Agelis, M. Matsoukas, A. Resvani, K. Kelaidonis, P. Keppa, T. Tselios, D. Vlahakos, **J. Matsoukas**
30th EPS, Helsinki, Finland, August 31 – September 5, ***2008***

157. Modifications of the Myelin Basic Protein epitope MBP87-99 divert Th2 to Th1: Immune responses in peripheral blood mononuclear cells (PBMC) from Multiple Sclerosis patients.
G.Deraos, **J. Matsoukas**
30th EPS, Helsinki, Finland, August 31 – September 5, **2008.**

158. *Efficient microwave-assisted synthesis of myelin epitopes MOG35-55 and MOG97-108 using CLTR-CL resin.*
I. Friligou, M.E.Androutsou, T.Tselios and **J. Matsoukas.**
30th EPS, Helsinki, Finland, August 31 – September 5, **2008.**

159. A vaccine toward multiple sclerosis.
Katsara, M., Yuriev, E., Ramsland, P.A., Deraos, G., **Matsoukas, J.,** and Apostolopoulos, V.
30th European Peptide Symposium", Helsinki, Finland, Europe, Aug.31-5 Sept. **2008.**

160. New Directions in he Immunotherapy of Multiple Sclerosis using a cocktail of Immunodominant Myelin Peptides Conjugated to Mannan as a Therapeutic Vaccine Drug Towards Clinical Phase I-II Studies.
Matsoukas J.
European School of Medicinal Chemistry, Urbino, Italy, September 13-18, 2009

161. Non Peptide Mimetics: A new Generation of Drugs
Matsoukas J.
6th Annual Meeting, Greej Society of Pharmacology, June 4-6, 2010

162. Efficient Microwave – Assisted Synthesis of Mitochondrial Signal Peptide using Cltr-Cl and Wang Resin.
Androutsou M-E, Agelis G., Matsoukas J.
31st European Peptide Symposium", Denmark, Copenhagen, Europe, 5-9 Septeber, ***2010***

163. From Peptides to Non Peptide Mimetics: The Examples of Angiotensin II and Myelin.
Matsoukas J.
31st European Peptide Symposium", Denmark, Copenhagen, Europe, 5-9 Septeber, ***2010***

164. Efficient Synthesis and Biological Evaluation of Substituted Imidazole AT1 ANG II Receptor Antagonists Based on 4(5)-Butylimidazole.
Resvani A., Slaninova J., Matsoukas J., Agelis G.
31st European Peptide Symposium", Denmark, Copenhagen, Europe, 5-9 Septeber, ***2010***

165. Synthesis and Biological Evaluation of 1-Benzyl and 1-Biphenylmethyl Substituted Imidazole AT1 ANG II Receptor Antagonists.
Kelaidonis K., Kalavrizioti D., Matsoukas J. Agelis G.
31st European Peptide Symposium", Denmark, Copenhagen, Europe, 5-9 Septeber, ***2010***

166. A Concise Synthesis, Docking Studies and Biological Evaluation of *N*-substituted 5-Butylimidazole Analogues as potent Angiotensin II Receptor Blockers
Agelis, A. Resvani, S. Durdagi, T. Tůmová, J. Slaninová, P. Giannopoulos, K. Spyridaki, G. Liapakis, D. Vlahakos, T. Mavromoustakos, J. Matsoukas
32st European Peptide Symposium", Athens, Greece, Augoust 31- Septeber 5, ***2012***

167. Rational Design, Efficient Synthesis, Biological Evaluation of New *N,N´*-bis-substituted Butylimidazole analogs as potent Angiotensin Receptor Blockers
G. Agelis, A. Resvani, C. Koukoulitsa, A. Afantitis, G. Melagraki, A. Siafaka, E. Gkini, T. Tůmová, K. Spyridaki, D. Kalavrizioti, M-E. Androutsou, J. Slaninová, G. Liapakis, D. Vlahakos, T. Mavromoustakos, J. Matsoukas
32st European Peptide Symposium", Athens, Greece, Augoust 31- Septeber 5, ***2012***

168. Facile and Efficient Syntheses of Structurally Modified *E*-urocanic acid analogs as potent Angiotensin II Receptor Blockers
B. Resvani, C. Nikolis, G. Liapakis D. Vlahakos, C. Koukoulitsa, D. Ntountaniotis, T. Mavromoustakos, J. Matsoukas, G. Agelis
32st European Peptide Symposium", Athens, Greece, Augoust 31- Septeber 5, ***2012***

169. Conformational Similarities and Differences of Angiotensin II (AII): AII Acetate vs TFA Salt in Solution
D.Potamitis, A. Resvani, M-E. Androutsou M. Zervou, P. Plotas, G. Agelis, P. Zoumpoulakis, J. Matsoukas
32st European Peptide Symposium", Athens, Greece, Augoust 31- Septeber 5, ***2012***

170. Transdermal delivery: New approach in anti-hypertensive therapy
M. Michalatou, M. E. Androutsou, T. Tselios, A. Resvani, G. Agelis, D. Vlahakos, J. Matsoukas
32st European Peptide Symposium", Athens, Greece, Augoust 31- Septeber 5, ***2012***

171. Rational Design and Synthesis of linear and cyclic Myelin Epitope Peptides: New Directions in the Immunotherapy of Multiple Sclerosis
John Matsoukas
32st European Peptide Symposium", Athens, Greece, Augoust 31- Septeber 5, ***2012***

172. Development and validation of a UPLC- MS analytical method for the control of the conjugation of $[Lys\text{-}Gly]_5\text{-}MOG_{35\text{-}55}$ with mannan
M. E. Androutsou, I. Friligou, J. Matsoukas, T. Tselios
32st European Peptide Symposium", Athens, Greece, Augoust 31- Septeber 5, ***2012***

173. Peptide Mimetics and Protein Mimicry in Drug Discovery and Drug Biotechnology
J. Matsoukas
5th International Conference of Industrial Bioprocesses IFIBiop, Taipei, China, 7 – 10 October, ***2012***

174. Immunotherapy of experimental autoimmune encephalomyelitis using APC-targeted myelin peptides in prophylactic and therapeutic vaccines.
Tseveleki V., Tselios T., Friligou I., Emmanouil M., Katsara M., Vamvakas S.S., Matsoukas J., Apostolopoulos V., Lassmann H., Probert L.
11th International Congress of Neuroimmunology, Boston (Massachusetts, USA) 4th-8th November, ***2012***

175. Regulatory T-cells in Relapsing-Remitting Multiple Sclerosis Patients: Effect of Disease Activity and Treatment Regimens.
Dimisianos N., Rodi M., Kalavrizioti D., de Lastic A.L., Sakellaraki P., Tapeinou A., Tselios T., Panagoulias I., Matsoukas J., Papathanasopoulos P., Mouzaki A.
15th *International Congress of Immunology, Milan, Italy, August 22-27,* ***2013***

Βραβευμένοι με Νόμπελ Ιατρικής και Χημείας στο Πανεπιστήμιο Πατρών

Προσκεκλημένοι του Καθηγητή Χημείας, Γιάννη Ματσούκα στα Συνέδρια Ιατρικής Χημείας

1. **Harald zur Hausen, Nobel Ιατρικής – 15^{ο} Συνέδριο, 2014**
   (Το πρώτο αντικαρκινικό εμβόλιο τραχήλου της μήτρας)

2. **Ada Yonath, Nobel Χημείας – 14^{ο} Συνέδριο, 2013**
   (Ανακάλυψη Αντιβιοτικών νέας γενιάς)

3. **James Watson, Nobel Ιατρικής – 12^{ο} Συνέδριο, 2011**
   (Ανακάλυψη της διπλής έλικας του DNA)

4. **Andrew Schally, Nobel Ιατρικής – 11^{ο} Συνέδριο, 2010**
   (Ανακάλυψη πρωτεΐνης γονιμότητας GnRH, του εγκεφάλου)

5. **Jean Marie Lehn, Nobel Χημείας – 9^{ο} Συνέδριο, 2008**
   (Υπερμόρια και υπερμοριακή Χημεία)















